505690_0_17_18_2_4::None::Distribution/NN of/IN Candida/NN albicans/NNS and/CC non/JJ -/: albicans/NNS Candida/NN species/NNS in/IN oral/JJ candidiasis/NN patients/NNS :/: Correlation/NN between/IN cell/NN surface/NN hydrophobicity/NN and/CC 
198131_1_16_17_10_11::None::long/JJ -/: term/NN users/NNS ,/, their/PRP$ smoking/NN behaviour/NN ,/, attachment/NN to/TO smoking/NN ,/, 
693828_2_2_3_15_16::None::A/DT systematic/JJ literature/NN search/NN was/VBD conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ 
484109_1_2_3_3_4::medicine.disease.treatments::For/IN penile/JJ cancer/NN surgical/JJ treatment/NN ,/, radiotherapy/NN 
110315_0_0_1_7_8::None::Chronic/JJ inguinodynia/NN is/VBZ one/CD of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN 
388589_2_97_98_44_45::None::-/: diabetes/NN ,/, age/NN gtgt/NN =/JJ 65/CD and/CC &/CC lt/NN ;/: 65/CD year/NN -/: old/JJ ,/, men/NNS and/CC women/NNS ,/, body/NN mass/NN index/NN gtgt/NN =/JJ 30/CD and/CC &/CC lt/NN ;/: 30/CD kg/NN //: m/NN (/( 2/CD )/) ,/, and/CC body/NN weight/NN gtgt/NN =/JJ 60/CD and/CC &/CC lt/NN ;/: 60/CD kg/NN ,/, were/VBD identified/VBN in/IN Medline/NNP ,/, Embase/NNP ,/, Web/NN of/IN 
183879_18_31_32_16_17::None::depressive/JJ mood/NN of/IN patients/NNS with/IN severe/JJ MDD/NN ;/: however/RB ,/, the/DT latter/JJ induced/JJ significantly/RB stronger/JJR and/CC more/RBR rapid/JJ beneficial/JJ effects/NNS ./. 
1926_1926_19_20_26_27::None::,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, TRADD/NN ,/, and/CC RIP/NN was/VBD similar/JJ in/IN 
784430_7_15_17_15_18::None::to/TO that/DT of/IN sodium/NN channel/NN blocking/VBG antiepileptic/JJ drugs/NNS ,/, 
850254_13_11_12_10_12::None::patients/NNS with/IN acute/JJ infection/NN ./. 
508103_4_18_19_23_24::None::STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC normalized/VBD myocardial/JJ steatosis/NN ,/, expression/NN 
312_312_33_34_35_36::POS_REG(-)_POLYMERIZE::inhibiting/JJ effect/NN of/IN profilin/NN on/IN actin/NN polymerization/NN ./. 
63_63_44_45_49_50::POS_ACTION_MEMBER::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
1546_1546_12_13_26_27::None::kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
1024_1024_39_40_32_33::POS_ACTION_BIND::RNA-binding/JJ surfaces/NNS of/IN HSH49/NN are/VBP not/RB required/VBN for/IN interaction/NN with/IN CUS1/NN ./. 
256031_1_26_27_37_38::None::absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN 
991_991_20_21_17_18::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
1289_1289_4_6_13_14::POS_ACTION_INTERACT::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
813_813_23_24_8_9::None::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
1908_1908_19_20_7_8::POS_ACTION_CONTROL::that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
856_856_37_38_24_25::POS_ACTION_LOCALIZE-TO::the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
798558_0_22_23_2_3::None::A/DT debilitating/JJ late/JJ -/: onset/NN disorder/NN of/IN the/DT premutation/NN in/IN the/DT FMR1/NN gene/NN is/VBZ the/DT neurodegenerative/JJ disorder/NN fragile/JJ X/NN -/: associated/VBN tremor/NN ataxia/NN syndrome/NN (/( FXTAS/NN 
1095_1095_17_18_22_23::None::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
295839_4_9_10_29_30::None::of/IN STAT3/NN and/CC MEK/NN using/VBG the/DT STAT3/NN inhibitor/NN LY5/NN and/CC MEK/NN inhibitor/NN Trametinib/NN exerts/VBZ significant/JJ anti/JJ -/: tumor/NN cell/NN efficacy/NN in/IN K/NN -/: Ras/NN mutant/NN pancreatic/JJ and/CC 
2222_2222_21_22_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
604261_0_32_33_52_53::None::the/DT glutamate/NN release/NN inhibitor/NN riluzole/NN ,/, a/DT drug/NN currently/RB used/VBN to/TO treat/VB amyotrophic/JJ lateral/JJ sclerosis/NN ,/, can/MD induce/VB apoptosis/NN in/IN GRM1/NN -/: expressing/VBG melanoma/NN cells/NNS ./. 
500377_1_6_7_12_13::None::essential/JJ hypertension/NN were/VBD treated/VBN with/IN the/DT beta/NN -/: blocker/NN metoprolol/NN and/CC followed/VBD up/RP 
728820_2_13_14_16_17::None::lower/JJR urinary/JJ tract/NN symptoms/NNS secondary/JJ to/TO BPH/NNP from/IN 2005/CD to/TO 
233540_0_13_14_22_24::None::measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN 
2107_2107_27_28_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
410_410_11_12_12_13::POS_ACTION_MEMBER::histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ ./. 
1940_1940_13_14_11_12::None::signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
18_18_6_7_4_5::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
1094_1094_18_19_16_17::None::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT 
28653_0_0_1_10_11::None::Photochemical/JJ reduction/NN of/IN iron/NN and/CC iron/NN uptake/NN by/IN Microcystis/NNPS were/VBD investigated/VBN in/IN a/DT freshwater/JJ 
759_759_20_24_12_13::None::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
241_241_13_17_0_1::None::Neuropilin-1/NN is/VBZ expressed/VBN by/IN endothelial/JJ and/CC tumor/NN cells/NNS as/IN an/DT isoform-specific/JJ receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN ./. 
87529_17_3_4_6_7::None::Advanced/NNP age/NN ,/, hypertension/NN ,/, and/CC prior/RB stroke/NN were/VBD associated/VBN 
227834_1_11_12_7_8::None::damage/NN to/TO leukocytic/JJ DNA/NN and/CC enhancement/NN of/IN homocysteine/NN (/( Hcy/NN )/) 
1075_1075_20_21_6_7::POS_ACTION_PHOSPHORYLATE::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
1908_1908_19_20_5_6::POS_ACTION_MEDIATE::results/NNS indicate/VBP that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
1380_1380_26_27_36_37::POS_ACTION_BIND::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
262795_4_0_1_6_7::None::It/PRP is/VBZ clear/JJ now/RB that/IN the/DT tumour/NN -/: promoting/VBG inflammatory/JJ 
558341_3_22_23_25_27::None::focused/VBN on/IN a/DT higher/JJR risk/NN of/IN myocardial/JJ infarction/NN in/IN subjects/NNS with/IN 
431_431_6_7_15_16::POS_ACTION_Causal::proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
1061_1061_6_7_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ 
253162_8_32_33_4_5::None::IgG/NN subclasses/NNS (/( IgG1/NN //: IgG2a/NN //: IgG2b/NN //: IgG3/NN )/) were/VBD elicited/VBN by/IN omvPV/NN and/CC in/IN a/DT lower/JJR magnitude/NN by/IN wPV/NN ,/, but/CC not/RB by/IN aPV/NN (/( IgG1/NN )/) or/CC infection/NN (/( IgG2a/NN //: 
529506_0_9_13_4_7::None::alveolar/JJ hemorrhage/NN from/IN systemic/JJ lupus/NN erythematosus/NN misdiagnosed/JJ as/RB high/JJ altitude/NN pulmonary/JJ edema/NN ./. 
1434_1434_11_12_72_73::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
1782_1782_7_8_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT 
1360_1360_7_8_4_5::None::affinity/NN of/IN yeast/NN profilin/NN for/IN rabbit/NN actin/NN (/( 2.9/CD microM/NN 
779_779_35_36_21_24::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
303626_0_19_20_21_22::medicine.drug_ingredient.active_moiety_of_drug::NPs/NNS )/) on/IN chromium/NN (/( Cr/NN )/) fractionation/NN in/IN 
686_686_29_30_29_30::None::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
438998_0_9_10_14_16::people.cause_of_death.includes_causes_of_death::occurrence/NN potentiate/VB the/DT anticancer/JJ effects/NNS of/IN everolimus/NN on/IN renal/JJ cancer/NN cells/NNS ./. 
1061_1061_25_27_15_16::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
565_565_39_40_28_29::None::the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, co-localizing/VBG with/IN the/DT known/JJ focal/JJ adhesion/NN components/NNS talin/NN and/CC vinculin/NN ./. 
397033_2_5_6_10_12::biology.organism_classification.lower_classifications::birds/NNS (/( carrion/NN crows/NNS ,/, Corvus/NN corone/NN ,/, common/JJ ravens/NNS ,/, Corvus/NNP corax/NN 
686_686_33_34_13_14::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1442_1442_23_24_4_5::POS_ACTION_BIND::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN can/MD not/RB directly/RB associate/JJ with/IN alpha-catenin/NN but/CC interacts/VBZ with/IN high/JJ affinity/NN with/IN beta-catenin/NN ,/, whereas/IN the/DT binding/NN of/IN gamma-catenin/NN (/( plakoglobin/NN )/) 
1686_1686_51_53_25_28::None::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
426593_3_10_11_20_21::None::I/PRP -/: 131/CD MIBG/NN could/MD achieve/VB high/JJ -/: probability/NN pain/NN reduction/NN ,/, the/DT objective/JJ response/NN was/VBD poor/JJ 
789814_0_7_8_13_14::None::(/( CABG/NN )/) surgery/NN remains/VBZ the/DT preferred/JJ mode/NN of/IN revascularization/NN in/IN patients/NNS with/IN 
360_360_13_14_8_9::POS_ACTION_BIND::of/IN the/DT N-terminal/JJ actin/NN binding/NN domain/NN of/IN human/JJ fimbrin/NN ./. 
2222_2222_39_40_23_24::NEG_ACTION_COLOCALIZE::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
157_157_8_9_24_25::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
323444_1_15_16_9_10::None::of/IN mesenteric/JJ ischaemia/NN secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP 
1500_1500_16_17_11_12::POS_ACTION_BIND::heterotrimer/NN of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN proteins/NNS ,/, displays/VBZ 
1599_1599_22_23_29_30::POS_ACTION_ASSEMBLE::that/DT of/IN a/DT talin/NN mediated/VBD mechanism/NN for/IN the/DT attachment/NN of/IN actin/NN filaments/NNS to/TO the/DT 
693466_12_3_4_9_10::None::HyperCVAD/NN chemotherapy/NN and/CC imatinib/NN is/VBZ an/DT effective/JJ regimen/NN for/IN Philadelphia/NNP -/: positive/JJ acute/JJ 
822180_0_28_29_24_25::None::the/DT major/JJ immunological/JJ complications/NNS associated/VBN with/IN allogeneic/JJ transplantation/NN ./. 
356086_0_0_1_24_25::medicine.disease.treatments::Cancer/NN stem/NN cells/NNS (/( CSCs/NNS )/) play/VBP an/DT important/JJ role/NN in/IN cancer/NN growth/NN ,/, self/NN -/: renewal/NN ,/, metastasis/NN ,/, recurrence/NN and/CC radio/NN //: chemotherapy/NN ./. 
265539_2_18_19_0_1::None::MS/NN is/VBZ an/DT inflammatory/JJ ,/, demyelinating/JJ ,/, neurodegenerative/JJ disease/NN of/IN the/DT CNS/NN During/IN the/DT last/JJ several/JJ decades/NNS ,/, experimental/JJ models/NNS of/IN MS/NN 
1737_1737_58_59_52_54::None::the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
616_616_17_18_18_19::POS_ACTION_MEMBER::six/CD sites/NNS and/CC histone/NN H4/NN had/VBD five/CD sites/NNS 
2222_2222_23_24_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
480543_0_9_10_31_32::None::68/CD )/) is/VBZ produced/VBN by/IN proton/NN irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN by/IN organic/JJ extraction/NN and/CC used/VBN in/IN a/DT medical/JJ isotope/NN generator/NN to/TO produce/VB Gallium/NNP -/: 68/CD 
534857_3_24_26_16_17::medicine.disease.risk_factors::use/NN in/IN 937/CD hypertensive/JJ patients/NNS with/IN ECG/NN left/VBD ventricular/JJ hypertrophy/NN in/IN atrial/JJ fibrillation/NN at/IN baseline/NN (/( 
367_367_24_25_28_30::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
991_991_20_21_4_5::POS_ACTION_Causal::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
2108_2108_18_19_17_18::None::kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 19/CD 
2_2_9_10_11_13::None::formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN */SYM DNA/NN complex/NN 
1160_1160_2_3_8_10::None::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN 
76705_14_13_14_22_23::medicine.risk_factor.diseases::rise/NN showed/VBD a/DT high/JJ prevalence/NN of/IN CVE/NN but/CC not/RB stroke/NN ,/, thus/RB CAD/NN might/MD have/VB a/DT 
1962_1962_22_23_24_25::None::the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
79843_0_39_40_37_38::None::years/NNS among/IN both/DT youth/NN and/CC adults/NNS for/IN its/PRP$ cognitive/JJ 
665_665_19_20_14_17::None::antibodies/NNS to/TO the/DT actin/NN binding/NN proteins/NNS Abp1p/NN and/CC cofilin/NN ./. 
101_101_22_23_24_25::None::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN 
243_243_30_32_0_2::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
367_367_32_33_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
668570_12_7_8_21_22::None::association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN in/IN postoperative/JJ depressive/JJ symptoms/NNS run/VBP counter/RB to/TO other/JJ available/JJ 
539_539_18_19_5_6::None::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
214422_1_36_38_12_13::None::following/VBG groups/NNS :/: control/JJ group/NN (/( control/NN )/) ,/, hydrogen/NN peroxide/NN group/NN (/( H2O2/NN )/) ,/, pretreated/VBN with/IN low/JJ concentration/NN dopamine/NN (/( DA/NN +/CC H2O2/NN )/) ,/, dopamine/NN receptor/NN l/NN (/( DR1/NN 
1843_1843_31_32_12_13::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
1754_1754_21_22_32_33::None::to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
805_805_5_9_0_4::None::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN 
315600_15_1_2_36_37::None::GHA/NN priming/NN chemotherapy/NN ,/, as/RB well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ side/JJ effects/NNS and/CC therapy/NN -/: related/JJ mortality/NN ./. 
279_279_30_31_19_20::None::a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
247832_2_6_7_45_46::None::studies/NNS suggest/VBP that/IN inflammatory/JJ processes/NNS have/VBP emerged/VBN critical/JJ in/IN the/DT pathogenesis/NN of/IN CVD/NNP in/IN OSAS/NNP A/NNP range/NN of/IN circulating/VBG inflammatory/JJ molecules/NNS has/VBZ been/VBN identified/VBN and/CC measured/VBN ,/, with/IN a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ damage/NN risk/NN ,/, such/JJ as/IN plasma/NN cytokines/NNS ,/, adhesion/NN molecules/NNS 
176455_12_5_6_3_5::None::Neoadjuvant/JJ radiotherapy/NN of/IN rectal/JJ cancer/NN represents/VBZ the/DT current/JJ standard/NN 
1144_1144_11_13_0_2::None::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP 
1940_1940_11_12_7_11::None::in/IN activation/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, 
278424_0_8_9_7_8::None::tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD breast/NN 
367_367_28_30_32_33::POS_ACTION_MEMBER::and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
697_697_2_3_23_25::None::In/IN Acanthamoeba/NN actin/NN polymerization/NN is/VBZ regulated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN profilin/NN ,/, which/WDT binds/VBZ to/TO actin/NN monomers/NNS ,/, and/CC by/IN capping/VBG protein/NN ,/, which/WDT both/DT 
315600_15_30_32_23_24::medicine.risk_factor.diseases::regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ side/JJ effects/NNS and/CC therapy/NN -/: 
776_776_24_26_26_27::POS_ACTION_MEMBER::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
1534_1534_26_29_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
3197_0_9_10_7_8::None::)/) is/VBZ an/DT investigational/JJ oral/JJ prodrug/NN of/IN the/DT HIV/NN 
245_245_0_1_10_11::POS_ACTION_BIND::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
2117_2117_18_19_2_3::None::We/PRP investigated/VBD actin/NN filament/NN turnover/NN rates/NNS ,/, length/NN ,/, number/NN ,/, barbed/VBN end/NN exposure/NN ,/, and/CC binding/NN of/IN cofilin/NN in/IN bovine/JJ arterial/JJ 
214422_1_18_20_22_23::medicine.drug.active_moieties::control/NN )/) ,/, hydrogen/NN peroxide/NN group/NN (/( H2O2/NN )/) ,/, pretreated/VBN 
1798_1798_33_34_24_26::None::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS 
126724_0_14_15_6_7::people.cause_of_death.includes_causes_of_death::Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN Bacteria/NNS the/DT Next/JJ -/: Generation/NNP Cancer/NNP Therapy/NN ?/. 
467117_12_2_3_17_19::None::Canine/NN orbital/JJ rhabdomyosarcoma/NN is/VBZ a/DT highly/RB malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC may/MD be/VB amenable/JJ to/TO surgical/JJ resection/NN in/IN older/JJR dogs/NNS 
356086_0_22_23_18_19::None::-/: renewal/NN ,/, metastasis/NN ,/, recurrence/NN and/CC radio/NN //: chemotherapy/NN ./. 
415007_0_32_35_1_2::medicine.disease.risk_factors::Familial/JJ hypercholesterolaemia/NN (/( FH/NN )/) is/VBZ an/DT autosomal/JJ co/NN -/: dominant/JJ disorder/NN that/WDT markedly/RB raises/VBZ plasma/NN low/JJ -/: density/NN lipoprotein/NN -/: cholesterol/NN (/( LDL/NN -/: C/NN )/) concentration/NN ,/, causing/VBG premature/JJ atherosclerotic/JJ coronary/JJ artery/NN disease/NN (/( CAD/NN )/) 
7_7_11_12_2_3::None::Absence/NN of/IN alpha-syntrophin/NN leads/VBZ to/TO structurally/RB aberrant/JJ neuromuscular/JJ synapses/NNS deficient/JJ in/IN utrophin/NN ./. 
1226_1226_5_6_2_3::POS_ACTION_RELATE::Saccharomyces/FW cerevisiae/FW PAC2/NN functions/NNS with/IN CIN1/NN ,/, 2/CD and/CC 
68_68_14_15_12_13::POS_ACTION_CORELATE::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, 
1380_1380_43_44_38_39::None::,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
288485_0_16_17_30_32::None::spinal/JJ image/NN -/: guided/VBN radiotherapy/NN (/( IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP 
112_112_3_4_14_16::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN 
228362_4_29_30_14_15::medicine.drug_ingredient.active_moiety_of_drug::vitro/FW ribosylation/NN and/CC trypsin/NN digestion/NN for/IN 24/CD or/CC 72h/CD on/IN the/DT viscoelastic/JJ behavior/NN of/IN the/DT whole/JJ murine/JJ IVD/NN Trypsin/NN treatment/NN resulted/VBD in/IN 
237860_0_4_5_19_20::None::2007/CD ,/, the/DT baby/NN woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN )/) named/VBN Lyuba/NNP was/VBD found/VBN frozen/VBN in/IN the/DT Siberian/JJ tundra/NN permafrost/NN along/IN the/DT 
522582_0_11_12_9_10::medicine.symptom.symptom_of::and/CC rumination/NN predict/VBP depressive/JJ and/CC anxiety/NN symptoms/NNS in/IN young/JJ 
178597_0_40_42_30_31::medicine.disease.treatments::no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN rejection/NN and/CC GvHD/NN in/IN patients/NNS with/IN acute/JJ leukemia/NN ./. 
669_669_16_17_11_12::None::the/DT presence/NN of/IN paxillin/NN ,/, talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS 
295529_1_4_5_13_14::None::is/VBZ the/DT only/JJ member/NN of/IN the/DT RAF/NN family/NN activated/VBN by/IN mutation/NN in/IN human/JJ cancers/NNS ./. 
984_984_0_1_20_21::POS_ACTION_SIMILAR::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
1169_1169_10_11_26_27::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
170773_3_47_48_33_34::None::wide/JJ association/NN studies/NNS conducted/VBN in/IN recent/JJ years/NNS on/IN electrocardiographic/JJ parameters/NNS ,/, highlighting/VBG their/PRP$ potential/NN in/IN uncovering/VBG new/JJ biological/JJ insights/NNS into/IN cardiac/JJ 
128605_11_37_39_22_23::None::,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN in/IN rectal/JJ cancer/NN ./. 
962_962_12_15_15_16::POS_ACTION_MEMBER::synthesis/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ./. 
833154_0_4_5_0_1::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN 
772940_6_1_2_0_1::None::In/IN patients/NNS with/IN chronic/JJ HBV/NN 
576_576_13_15_22_23::None::,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN effective/JJ depolymerization/NN of/IN actin/NN filaments/NNS ./. 
1502_1502_14_15_18_19::None::localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT ICP8/NN or/CC POL/NN replication/NN 
267813_3_10_11_62_64::medicine.disease.treatments::-/: TR/NN )/) diagnosis/NN of/IN bipolar/JJ disorder/NN ,/, manic/JJ ,/, hypomanic/JJ ,/, or/CC mixed/JJ episode/NN ,/, were/VBD recruited/VBN over/IN a/DT 6/CD year/NN period/NN from/IN two/CD academic/JJ outpatient/NN programs/NNS for/IN a/DT double/JJ -/: blinded/VBN ,/, placebo/NN -/: controlled/JJ trial/NN in/IN which/WDT subjects/NNS were/VBD randomized/VBN in/IN a/DT 2/CD :/: 2/CD :/: 1/CD ratio/NN to/TO risperidone/NN solution/NN ,/, valproic/JJ acid/NN ,/, or/CC placebo/NN 
127291_4_65_66_34_35::None::the/DT artificial/JJ vessel/NN bypass/NN was/VBD done/VBN between/IN the/DT infra/NN -/: renal/JJ aorta/NN and/CC distal/JJ portion/NN of/IN the/DT splenic/JJ artery/NN in/IN 7/CD cases/NNS ;/: the/DT splenectomy/NN was/VBD done/VBN in/IN 2/CD cases/NNS ;/: the/DT splenectomy/NN in/IN combination/NN with/IN ligation/NN of/IN 
12641_5_4_5_2_3::None::In/IN those/DT continued/VBN on/IN antidepressants/NNS (/( AD/NN )/) 
229_229_15_16_11_12::POS_REG(+)_PHOSPHORYLATE::(/( flk-1/NN //: KDR/NN )/) tyrosine-autophosphorylation/NN by/IN VEGF/NN which/WDT was/VBD maximal/JJ 
1248_1248_4_5_9_10::POS_ACTION_MEMBER::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
227756_3_27_28_0_1::None::We/PRP use/VBP the/DT directly/RB dated/VBN ancient/JJ wolf/NN genome/NN to/TO recalibrate/VB the/DT molecular/JJ timescale/NN of/IN wolves/NNS and/CC dogs/NNS and/CC find/VB that/IN the/DT mutation/NN rate/NN is/VBZ substantially/RB slower/JJR than/IN assumed/VBN by/IN most/JJS previous/JJ 
218696_6_0_1_33_36::medicine.risk_factor.diseases::Diabetics/NNS were/VBD older/JJR (/( 64/CD vs/CC 62/CD years/NNS ,/, P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, co/SYM -/: morbidities/NNS ,/, and/CC triple/JJ -/: vessel/NN coronary/JJ artery/NN disease/NN ./. 
1889_1889_5_6_11_13::POS_ACTION_ACTIVATE::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
1726_1726_23_24_8_9::None::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
97678_0_12_13_10_11::None::and/CC Expenditures/NNS among/IN Elderly/NNP Medicare/NNP Beneficiaries/NNS ./. 
1095_1095_35_36_22_23::POS_ACTION_LOCALIZE::,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
177255_4_12_13_8_9::None::to/TO protect/VB from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN socks/NNS ./. 
552813_1_2_3_40_43::None::Patients/NNS with/IN BMS/NN (/( EDSS/NN ltlt/NN =/JJ 3/CD after/IN 20/CD years/NNS disease/NN duration/NN )/) were/VBD re/SYM -/: assessed/VBN 25/CD -/: 30/CD years/NNS post/NN -/: MS/NN symptom/NN onset/NN for/IN :/: EDSS/NNS ,/, HRQoL/NN (/( MSQoL/NN -/: 54/CD )/) ,/, depression/NN (/( Beck/NNP Depression/NNP Inventory/NNP -/: II/CD )/) 
428759_7_12_13_18_19::None::ovarian/JJ suppression/NN in/IN premenopausal/JJ early/JJ breast/NN cancer/NN have/VBP been/VBN selected/VBN as/IN the/DT last/JJ 
434463_2_37_38_21_22::None::,/, with/IN the/DT Pall/NN Lipipor/NN (/( Registered/NNP )/) TNA/NNP and/CC Lipipor/NNP NLF/NNP intravenous/JJ in/IN -/: line/NN filters/NNS and/CC to/TO assay/VB the/DT content/NN before/IN 
75211_5_10_12_31_34::medicine.disease.treatments::Indian/JJ women/NNS with/IN breast/NN cancer/NN ,/, in/IN the/DT age/NN group/NN of/IN 34/CD to/TO 60/CD years/NNS ,/, who/WP had/VBD poorly/RB differentiated/VBN breast/NN carcinoma/NN and/CC underwent/VBD modified/VBN radical/JJ mastectomy/NN ./. 
394127_6_13_14_19_20::medicine.disease.risk_factors::%/NN )/) ,/, endometrium/NN (/( 17.1/CD %/NN )/) ,/, breast/NN (/( 14.3/CD %/NN 
726738_8_20_22_0_1::None::The/DT rates/NNS of/IN antiviral/JJ prophylaxis/NN were/VBD lower/JJR for/IN doctors/NNS treating/VBG lung/NN ,/, breast/NN and/CC colorectal/JJ cancers/NNS than/IN for/IN those/DT treating/VBG hematological/JJ malignancies/NNS (/( all/DT p/NN 
373757_6_5_6_41_44::None::with/IN patients/NNS without/IN stroke/NN ,/, patients/NNS with/IN stroke/NN were/VBD more/RBR likely/JJ to/TO be/VB older/JJR and/CC to/TO have/VB diabetes/NN mellitus/NN ,/, hypertension/NN ,/, atrial/JJ fibrillation/NN ,/, hyperlipidaemia/NN ,/, chronic/JJ kidney/NN disease/NN ,/, ischaemic/JJ heart/NN disease/NN ,/, peripheral/JJ arterial/JJ disease/NN and/CC left/VBD ventricular/JJ dysfunction/NN (/( p/NN =/JJ 
849947_0_7_8_6_7::biology.organism_classification.lower_classifications::hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
131_131_7_8_5_6::POS_ACTION_CORELATE::was/VBD seen/VBN between/IN E-cadherin/NN and/CC alpha-catenin/NN expression/NN ,/, in/IN 
1240_1240_18_19_7_8::POS_ACTION_SQSIMILAR::coding/VBG region/NN for/IN RAD51/NN protein/NN share/NN homology/NN with/IN the/DT damage/NN response/NN sequence/NN element/NN of/IN RAD54/NN ,/, an/DT upstream/JJ 
278424_0_11_13_2_3::None::S6/NN kinase/NN signaling/NN :/: tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD breast/NN cancer/NN cohorts/NNS ./. 
106_106_6_7_2_3::None::mDia/NN binds/VBZ profilin/NN likely/JJ to/TO promote/VB actin/NN polymerization/NN ./. 
856_856_16_18_40_41::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
333090_0_5_6_7_8::None::for/IN depression/NN and/CC anxiety/NN in/IN individuals/NNS post/NN -/: stroke/NN 
856_856_40_41_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
454283_3_7_8_1_2::None::At/IN pH/NN 6.0/CD ,/, arsenate/NN inhibits/VBZ the/DT formation/NN of/IN lepidocrocite/NN and/CC 
124453_5_20_21_20_21::medicine.drug_ingredient.active_moiety_of_drug::plants/NNS by/IN inhibiting/VBG Cu/NN uptake/NN and/CC regulating/VBG 
1538_1538_12_13_11_12::POS_ACTION_MEMBER::partner/NN of/IN the/DT Rap1A/NN GTPase/NN and/CC associates/VBZ with/IN 
139515_2_46_48_59_60::medicine.symptom.symptom_of::hematuria/NN ,/, and/CC abdominal/JJ pain/NN and/CC confirmed/VBD pathologically/RB by/IN his/PRP$ renal/JJ and/CC skin/NN biopsies/NNS demonstrating/VBG leukocytoclastic/JJ vasculitis/NN and/CC IgA/NN complexes/NNS 
68_68_14_15_16_17::POS_ACTION_CORELATE::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB 
991_991_15_16_4_5::POS_ACTION_Causal::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
984_984_20_21_0_1::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
1480_1480_12_13_2_3::None::The/DT exogeneous/JJ cofilin/NN ,/, but/CC not/RB ADF/NN ,/, caused/VBD quick/JJ disassembly/NN of/IN actin/NN filaments/NNS and/CC accumulated/VBN 
1759_1759_40_41_10_11::None::EGF/NN stimulation/NN recruits/VBZ cofilin/NN to/TO the/DT leading/JJ edge/NN where/WRB its/PRP$ severing/VBG activity/NN is/VBZ activated/VBN ,/, leading/VBG to/TO the/DT generation/NN of/IN short/JJ actin/NN filaments/NNS with/IN free/JJ barbed/VBN ends/NNS that/WDT participate/VBP in/IN the/DT nucleation/NN of/IN actin/NN polymerization/NN ./. 
2030_2030_3_4_18_19::POS_ACTION_BIND::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ 
367_367_32_33_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
779_779_35_36_6_7::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
350698_1_16_17_15_16::medicine.disease.symptoms::accompanied/VBN by/IN an/DT accelerated/VBN atherosclerosis/NN ./. 
671646_0_10_12_0_1::medicine.disease.treatments::Surgical/NNP treatment/NN is/VBZ an/DT important/JJ strategy/NN for/IN the/DT treatment/NN of/IN spinal/JJ tuberculosis/NN (/( TB/NN )/) 
1345_1345_12_13_3_4::POS_ACTION_BIND::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
365169_1_38_39_12_13::medicine.disease.treatments::tuberculosis/NN despite/IN recent/JJ isoniazid/NN prophylactic/NN therapy/NN ,/, non/JJ -/: tuberculous/JJ mycobacterial/JJ disease/NN ,/, chronic/JJ airways/NNS obstruction/NN ,/, and/CC spontaneous/JJ pneumothorax/NN -/: and/CC the/DT difficulties/NNS ,/, which/WDT arose/VBD ,/, in/IN diagnosis/NN and/CC management/NN of/IN 
792620_5_28_29_16_17::biology.organism_classification.lower_classifications::activity/NN in/IN carrageenan/NN rat/NN induced/VBD paw/NN oedema/NN and/CC complete/JJ Freund/NN whosewhat/NN adjuvant/JJ induced/VBN arthritis/NN in/IN rats/NNS ./. 
778878_10_15_16_18_19::None::antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN 
12271_2_94_95_4_5::None::this/DT study/NN ,/, synthetic/JJ heptapeptides/NNS (/( Lys/SYM -/: Trp/SYM -/: Tyr/SYM -/: Lys/SYM -/: Asp/NN -/: Gly/SYM -/: Asp/NN )/) coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN d/SYM -/: Lys/NNS at/IN the/DT N/NN -/: terminus/NN ,/, (/( Btn/NNP )/) dKP6/NN and/CC dK/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, were/VBD investigated/VBN for/IN their/PRP$ effects/NNS on/IN PAF/NN -/: induced/VBN inflammation/NN ./. 
763530_0_11_13_40_43::None::risk/NN factors/NNS for/IN esophageal/NN adenocarcinoma/NN and/CC its/PRP$ main/JJ precursor/NN ,/, Barrett/NNP whosewhat/NN esophagus/NN ;/: however/RB ,/, there/EX are/VBP no/DT known/JJ biological/JJ mechanisms/NNS for/IN these/DT associations/NNS or/CC regarding/VBG why/WRB only/RB some/DT patients/NNS with/IN gastroesophageal/NN reflux/NN disease/NN develop/VBP Barrett/NNP whosewhat/NN 
668570_12_1_2_25_26::None::Our/PRP$ findings/NNS of/IN no/DT association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN in/IN postoperative/JJ depressive/JJ symptoms/NNS run/VBP counter/RB to/TO other/JJ available/JJ evidence/NN ,/, potentially/RB attributable/JJ 
243_243_36_37_32_35::None::through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
776_776_28_29_24_26::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
423051_1_17_18_5_6::None::suggests/VBZ that/IN accelerated/VBN atherosclerosis/NN and/CC related/JJ cardiovascular/JJ comorbidities/NNS in/IN RA/NN are/VBP confounded/VBN not/RB only/RB by/IN traditional/JJ risk/NN factors/NNS (/( 
370565_0_30_31_33_35::None::,/, present/JJ with/IN symptoms/NNS of/IN severe/JJ neck/NN pain/NN ,/, rigidity/NN ,/, 
1061_1061_2_3_36_37::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
591709_2_5_6_20_21::None::increasing/VBG ease/NN in/IN generating/VBG genomic/JJ data/NNS ,/, as/RB well/RB as/IN recent/JJ ,/, although/IN incomplete/JJ descriptions/NNS of/IN potential/JJ COX/NNP sequences/NNS in/IN Mollusca/NNP ,/, 
1926_1926_19_20_13_14::None::as/IN that/DT of/IN FLICE/NNP ,/, Fas/NN ,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, 
178116_0_10_12_4_5::None::phosphatase/NN 2A/NN regulatory/JJ subunits/NNS affecting/VBG plant/NN innate/JJ immunity/NN ,/, energy/NN metabolism/NN ,/, and/CC flowering/NN 
725976_10_4_5_29_30::None::increasing/VBG preload/NN by/IN injecting/VBG 50/CD mul/NN of/IN 30/CD %/NN NaCl/NN demonstrated/VBD that/IN the/DT CHF/NN heart/NN had/VBD lower/JJR functional/JJ reserve/NN ;/: this/DT may/MD be/VB associated/VBN with/IN congestion/NN in/IN coronary/JJ microcirculation/NN ./. 
1373_1373_16_17_4_5::NEG_ACTION_RELATE::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
515_515_10_11_7_8::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
388589_2_57_58_95_96::None::-/: old/JJ ,/, men/NNS and/CC women/NNS ,/, body/NN mass/NN index/NN gtgt/NN =/JJ 30/CD and/CC &/CC lt/NN ;/: 30/CD kg/NN //: m/NN (/( 2/CD )/) ,/, and/CC body/NN weight/NN gtgt/NN =/JJ 60/CD and/CC &/CC lt/NN ;/: 60/CD kg/NN ,/, were/VBD identified/VBN in/IN Medline/NNP ,/, Embase/NNP ,/, 
843828_6_56_57_25_26::None::1.08/CD )/) ,/, male/JJ gender/NN (/( 2.29/CD ,/, 1.57/CD -/: 3.35/CD )/) ,/, Hoehn/NNP &/CC amp/NNP ;/: Yahr/NNP (/( HY/NNP )/) stage/NN gtgt/NN =/JJ 2.5/CD (/( 1.54/CD ,/, 1.07/CD -/: 2.22/CD )/) ,/, UPDRS/NNP motor/NN score/NN gtgt/NN =/JJ 
742394_1_14_15_15_16::None::among/IN HIV/NN -/: positive/JJ patients/NNS compared/VBN with/IN HIV/NN 
854528_1_24_25_29_30::None::Kano/NNP ,/, northern/JJ Nigeria/NNP ,/, were/VBD screened/VBN by/IN amplification/NN and/CC sequencing/NN of/IN 
186521_6_52_55_43_44::None::with/IN known/JJ clinical/JJ variables/NNS ,/, such/JJ as/IN left/JJ ventricular/JJ ejection/NN fraction/NN and/CC brain/NN natriuretic/JJ peptide/NN ./. 
776_776_24_26_4_6::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN 
785586_0_2_3_15_16::medicine.disease.treatments::Pancreaticoduodenectomy/NN (/( PD/NN )/) is/VBZ one/CD of/IN the/DT most/RBS difficult/JJ and/CC dangerous/JJ operations/NNS in/IN general/JJ surgery/NN ./. 
923_923_4_5_7_8::POS_ACTION_BIND::measurements/NNS indicate/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ the/DT affinity/NN 
596785_1_1_2_15_16::None::Since/IN December/NNP 2010/CD ,/, 15/CD pts/NNS were/VBD referred/VBN for/IN surgical/JJ ablation/NN due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ dilatation/NN 
2148_2148_4_5_56_57::POS_REG(0)_Assembly::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
151_151_64_65_0_1::None::Aprotinin/NN inhibited/VBD platelet/NN aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN )/) with/IN IC50/NN 200/CD kIU.ml-1/NN ,/, and/CC inhibited/VBD the/DT rise/NN of/IN cytosolic/JJ free/JJ calcium/NN concentration/NN in/IN platelets/NNS stimulated/VBN by/IN thrombin/NN (/( 0.1/CD U.ml-1/NN )/) in/IN the/DT absence/NN and/CC in/IN the/DT presence/NN of/IN Ca2/NN +/CC 0.5/CD mmol.L-1/NN (/( IC50/NN 117/CD and/CC 50/CD kIU.ml-1/NN ,/, respectively/RB )/) ,/, but/CC had/VBD no/DT effect/NN on/IN the/DT amounts/NNS of/IN actin/NN and/CC myosin/NN heavy/JJ 
264611_0_7_8_14_15::None::conjunction/NN with/IN an/DT independent/JJ life/NN style/NN is/VBZ one/CD of/IN the/DT major/JJ goals/NNS of/IN rehabilitation/NN 
872597_0_2_3_13_14::None::Coyotes/NNS (/( Canis/NN latrans/NNS )/) are/VBP an/DT important/JJ species/NNS in/IN human/JJ -/: inhabited/VBN areas/NNS ./. 
429251_0_11_12_2_3::None::Accumulating/VBG evidence/NN suggests/VBZ that/IN dopamine/NN (/( DA/NN )/) is/VBZ involved/VBN in/IN altering/VBG neural/JJ activity/NN and/CC 
488879_8_11_12_12_13::None::treatment/NN of/IN unifocal/JJ autonomous/JJ adenomas/NNS ./. 
333054_4_24_25_36_37::None::,/, a/DT higher/JJR lignin/NN accumulation/NN may/MD occur/VB in/IN the/DT stem/NN ,/, thus/RB implying/VBG lower/JJR quality/NN biomass/NN for/IN bioethanol/NN production/NN 
1758_1758_22_23_19_20::None::,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
938_938_14_15_9_11::None::cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
686_686_31_32_33_34::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
609976_0_7_8_0_1::medicine.disease.risk_factors::Hypertension/NN and/CC diabetes/NN as/IN risk/NN factors/NNS for/IN dementia/NN :/: A/DT secondary/JJ 
686_686_29_30_33_34::None::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
566289_3_25_26_0_1::None::TS/NN should/MD be/VB considered/VBN in/IN any/DT immunocompromised/JJ patient/NN with/IN a/DT papular/JJ facial/JJ eruption/NN reminiscent/NN of/IN acne/NN vulgaris/NN and/CC with/IN keratotic/JJ spiny/NN papules/NNS as/IN a/DT distinctive/JJ feature/NN ./. 
349514_1_22_24_20_21::None::is/VBZ important/JJ to/TO investigate/VB whether/IN heart/NN rate/NN variability/NN biofeedback/NN (/( 
367_367_0_2_24_25::POS_ACTION_LOCALIZE::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
469705_8_33_34_7_8::medicine.symptom.symptom_of::to/TO determine/VB effective/JJ depression/NN screening/NN and/CC evidence/NN -/: based/VBN interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN patients/NNS in/IN this/DT socio/NN -/: cultural/JJ context/NN ,/, as/IN intervening/VBG in/IN depression/NN may/MD decrease/VB pain/NN perception/NN ./. 
363545_0_41_42_16_17::None::great/JJ interest/NN since/IN alterations/NNS in/IN monoaminergic/JJ transmission/NN are/VBP reported/VBN to/TO be/VB related/VBN to/TO neurodegenerative/JJ diseases/NNS such/JJ as/IN Parkinson/NNP whosewhat/NN and/CC Alzheimer/NN whosewhat/NN diseases/NNS and/CC psychiatric/JJ disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, 
1286_1286_3_6_8_9::POS_ACTION_MEMBER::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, 
2222_2222_13_14_15_16::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
315603_0_16_17_18_19::None::with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT 
813_813_8_9_23_24::POS_ACTION_INTERACT::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
1087_1087_23_24_10_12::None::profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN 
256031_1_37_38_8_10::None::,/, a/DT validated/VBN computer/NN simulation/NN model/NN ,/, and/CC data/NNS from/IN the/DT ADDITION/NNP -/: Europe/NNP study/NN to/TO estimate/VB the/DT absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN 
189641_0_13_14_4_5::None::the/DT face/NN of/IN urbanisation/NN ,/, surplus/NN energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD 
1167_1167_3_4_12_13::POS_ACTION_LOCALIZE::Recent/JJ evidence/NN that/IN profilin/NN inhibits/VBZ phospholipase/NN C/NN and/CC enhances/VBZ nucleotide/NN exchange/NN of/IN actin/NN has/VBZ led/VBN some/DT 
2000_2000_0_3_10_11::None::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD co-localized/VBN with/IN beta-catenin/NN ,/, an/DT important/JJ 
846_846_16_17_12_13::POS_ACTION_BIND::the/DT polymerization/NN of/IN actin/NN from/IN A/DT :/: Tbeta4/NN ./. 
582775_5_119_120_2_3::None::Short/JJ -/: term/NN adverse/JJ events/NNS occurred/VBD in/IN 20.15/CD %/NN (/( 81/CD //: 402/CD )/) ,/, including/VBG rash/NN (/( 3.5/CD %/NN ;/: 14/CD //: 402/CD )/) ,/, pruritus/NN (/( 1.2/CD %/NN ;/: 5/CD //: 402/CD )/) ,/, nausea/NN (/( 2.2/CD %/NN ;/: 9/CD //: 402/CD )/) ,/, headache/NN (/( 0.7/CD %/NN ;/: 3/CD //: 402/CD )/) ,/, skin/NN allergies/NNS (/( 4.0/CD %/NN ;/: 16/CD //: 402/CD )/) ,/, fever/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, palpitations/NNS (/( 3.0/CD %/NN ;/: 12/CD //: 402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN ;/: 4/CD //: 402/CD )/) ,/, hypertension/NN (/( 2.2/CD %/NN 
1081_1081_39_40_5_6::None::indicate/VBP that/IN even/RB profilins/NNS of/IN highly/RB distant/JJ evolutionary/JJ origin/NN can/MD functionally/RB substitute/VB for/IN each/DT other/JJ and/CC support/VBP the/DT hypothesis/NN that/IN in/IN animal/NN cells/NNS ,/, profilins/NNS are/VBP engaged/VBN in/IN regulating/VBG either/CC the/DT stability/NN or/CC the/DT kinetic/JJ properties/NNS of/IN actin/NN filaments/NNS ./. 
510001_0_3_4_0_2::None::Sex/NN chromosomes/NNS have/VBP evolved/VBN independently/RB in/IN phylogenetically/RB 
963135_4_22_23_24_25::None::1000/CD mg/NN //: day/NN for/IN calcium/NN ,/, 800/CD IU/NN 
508103_4_24_25_18_19::medicine.disease.risk_factors::STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC normalized/VBD myocardial/JJ steatosis/NN ,/, expression/NN of/IN 
833154_0_2_3_8_9::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN department/NN ./. 
373923_0_109_110_102_105::None::diabetic/JJ patients/NNS without/IN coronary/JJ artery/NN disease/NN ,/, hypertension/NN or/CC other/JJ potential/JJ aetiologies/NNS ,/, as/IN 
398_398_20_21_10_11::None::of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
427077_12_8_9_4_5::None::-/: Klotho/NNP correlated/VBD positively/RB with/IN eGFR/NN and/CC serum/NN calcium/NN (/( Cas/NNS 
25979_5_17_18_15_16::None::on/IN ethnicity/NN (/( White/NNP ,/, Black/NNP ,/, Asian/NNP or/CC 
769684_3_8_9_6_7::medicine.disease.symptoms::completed/VBD the/DT Hospital/NNP Anxiety/NN and/CC Depression/NN Scale/NNP (/( HADS/NNS 
367_367_26_27_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
676724_2_18_19_26_27::None::achieved/VBN by/IN a/DT combination/NN of/IN streptozotocin/NN and/CC nicotinamide/NN (/( NA/NN -/: STZ/NN )/) ,/, whereas/IN 
1457_1457_34_35_34_35::None::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: 
710948_4_13_14_31_32::None::immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB after/IN beginning/VBG treatment/NN with/IN fingolimod/NN ,/, once/RB the/DT 
367_367_5_7_28_30::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
1017_1017_4_5_9_10::None::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
966_966_9_10_11_12::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN were/VBD seen/VBN in/IN 
1771_1771_19_20_15_16::None::I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
170773_3_0_1_38_39::None::We/PRP discuss/VBP the/DT challenges/NNS currently/RB faced/VBN in/IN unraveling/NN genetic/JJ factors/NNS that/WDT predispose/VBP to/TO sudden/JJ cardiac/JJ death/NN in/IN the/DT setting/NN of/IN sequela/NN of/IN coronary/JJ artery/NN disease/NN and/CC present/VB the/DT genome/NN -/: wide/JJ association/NN studies/NNS conducted/VBN in/IN recent/JJ years/NNS on/IN electrocardiographic/JJ parameters/NNS ,/, highlighting/VBG 
996_996_31_34_29_30::POS_ACTION_MEMBER::the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
593_593_5_6_19_20::POS_ACTION_HUMANMADE::show/VBP that/IN the/DT Arp2/NN subunit/NN of/IN the/DT complex/NN can/MD be/VB chemically/RB cross-linked/VBN to/TO the/DT actin-binding/JJ site/NN of/IN profilin/NN ./. 
980_980_12_13_5_6::None::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC 
1992_1992_19_20_10_11::None::reports/NNS that/IN intact/JJ talin/NN induces/VBZ cross-linking/NN as/RB well/RB as/IN filament/NN shortening/VBG on/IN actin/NN networks/NNS ./. 
2107_2107_27_28_9_10::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
543881_0_9_11_0_2::people.cause_of_death.includes_causes_of_death::Rheumatoid/JJ arthritis/NN (/( RA/NN )/) is/VBZ a/DT chronic/JJ autoimmune/JJ inflammatory/JJ disease/NN of/IN unknown/JJ aetiology/NN 
22_22_54_55_0_1::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
556_556_24_25_12_13::None::,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
307348_1_22_23_43_44::None::wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, mood/NN or/CC anxiety/NN disorders/NNS ,/, motor/NN impairments/NNS ,/, chronic/JJ pain/NN ,/, and/CC epilepsy/NN ./. 
906557_3_44_45_52_53::medicine.disease.symptoms::,/, cancer/NN ,/, diabetes/NN ,/, neurodegenerative/JJ diseases/NNS ,/, vitiligo/NN and/CC virus/NN infections/NNS ./. 
540781_2_20_21_6_7::None::HIV/NN -/: 1/CD drug/NN resistance/NN is/VBZ therefore/RB of/IN great/JJ importance/NN to/TO evaluate/VB the/DT current/JJ sensitivity/NN of/IN antiretroviral/JJ agents/NNS and/CC is/VBZ urgently/RB 
996_996_31_34_27_28::POS_ACTION_MEMBER::coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
289843_2_7_9_3_4::None::Half/NN of/IN reported/VBN cases/NNS are/VBP associated/VBN with/IN systemic/JJ diseases/NNS such/JJ as/IN arthritis/NN 
1434_1434_72_73_14_15::POS_ACTION_MEMBER::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
1633_1633_26_27_15_16::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
871_871_27_28_21_25::None::calponin/NN and/CC the/DT smooth/JJ muscle/NN myosin/NN heavy-chain/JJ isoforms/NNS of/IN SM1/NN and/CC SM2/NN )/) 
119285_0_7_9_25_26::None::simultaneous/JJ generation/NN of/IN hydroxyl/NN radical/NN (/( */SYM OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) by/IN the/DT reaction/NN of/IN ozone/NN (/( O3/NN )/) 
456531_7_14_15_31_32::medicine.medical_treatment.used_to_treat::self/NN -/: care/NN activities/NNS in/IN insulin/NN injection/NN ,/, particularly/RB among/IN Japanese/JJ patients/NNS &/CC lt/NN ;/: 65/CD years/NNS with/IN type/NN 2/CD diabetes/NN ./. 
218394_4_1_2_13_14::None::To/TO determine/VB the/DT effect/NN of/IN prehospital/JJ thrombolysis/NN for/IN acute/JJ ischemic/JJ stroke/NN administered/VBN in/IN specialized/VBN ambulances/NNS on/IN delay/NN 
702752_2_2_3_23_24::None::Here/RB we/PRP investigated/VBD the/DT role/NN of/IN piceatannol/NN ,/, a/DT well/RB -/: known/JJ Syk/NN inhibitor/NN ,/, in/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, and/CC differentiation/NN using/VBG isolated/VBN murine/JJ 
695_695_9_10_15_17::POS_ACTION_SUPPRESS::concentrations/NNS of/IN Acanthamoeba/NN profilin/NN inhibit/VBP the/DT elongation/NN rate/NN of/IN muscle/NN actin/NN filaments/NNS measured/VBN directly/RB 
686_686_13_14_23_24::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT 
345363_0_3_4_0_1::None::Factor/NN structure/NN and/CC psychometric/JJ properties/NNS of/IN the/DT 
805_805_10_11_0_4::None::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN in/IN the/DT 
334920_0_0_1_13_14::None::Studies/NNS of/IN the/DT retroviruses/NNS have/VBP focused/VBN on/IN the/DT specific/JJ interaction/NN of/IN the/DT nucleocapsid/JJ protein/NN with/IN a/DT packaging/NN 
429251_0_9_10_25_26::None::DA/NN )/) is/VBZ involved/VBN in/IN altering/VBG neural/JJ activity/NN and/CC gene/NN expression/NN in/IN a/DT zebra/NN finch/NN cortical/JJ -/: basal/JJ ganglia/NN circuit/NN specialized/VBN for/IN singing/NN 
667084_2_0_1_15_16::None::It/PRP is/VBZ also/RB associated/VBN with/IN an/DT increased/VBN prevalence/NN of/IN mental/JJ health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, and/CC suicidal/JJ 
95871_3_27_28_25_26::medicine.drug.active_moieties::,/, despite/IN elevated/JJ erythropoietin/NN (/( EPO/NN )/) levels/NNS ./. 
1946_1946_37_38_27_28::None::identical/JJ to/TO chick/NN cofilin/NN and/CC 66/CD %/NN identical/JJ to/TO chick/NN actin-depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, two/CD 
430599_3_3_4_20_21::None::proteinuria/NN ,/, diminished/VBD GFR/NN )/) are/VBP more/RBR pronounced/JJ in/IN group/NN SP/NN than/IN normotensive/JJ group/NN WKY/NN and/CC hypertensive/JJ group/NN SC/NN without/IN mesangial/JJ cell/NN injury/NN ./. 
441793_0_7_8_23_25::None::determine/VB if/IN low/JJ serum/NN 25/CD -/: hydroxyvitamin/NN D/NN (/( 25/CD [/( OH/NN ]/) D/NN )/) is/VBZ associated/VBN with/IN incident/NN heart/NN failure/NN (/( HF/NN )/) 
326684_5_3_4_17_19::None::Miltefosine/NNP is/VBZ equally/RB efficacious/JJ to/TO and/CC may/MD be/VB as/IN tolerable/JJ as/IN liposomal/JJ amphotericin/NN B/NN The/DT most/RBS common/JJ adverse/JJ effects/NNS of/IN miltefosine/NN are/VBP 
12271_2_4_5_60_61::None::this/DT study/NN ,/, synthetic/JJ heptapeptides/NNS (/( Lys/SYM -/: Trp/SYM -/: Tyr/SYM -/: Lys/SYM -/: Asp/NN -/: Gly/SYM -/: Asp/NN )/) coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
14211_8_27_28_32_33::medicine.medical_treatment.used_to_treat::the/DT outcome/NN of/IN fludarabine/NN -/: based/VBN chemotherapy/NN in/IN CLL/NN patients/NNS ./. 
322970_7_1_3_62_63::None::Multilevel/JJ logistic/JJ regression/NN models/NNS controlled/VBN for/IN individual/JJ characteristics/NNS and/CC testedfor/NN interaction/NN between/IN period/NN and/CC SES/NN In/IN both/DT periods/NNS ,/, high/JJ SES/NN respondents/NNS (/( in/IN all/DT indicators/NNS )/) had/VBD lower/JJR current/JJ smoking/NN levels/NNS and/CC higher/JJR cessation/NN ratios/NNS than/IN those/DT of/IN middle/JJ or/CC low/JJ SES/NNP Inequalities/NNS in/IN current/JJ smoking/NN increased/VBD significantly/RB in/IN poorly/RB educated/VBN adults/NNS of/IN 45/CD -/: 64/CD years/NNS of/IN age/NN (/( Odds/NNS Ratio/NN (/( OR/NN )/) 
275947_1_20_21_16_18::medicine.risk_factor.diseases::alphanu/NN integrin/NN in/IN bladder/NN cancer/NN decreases/VBZ the/DT infection/NN efficiency/NN of/IN adenovirus/NN 
159983_7_18_19_7_8::None::affinity/NN of/IN methyl/NN eugenol/NN for/IN the/DT resting/VBG and/CC inactivated/VBN states/NNS of/IN the/DT channel/NN also/RB demonstrated/VBD that/IN methyl/NN eugenol/NN 
872_872_6_7_8_9::None::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN 
411693_2_26_28_10_11::None::value/NN of/IN maximum/NN standardized/JJ uptake/NN value/NN (/( SUVmax/NN )/) determined/VBN by/IN pancreatic/JJ ductal/JJ cancers/NNS is/VBZ also/RB applicable/JJ for/IN other/JJ pancreatic/JJ tumors/NNS ./. 
2146_2146_14_15_11_13::None::both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
816806_0_11_12_26_27::None::MDR/NN )/) has/VBZ fueled/VBN considerable/JJ interest/NN in/IN the/DT development/NN of/IN novel/JJ synthetic/JJ antitumor/NN agents/NNS with/IN cytotoxicity/NN against/IN cancer/NN cell/NN lines/NNS with/IN MDR/NN 
800292_15_29_30_33_35::None::and/CC open/JJ surgical/JJ access/NN could/MD influence/VB clinical/JJ decision/NN making/NN ./. 
1647_1647_17_18_13_15::None::thymosin/NN beta4/NN and/CC profilin/NN II/CD to/TO inhibit/VB actin/NN nucleation/NN and/CC restores/VBZ 
1025_1025_14_19_0_1::POS_ACTION_SIMILAR::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ 
776_776_28_29_29_30::POS_ACTION_MEMBER::protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
590437_1_4_5_29_30::None::-/: N/NN -/: methyl/NN -/: gamma/NN -/: [/( 4/LS -/: (/( trifluoromethyl/NN )/) phenoxy/NN ]/) benzenepropanamine/NN hydrochloride/NN ;/: FLX/NNP )/) are/VBP frequently/RB used/VBN to/TO treat/VB depression/NN in/IN PD/NN patients/NNS ./. 
1474_1474_21_24_29_31::None::of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
397285_3_0_1_11_12::None::IL/NN -/: 10/CD ,/, an/DT anti/JJ -/: inflammatory/JJ cytokine/NN associated/VBN with/IN tumour/NN malignancy/NN ,/, causes/VBZ 
878537_3_10_11_24_25::None::calculated/VBN in/IN 2179/CD patients/NNS who/WP underwent/VBD a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT Intermountain/NNP Heart/NNP Collaborative/NNP Study/NNP ./. 
32435_3_23_24_29_30::None::and/CC fatigue/NN in/IN addition/NN to/TO measures/NNS of/IN depression/NN ,/, anxiety/NN ,/, and/CC posttraumatic/JJ 
567_567_10_11_20_21::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
849947_0_7_8_0_1::None::Congenital/JJ peritoneopericardial/JJ diaphragmatic/JJ hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
1486_1486_24_25_60_61::POS_ACTION_STIMULATE::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
721_721_13_14_9_10::POS_ACTION_LOCALIZE::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC 
1439_1439_24_25_16_17::None::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
503061_9_16_17_7_8::None::study/NN shows/VBZ that/IN NXT/NNP can/MD inhibit/VB the/DT development/NN of/IN diabetic/JJ retinopathy/NN and/CC suggests/VBZ a/DT new/JJ potential/JJ 
16_16_28_29_32_33::POS_ACTION_DISRUPT::expected/VBN ,/, since/IN beta-catenin/NN binding/NN disrupts/VBZ the/DT alpha-catenin/NN dimer/NN ./. 
725976_10_10_11_18_19::None::of/IN 30/CD %/NN NaCl/NN demonstrated/VBD that/IN the/DT CHF/NN heart/NN had/VBD lower/JJR functional/JJ reserve/NN ;/: this/DT 
556_556_10_11_12_13::None::nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
93_93_6_7_54_55::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
322_322_19_20_19_20::None::the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
865_865_11_14_17_18::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
156299_3_28_30_12_13::medicine.disease.treatments::two/CD or/CC three/CD radiofrequency/NN (/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN malignant/JJ lung/NN tumors/NNS with/IN a/DT maximum/JJ 
178597_0_13_14_30_31::None::based/VBN on/IN the/DT infusion/NN of/IN high/JJ numbers/NNS of/IN T/NN -/: cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN 
288_288_10_12_13_14::None::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ 
1716_1716_17_18_4_5::None::results/NNS demonstrate/VBP that/IN cofilin/NN plays/VBZ a/DT crucial/JJ role/NN in/FW vivo/FW in/IN rapid/JJ remodeling/NN of/IN the/DT cortical/JJ actin/NN meshwork/NN into/IN bundles/NNS 
855088_0_16_17_6_7::None::the/DT Arndt/NNP endobronchial/JJ blocker/NN has/VBZ not/RB gained/VBN widespread/JJ acceptance/NN during/IN video/NN -/: assisted/VBN thoracoscopic/JJ surgery/NN (/( VATS/NNS 
169857_11_12_13_18_19::None::,/, 86.7/CD %/NN experienced/VBD a/DT significant/JJ AHI/NNP reduction/NN to/TO moderate/JJ or/CC mild/JJ disease/NN 
173493_0_13_14_19_20::None::actuated/VBN dry/JJ -/: powder/NN inhaler/NN designed/VBN to/TO deliver/VB similar/JJ combinations/NNS of/IN budesonide/NN and/CC 
2064_2064_8_9_6_7::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN 
226600_0_1_2_8_9::medicine.drug_ingredient.active_moiety_of_drug::Although/IN fluoridated/JJ toothpastes/NNS are/VBP among/IN the/DT most/RBS accessible/JJ fluoride/NN sources/NNS for/IN caries/NNS 
1977_1977_22_23_16_17::None::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
1069_1069_29_30_26_27::POS_ACTION_BIND::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
125255_5_32_34_20_21::medicine.disease.risk_factors::,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: myocardial/JJ infarction/NN remodeling/NN or/CC heart/NN failure/NN ,/, and/CC post/NN 
567_567_7_9_20_21::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
710948_4_38_39_8_9::None::disease/NN ,/, the/DT patient/NN developed/VBD immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB after/IN beginning/VBG treatment/NN with/IN fingolimod/NN ,/, once/RB the/DT PML/NN had/VBD become/VBN stabilised/VBN ./. 
604261_0_33_34_41_44::medicine.medical_treatment.used_to_treat::glutamate/NN release/NN inhibitor/NN riluzole/NN ,/, a/DT drug/NN currently/RB used/VBN to/TO treat/VB amyotrophic/JJ lateral/JJ sclerosis/NN ,/, can/MD induce/VB 
112_112_18_19_14_16::POS_ACTION_MEMBER::a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
414579_11_42_44_22_23::None::These/DT differences/NNS in/IN arterial/JJ pressures/NNS and/CC use/NN of/IN norepinephrine/NN between/IN the/DT groups/NNS were/VBD not/RB found/VBN to/TO be/VB significant/JJ when/WRB entered/VBN in/IN the/DT binary/JJ logistic/JJ regression/NN model/NN ./. 
799750_8_4_5_13_15::None::borderline/JJ and/CC malignant/JJ phyllode/NN tumors/NNS have/VBP different/JJ distant/JJ metastasis/NN risk/NN ,/, different/JJ primary/JJ tumor/NN size/NN and/CC different/JJ 
247832_2_35_36_6_7::medicine.disease.symptoms::studies/NNS suggest/VBP that/IN inflammatory/JJ processes/NNS have/VBP emerged/VBN critical/JJ in/IN the/DT pathogenesis/NN of/IN CVD/NNP in/IN OSAS/NNP A/NNP range/NN of/IN circulating/VBG inflammatory/JJ molecules/NNS has/VBZ been/VBN identified/VBN and/CC measured/VBN ,/, with/IN a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ 
1254_1254_11_12_9_11::None::localization/NN of/IN the/DT actin-binding/JJ protein/NN cofilin/NN in/IN stimulated/VBN human/JJ 
750_750_7_8_21_22::None::integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ with/IN and/CC might/MD be/VB mediated/VBN by/IN its/PRP$ enhanced/VBN binding/NN to/TO talin/NN ./. 
202727_3_10_11_2_3::None::Exclusive/JJ breast/NN feeding/NN reduces/VBZ infant/NN mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN 
1122_1122_23_24_8_9::POS_ACTION_BIND::could/MD regulate/VB the/DT actin/NN binding/NN and/CC bundling/VBG properties/NNS of/IN fimbrin/NN ,/, or/CC it/PRP could/MD regulate/VB the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
350981_0_29_30_5_6::None::Anxiety/NN and/CC Affective/JJ Spectrum/NN Disorder/NN of/IN Mind/NNP and/CC Body/NNP -/: The/NNP ALPIM/NNP (/( Anxiety/NN -/: Laxity/NN -/: Pain/NN -/: Immune/JJ -/: Mood/NN )/) Syndrome/NN :/: A/DT Preliminary/JJ Report/NNP ./. 
1617_1617_2_3_21_22::POS_REG(0)_ASSEMBLE::The/DT protein/NN profilin/NN binds/VBZ to/TO both/DT actin/NN and/CC the/DT head/NN groups/NNS of/IN poly/NN )/) phosphoinositide/NN )/) s/NNS and/CC may/MD regulate/VB both/DT actin/NN assembly/NN and/CC the/DT 
246_246_11_13_3_4::None::A/DT 2.2-kb/JJ truncated/VBN NRP1/NN cDNA/NN was/VBD cloned/VBN that/IN encodes/VBZ a/DT 644-aa/JJ soluble/JJ NRP1/NN (/( sNRP1/NN )/) 
874_874_10_11_7_8::POS_ACTION_COLOCALIZE::demonstrate/VBP that/IN histone/NN H3/NN and/CC histone/NN H4/NN synthesized/VBN in/IN young/JJ 
1296_1296_9_10_3_4::POS_REG(+)_MODIFY::Stimulus-dependent/JJ disorganization/NN of/IN actin/NN filaments/NNS induced/VBN by/IN overexpression/NN of/IN cofilin/NN in/IN C2/NN myoblasts/NNS 
242314_4_7_9_77_78::None::ORS/NN )/) and/CC zinc/NN sulphate/NN dispersible/JJ tablets/NNS for/IN diarrhea/NN were/VBD available/JJ in/IN all/DT HC/NNP IIs/NNP and/CC IIIs/NNS and/CC in/IN only/RB 60/CD %/NN of/IN HC/NNP IVs/NNP Procaine/NNP benzyl/NN penicillin/NN injection/NN powder/NN for/IN treatment/NN of/IN sepsis/NN was/VBD available/JJ in/IN the/DT majority/NN of/IN all/DT HCs/NNS with/IN :/: 100/CD %/NN of/IN HC/NN of/IN IVs/NNS ,/, 83/CD %/NN of/IN HC/NN IIIs/NNS and/CC 82/CD %/NN of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN 
260299_3_5_6_26_27::None::we/PRP report/VBP the/DT case/NN of/IN a/DT 49/CD -/: year/NN -/: old/JJ ,/, chronic/JJ smoker/NN ,/, who/WP incidentally/RB had/VBD a/DT laryngeal/JJ growth/NN detected/VBN during/IN flexible/JJ bronchoscopy/NN examination/NN for/IN evaluation/NN 
259277_3_22_23_17_18::medicine.disease.risk_factors::,/, hypertension/NN and/CC diabetes/NN in/IN patients/NNS with/IN lacunar/NN stroke/NN ,/, and/CC vascular/JJ 
619_619_26_29_43_44::None::the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
118_118_11_12_4_5::POS_ACTION_COPRECIPITATE::of/IN beta-catenin/NN or/CC E-cadherin/NN immunoprecipitates/NNS from/IN BMMC/NN lysate/NN revealed/VBD that/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
501715_7_24_26_17_20::medicine.risk_factor.diseases::in/IN patients/NNS with/IN chronic/JJ kidney/NN disease/NN and/CC in/IN those/DT with/IN diabetes/NN mellitus/NN ./. 
1061_1061_19_20_36_37::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1055_1055_0_1_22_23::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
803668_11_0_1_21_22::None::Individuals/NNS living/VBG with/IN MS/NN who/WP report/VBP high/JJ levels/NNS of/IN chronic/JJ pain/NN and/CC depressive/JJ symptoms/NNS may/MD benefit/VB from/IN treatment/NN approaches/NNS that/WDT can/MD address/VB sleep/NN ,/, fatigue/NN 
381889_8_34_35_18_19::None::,/, self/NN reported/VBD health/NN status/NN (/( Short/JJ Form/NN -/: 36/CD Health/NNP Survey/NN )/) and/CC anxiety/NN //: depression/NN (/( Hospital/NN Anxiety/NN and/CC Depression/NN Scale/NNP 
367_367_24_25_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
237202_1_23_24_42_43::None::oral/JJ triple/JJ regimen/NN administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN recurrent/JJ hepatitis/NN C/NN ,/, one/CD with/IN GT/NN 1a/NN and/CC 5/CD with/IN GT/NN 1b/NN ./. 
565841_0_3_5_9_10::None::Several/JJ clinical/JJ and/CC epidemiological/JJ studies/NNS demonstrated/VBD an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
128715_9_28_29_30_31::None::-/: 10/CD &/CC amp/NN ;/: TGF/NN -/: beta/NN production/NN 
202451_1_11_12_9_10::medicine.drug.active_moieties::of/IN the/DT host/NN N2/NN ,/, N5/NN -/: bis/NN (/( 
157_157_1_2_14_15::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT 
567_567_20_21_14_15::None::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
512613_1_22_23_1_2::None::Neuroticism/NNP correlated/VBD strongly/RB with/IN the/DT general/JJ distress/NN //: negative/JJ affectivity/JJ symptoms/NNS (/( depressed/JJ mood/NN ,/, anxious/JJ mood/NN ,/, worry/NN )/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS 
255381_4_0_2_8_9::None::The/DT National/NNP Cancer/NNP registry/NN was/VBD searched/VBN for/IN esophageal/NN cancers/NNS from/IN 1986/CD to/TO 
1486_1486_24_25_41_44::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
93_93_22_23_28_29::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1553_1553_38_39_32_33::POS_ACTION_COLOCALIZE::daltons/NNS )/) ,/, fimbrin/NN (/( 68,000/CD daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS 
547287_4_9_10_15_16::medicine.disease.risk_factors::types/NNS of/IN gynecological/JJ cancer/NN was/VBD 39.0/CD %/NN higher/JJR in/IN colorectal/JJ cancer/NN patients/NNS than/IN 
900999_12_25_26_17_18::medicine.disease.symptoms::characters/NNS of/IN smaller/JJR tumor/NN size/NN and/CC normal/JJ serum/NN BUN/NN level/NN at/IN diagnosis/NN ./. 
1168_1168_26_27_29_30::POS_ACTION_LOCALIZE::member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN filament/NN bundling/VBG or/CC 
1075_1075_8_9_11_12::None::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN 
1850_1850_0_1_10_11::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
242314_4_135_136_66_67::None::of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN only/RB 30/CD %/NN of/IN the/DT HC/NNP IIs/NNPS and/CC 40/CD %/NN of/IN the/DT HC/NN IVs/NNS The/DT most/RBS uncommon/JJ were/VBD child/NN -/: friendly/JJ priority/NN medicines/NNS for/IN malaria/NN with/IN :/: Artesunate/NN injection/NN in/IN only/RB 6/CD %/NN of/IN HC/NNP IIs/NNP ,/, 14/CD %/NN of/IN HC/NN IIIs/NNS and/CC 20/CD %/NN of/IN HC/NN IVs/NNS ;/: Artemether/NNP lumefantrine/NN dispersible/JJ tablets/NNS and/CC rectal/JJ artesunate/NN were/VBD missing/VBG 
13078_0_18_19_17_18::None::childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN patients/NNS :/: IL/NN -/: 
1850_1850_10_11_0_1::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
710191_0_1_2_24_26::medicine.medical_treatment.used_to_treat::Prolonged/JJ radiation/NN time/NN and/CC low/JJ nadir/NN hemoglobin/NN during/IN postoperative/JJ concurrent/JJ chemoradiotherapy/NN are/VBP both/DT poor/JJ prognostic/JJ factors/NNS with/IN synergistic/JJ effect/NN on/IN locally/RB advanced/JJ head/NN and/CC neck/NN cancer/NN patients/NNS ./. 
161979_1_52_53_34_35::people.cause_of_death.includes_causes_of_death::genomic/JJ changes/NNS in/IN glioblastoma/NN ,/, new/JJ correlations/NNS have/VBP been/VBN discovered/VBN between/IN alterations/NNS at/IN the/DT genomics/NNS level/NN and/CC radiological/JJ imaging/NN features/NNS in/IN cancer/NN patients/NNS ./. 
2198_2198_20_21_5_6::None::-/: or/CC islet-type/JJ glucokinase/NN was/VBD transiently/RB expressed/VBN in/IN COS-7/NN cells/NNS ,/, the/DT expressed/VBN glucokinase/NN was/VBD also/RB co-localized/VBN with/IN actin/NN filaments/NNS in/IN the/DT 
364545_7_15_16_10_11::None::MS/NN type/NN 1/CD fimbriae/NN in/IN the/DT induction/NN of/IN cytokine/NN expression/NN and/CC secretion/NN 
769586_0_1_2_0_1::medicine.disease.symptoms::Subclinical/JJ atherosclerosis/NN has/VBZ been/VBN recently/RB 
618_618_3_4_1_2::None::How/WRB profilin/NN promotes/VBZ actin/NN filament/NN assembly/NN in/IN 
2107_2107_15_16_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
2076_2076_8_9_16_18::None::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN 
259511_0_15_16_6_7::None::year/NN -/: old/JJ male/NN with/IN past/JJ medical/JJ history/NN of/IN benign/JJ prostatic/JJ hyperplasia/NN presented/VBN to/TO the/DT emergency/NN 
296387_0_11_12_8_9::None::,/, an/DT increasing/VBG number/NN of/IN acute/JJ gastroenteritis/NN cases/NNS were/VBD reported/VBN 
1534_1534_26_29_16_17::None::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
1916_1916_4_5_19_20::POS_ACTION_BIND::our/PRP$ knowledge/NN ,/, AF-6/NN is/VBZ the/DT only/JJ integral/JJ component/NN in/IN cell-cell/JJ junctions/NNS discovered/VBN thus/RB far/RB that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD 
332464_0_4_5_0_1::None::Low/JJ -/: density/NN lipoprotein/NN cholesterol/NN (/( LDL/NN -/: 
259065_5_35_36_2_3::None::Correlations/NNS between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN ,/, depression/NN ,/, and/CC personality/NN disorders/NNS )/) were/VBD also/RB examined/VBN and/CC compared/VBN to/TO those/DT generated/VBN using/VBG explicit/JJ measures/NNS 
1061_1061_24_25_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
398_398_20_21_8_9::None::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
93_93_57_58_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
703552_5_26_27_33_34::None::family/NN members/NNS in/IN retinal/JJ layers/NNS ,/, using/VBG an/DT in/FW vivo/FW model/NN of/IN type/NN 1/CD 
377_377_12_13_10_11::POS_ACTION_COLOCALIZE::bands/NNS corresponding/VBG to/TO actin/NN and/CC fimbrin/NN and/CC several/JJ proteins/NNS 
473269_0_8_10_20_24::None::)/) is/VBZ a/DT neurodegenerative/JJ disorder/NN characterized/VBN by/IN loss/NN of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ 
162957_0_38_39_43_44::None::atopic/JJ dermatitis/NN (/( AD/NN )/) elicited/VBN by/IN epicutaneous/JJ sensitization/NN with/IN ovalbumin/NN (/( 
263791_3_38_39_8_9::None::early/JJ and/CC aggressive/JJ control/NN of/IN inflammation/NN in/IN RA/NN patients/NNS ,/, particularly/RB those/DT with/IN seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC gt/NN ;/: 10/CD years/NNS )/) ,/, and/CC //: or/CC extra/JJ -/: articular/JJ manifestations/NNS 
1498_1498_15_16_4_5::None::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD 
710476_3_2_3_0_1::None::Participants/NNS completed/VBD measures/NNS of/IN global/JJ mental/JJ 
1105_1105_0_1_6_9::None::p21/NN (/( p21WAF1/Cip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN 
714308_1_30_31_16_17::None::(/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ PARP/NN inhibitors/NNS are/VBP being/VBG developed/VBN to/TO treat/VB various/JJ malignancies/NNS ./. 
597523_1_19_20_18_20::None::)/) and/CC Brassica/NNP rapa/NN (/( turnip/NN )/) 
1144_1144_17_18_11_13::None::to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
450573_0_33_34_26_27::None::death/NN proteins/NNS whosewhat/NN expression/NN and/CC their/PRP$ correlation/NN following/VBG facial/JJ nerve/NN distal/JJ transection/NN or/CC crush/NN 
431465_3_29_30_12_13::None::afforded/VBD the/DT azide/NN product/NN in/IN 70/CD %/NN ee/NN ,/, representing/VBG a/DT Mn/NN -/: catalyzed/VBN enantioselective/JJ aliphatic/JJ C/NN -/: H/NN azidation/NN reaction/NN ./. 
907653_2_1_2_23_24::None::Our/PRP$ aim/NN was/VBD to/TO compare/VB in/IN regular/JJ care/NN the/DT effects/NNS of/IN (/( 1/LS )/) an/DT Internet/NN -/: based/VBN patient/NN provider/NN communication/NN service/NN (/( IPPC/NN )/) ,/, (/( 
1321_1321_0_4_9_11::None::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN 
538077_4_22_23_22_24::biology.organism_classification.lower_classifications::IC50/NN values/NNS against/IN Plasmodium/NN falciparum/NN 3D7/NN of/IN 0.310/CD 
300324_0_0_1_50_51::None::In/IN this/DT study/NN ,/, hyaluronic/JJ acid/NN (/( HA/NN )/) //: poly/NN (/( lactic/NN -/: co/SYM -/: glycolic/JJ acid/NN ,/, PLGA/NN )/) core/NN //: shell/NN fiber/NN meshes/VBZ loaded/VBN with/IN epigallocatechin/NN -/: 3/LS -/: O/SYM -/: gallate/NN (/( EGCG/NN )/) (/( HA/NNP //: PLGA/NNP -/: E/NN )/) for/IN application/NN to/TO tissue/NN engineering/NN scaffolds/NNS for/IN skin/NN regeneration/NN 
2013_2013_0_1_9_10::POS_ACTION_BIND::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
1486_1486_35_40_32_33::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
763152_3_11_12_14_15::biology.organism_classification.lower_classifications::nonassociative/JJ behavior/NN in/IN Drosophila/FW where/WRB female/JJ flies/NNS detect/VBP the/DT presence/NN 
288485_0_22_23_32_33::None::IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP Thirty/CD 
1206_1206_3_4_5_6::POS_ACTION_MODIFY::Requirement/NN of/IN yeast/NN fimbrin/NN for/IN actin/NN organization/NN and/CC morphogenesis/NN 
467117_12_0_1_9_10::None::Canine/NN orbital/JJ rhabdomyosarcoma/NN is/VBZ a/DT highly/RB malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC 
63_63_25_26_44_45::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, 
1817_1817_9_10_4_5::None::is/VBZ consistent/JJ with/IN cofilin/NN activation/NN being/VBG required/VBN for/IN actin/NN reorganization/NN during/IN exocytosis/NN 
1380_1380_34_35_36_37::None::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
202687_5_26_27_13_14::None::of/IN two/CD different/JJ phenols/NNS and/CC the/DT ortho/NN and/CC para/NN C/NN -/: H/NN bond/NN of/IN phenols/NNS were/VBD coupled/VBN together/RB ./. 
275933_7_56_57_1_2::None::When/WRB describing/VBG leukemia/NN predisposition/NN due/JJ to/TO hereditary/JJ cancer/NN syndromes/NNS ,/, the/DT following/VBG 6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN repair/NN syndromes/NNS ,/, (/( 2/LS )/) cell/NN cycle/NN //: differentiation/NN syndromes/NNS ,/, (/( 3/LS )/) bone/NN marrow/NN failure/NN syndromes/NNS ,/, (/( 4/LS )/) telomere/NN maintenance/NN syndromes/NNS ,/, (/( 
212_212_27_28_24_25::None::the/DT ectodomain/NN of/IN E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN 
422301_6_28_29_24_25::biology.organism_classification.lower_classifications::shells/NNS of/IN some/DT turtles/NNS are/VBP homologous/JJ to/TO reptilian/JJ scales/NNS ./. 
1380_1380_26_27_38_39::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
648_648_6_9_1_3::POS_ACTION_MEMBER::Human/JJ platelet/NN P-235/NN ,/, a/DT talin-like/JJ actin/NN binding/NN protein/NN ,/, binds/VBZ selectively/RB 
1535_1535_7_8_11_14::POS_ACTION_COLOCALIZE::lipids/NNS and/CC express/VBP desmin/JJ intermediate/JJ filaments/NNS ,/, alpha-smooth/JJ muscle/NN actin/NN ,/, and/CC smooth/VB 
119285_0_5_6_14_15::None::work/NN ,/, simultaneous/JJ generation/NN of/IN hydroxyl/NN radical/NN (/( */SYM OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN 
99729_5_6_7_15_18::None::-/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ attack/NN ,/, peripheral/JJ arterial/JJ disease/NN ,/, myocardial/JJ infarction/NN 
279_279_12_13_30_31::None::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
46_46_3_4_8_9::POS_REG(+)_DECREASE::Addition/NN of/IN Acanthamoeba/NN profilin/NN in/IN molar/JJ ratios/NNS to/TO actin/NN of/IN about/IN 1.1:1/CD 
526387_8_0_1_11_12::None::These/DT results/NNS suggest/VBP that/IN DcEV/NN is/VBZ a/DT novel/JJ species/NNS of/IN the/DT genus/NN Enterovirus/NN in/IN Picornaviridae/NNP 
1321_1321_9_11_26_27::None::)/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1580_1580_25_26_18_19::None::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
159605_0_25_26_24_26::None::degradation/NN of/IN organic/JJ dyes/NNS with/IN hydrogen/NN peroxide/NN 
678566_0_4_5_27_28::None::putative/JJ Major/JJ Facilitator/NNP Superfamily/NNP (/( MFS/NNP )/) transporter/NN ,/, SV2A/NN ,/, is/VBZ the/DT target/NN for/IN levetiracetam/NN (/( LEV/NN )/) ,/, which/WDT is/VBZ a/DT successful/JJ anti/JJ -/: epileptic/JJ drug/NN ./. 
235710_2_3_4_9_10::None::To/TO investigate/VB the/DT adjuvant/JJ cabergoline/NN therapy/NN effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN 
1546_1546_12_13_5_6::POS_ACTION_MEMBER::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
1901_1901_25_28_31_32::POS_ACTION_MEMBER::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, 
93_93_54_55_57_58::POS_ACTION_DOWNREGULATE::,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1052_1052_18_20_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
1760_1760_13_14_5_6::None::phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
18_18_6_7_18_20::None::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
1178_1178_14_15_2_3::None::Recombinant/JJ human/JJ beta-catenin/NN can/MD simultaneously/RB bind/VB to/TO the/DT alpha-catenin/actin/NN complex/NN but/CC does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
660282_0_0_1_9_10::None::To/TO evaluate/VB the/DT influence/NN of/IN timing/NN of/IN salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN 
2000_2000_0_3_4_5::None::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD 
1737_1737_39_40_58_59::None::the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
89_89_17_18_1_2::None::Although/IN talin/NN has/VBZ been/VBN suggested/VBN to/TO act/VB as/IN a/DT linkage/NN protein/NN mediating/VBG the/DT attachment/NN of/IN GPIIb-IIIa/NN to/TO actin/NN filaments/NNS ,/, direct/JJ 
910_910_3_4_9_11::None::Isolation/NN of/IN human/JJ delta-catenin/NN and/CC its/PRP$ binding/NN specificity/NN with/IN presenilin/NN 1/CD ./. 
28653_0_1_2_32_33::None::Photochemical/JJ reduction/NN of/IN iron/NN and/CC iron/NN uptake/NN by/IN Microcystis/NNPS were/VBD investigated/VBN in/IN a/DT freshwater/JJ medium/NN (/( pH/NN 8/CD )/) containing/VBG a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN (/( Mg/NN )/) ion/NN concentrations/NNS (/( 0.002/CD 
2_2_11_13_9_10::POS_ACTION_BIND::formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN */SYM DNA/NN complex/NN 
748_748_20_21_13_14::POS_ACTION_BIND::fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
109645_7_11_12_12_13::None::the/DT non/JJ -/: BRCA/NN families/NNS with/IN a/DT 6.36/CD 
156299_3_28_30_16_17::None::(/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN malignant/JJ lung/NN tumors/NNS with/IN a/DT maximum/JJ 
539_539_5_6_18_19::POS_ACTION_Causal::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
524_524_40_41_25_26::POS_ACTION_SQSIMILAR::similarity/NN with/IN host/NN WASP/NNP family/NN proteins/NNS :/: an/DT acidic/JJ stretch/NN ,/, an/DT actin/NN monomer-binding/JJ region/NN ,/, and/CC a/DT cofilin/NN homology/NN sequence/NN ./. 
528491_0_39_40_1_2::medicine.disease.symptoms::Chronic/JJ pain/NN is/VBZ common/JJ during/IN childhood/NN and/CC adolescence/NN and/CC is/VBZ associated/VBN with/IN negative/JJ outcomes/NNS such/JJ as/IN increased/VBN severity/NN of/IN pain/NN ,/, reduced/VBD function/NN (/( eg/FW missing/VBG school/NN )/) ,/, and/CC low/JJ mood/NN (/( eg/FW high/JJ levels/NNS of/IN depression/NN and/CC anxiety/NN )/) ./. 
22703_5_11_13_14_15::medicine.drug.active_moieties::significantly/RB reduced/VBD the/DT adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) -/: mediated/VBN 
761082_2_17_18_38_39::None::score/NN in/IN predicting/VBG pregnancy/NN in/IN infertile/JJ Italian/JJ endometriosis/NN women/NNS ;/: (/( ii/LS )/) evaluate/VB the/DT predictive/JJ value/NN of/IN EFI/NNP score/NN on/IN ART/NN outcome/NN for/IN patients/NNS who/WP previously/RB attempted/VBD 
95871_5_8_9_10_11::medicine.drug_ingredient.active_moiety_of_drug::was/VBD assessed/VBN for/IN norepinephrine/NN (/( NE/NN )/) levels/NNS ,/, 
1345_1345_12_13_6_7::None::WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
125255_5_45_46_43_44::None::are/VBP modified/VBN by/IN phosphorylation/NN //: de/FW -/: phosphorylation/NN and/CC 
686_686_31_32_13_14::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1761_1761_15_16_13_15::None::,/, the/DT HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN 
456127_2_31_32_22_23::None::NWs/NNS ,/, in/IN contrast/NN to/TO a/DT recent/JJ report/NN (/( Razavieh/NN A/NN et/FW al/FW ACS/NNP Nano/NNP 8/CD 
205_205_4_5_2_3::None::BACKGROUND/NN :/: p27/NN (/( Kip1/NN )/) ,/, a/DT 
249535_0_6_8_4_5::None::profile/NN of/IN serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: 
831553_2_24_26_13_14::medicine.symptom.symptom_of::(/( eg/FW ,/, depression/NN )/) ,/, physiological/JJ (/( eg/FW ,/, hypothyroidism/NN )/) mechanisms/NNS ,/, sleep/VB disorders/NNS (/( eg/FW ,/, 
142199_1_15_16_7_8::None::erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN causes/VBZ a/DT spectrum/NN of/IN symptomatology/NN ranging/VBG from/IN asymptomatic/JJ 
1169_1169_13_16_17_18::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
243_243_3_4_36_37::POS_ACTION_RELATE::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
363545_0_37_39_41_42::people.cause_of_death.includes_causes_of_death::whosewhat/NN diseases/NNS and/CC psychiatric/JJ disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, 
2107_2107_27_28_24_26::None::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
247970_0_22_23_17_18::None::CMFE/NN )/) in/IN mice/NNS treated/VBN with/IN methotrexate/NN (/( MTX/NN )/) ./. 
38849_2_14_15_21_22::None::,/, they/PRP are/VBP common/JJ in/IN murine/JJ models/NNS of/IN radiation/NN -/: induced/VBN AML/NN ,/, and/CC 
1537_1537_16_17_18_19::POS_ACTION_COLOCALIZE:::/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC brush/NN border/NN 
1535_1535_11_14_7_8::None::lipids/NNS and/CC express/VBP desmin/JJ intermediate/JJ filaments/NNS ,/, alpha-smooth/JJ muscle/NN actin/NN ,/, and/CC smooth/VB 
311030_10_14_15_0_1::medicine.drug_ingredient.active_moiety_of_drug::Dopamine/NN release/NN was/VBD stimulated/VBN by/IN applying/VBG ATP/NN which/WDT activated/VBD P2X2/NN channels/NNS specifically/RB expressed/VBN in/IN dopaminergic/JJ neurons/NNS ./. 
913_913_22_23_20_21::POS_ACTION_UNBIND::release/NN of/IN G/NN actin/NN from/IN profilin/NN or/CC promoting/VBG the/DT 
742394_1_27_28_20_21::None::with/IN HIV/NN -/: negative/JJ patients/NNS ,/, and/CC at/IN a/DT higher/JJR rate/NN ./. 
1286_1286_12_13_3_6::None::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
2146_2146_6_7_11_13::POS_ACTION_PHOSPHORYLATE::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
492693_2_23_24_120_121::medicine.drug_ingredient.active_moiety_of_drug::K/NN in/IN (/( NH3/NN )/) yCs0/NN .4/CD FeSe/NN at/IN 11/CD and/CC 13/CD GPa/NN Surprisingly/RB ,/, superconductivity/NN re/SYM -/: appeared/VBD rapidly/RB above/IN 13/CD GPa/NN ,/, with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB accompanied/VBN by/IN a/DT structural/JJ transition/NN ,/, as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS above/IN 4.9/CD K/NN The/DT observation/NN of/IN a/DT double/JJ -/: dome/NN superconducting/JJ phase/NN may/MD provide/VB a/DT hint/NN for/IN pursuing/VBG the/DT superconducting/VBG coupling/NN -/: mechanism/NN of/IN ammoniated/JJ //: non/JJ -/: 
262795_4_0_1_2_3::None::It/PRP is/VBZ clear/JJ now/RB that/IN the/DT 
1372_1372_1_2_31_32::None::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
151063_0_7_8_14_15::None::and/CC carboplatin/NN (/( CBP/NN )/) are/VBP widely/RB used/VBN for/IN the/DT combined/JJ chemotherapy/NN of/IN non/JJ 
725268_1_37_38_26_27::None::plays/NNS in/IN this/DT procedure/NN and/CC there/EX are/VBP no/DT reports/NNS of/IN how/WRB variability/NN changes/NNS with/IN predicted/VBN indifference/NN ./. 
605_605_20_21_18_19::None::products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN 
214_214_22_25_6_7::POS_ACTION_LOCALIZE-TO::exchange/NN rapidly/RB between/IN actin/NN molecules/NNS ,/, low/JJ concentrations/NNS of/IN profilin/NN can/MD overcome/VB the/DT inhibitory/JJ effects/NNS of/IN high/JJ concentrations/NNS of/IN thymosin/NN beta/NN 4/CD on/IN the/DT nucleotide/NN 
1534_1534_9_10_16_17::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN 
93177_0_31_32_12_14::None::syndrome/NN distinct/JJ from/IN multiple/JJ sclerosis/NN (/( MS/NN )/) that/WDT is/VBZ associated/VBN with/IN serum/NN aquaporin/NN -/: 4/CD immunoglobulin/NN G/NN antibodies/NNS (/( AQP4/NN -/: IgG/NN )/) ./. 
275299_5_19_20_5_6::None::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC calcium/NN signaling/NN pathways/NNS as/IN revealed/VBN by/IN gene/NN ontology/NN 
186443_2_3_4_12_14::medicine.disease.treatments::Patients/NNS diagnosed/VBD with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) 
319920_0_47_48_37_38::None:://: hostility/NN as/IN major/JJ components/NNS of/IN psychiatric/JJ symptoms/NNS in/IN acute/JJ mania/NN or/CC mixed/JJ episodes/NNS in/IN a/DT series/NN 
452979_10_15_17_13_14::None::diabetes/NN mellitus/NN among/IN blacks/NNS with/IN metabolic/JJ syndrome/NN ./. 
653_653_8_9_2_3::POS_ACTION_BIND::Identification/NN of/IN alpha-syntrophin/NN binding/NN to/TO syntrophin/NN triplet/NN ,/, dystrophin/NN ,/, and/CC utrophin/NN 
750_750_7_8_3_5::POS_ACTION_INTERACT::Increased/VBN interaction/NN of/IN beta1D/NN integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ 
741231_0_3_5_12_13::None::Relationship/NN between/IN low/JJ blood/NN pressure/NN and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN 
632_632_16_17_4_5::None::,/, regulation/NN of/IN profilin/NN function/NN is/VBZ generally/RB unknown/JJ and/CC controversy/NN exists/VBZ regarding/VBG profilin/NN effects/NNS on/IN actin/NN polymerization/NN ./. 
588835_2_10_11_0_1::None::We/PRP traced/VBD the/DT ontogenetic/JJ development/NN of/IN this/DT feature/NN in/IN 56/CD fetal/JJ specimens/NNS from/IN 10/CD 
1373_1373_16_17_11_12::POS_ACTION_MUTUALCOMPLEX::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
522_522_21_22_1_2::None::Full-length/JJ beta-catenin/NN ,/, beta-catenin/NN mutant/JJ proteins/NNS with/IN NH2-terminal/JJ deletions/NNS before/IN (/( deltaN90/NN )/) or/CC after/IN (/( deltaN131/NN ,/, deltaN151/NN )/) the/DT alpha-catenin/NN binding/NN site/NN ,/, 
1652_1652_20_21_18_19::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS 
405577_1_9_11_2_3::None::In/IN the/DT plasma/NN ,/, PCI/NN physiologically/RB inhibits/VBZ an/DT anticoagulant/JJ serine/NN protease/NN ,/, activated/VBN protein/NN 
555_555_5_6_47_48::POS_ACTION_Assembly::pull-down/JJ performed/VBN with/IN Tax/NN deletion/NN mutants/NNS and/CC peptide/NN competition/NN have/VBP localized/VBN the/DT site/NN in/IN Tax/NN critical/JJ for/IN binding/VBG CBP/p300/NN to/TO a/DT highly/RB protease-sensitive/JJ region/NN around/IN amino/NN acid/NN residues/NNS 81/CD to/TO 95/CD (/( 81QRTSKTLKVLTPPIT95/NN )/) which/WDT lies/VBZ between/IN the/DT domains/NNS previously/RB proposed/VBN to/TO be/VB important/JJ for/IN CREB/NN binding/NN and/CC Tax/NN 
323306_3_7_8_19_20::None::underwent/VBD 19/CD anesthetic/JJ procedures/NNS ,/, of/IN which/WDT 13/CD were/VBD &/CC lt/NN ;/: 2/CD h/NN in/IN duration/NN and/CC seven/CD were/VBD 
740032_2_39_40_16_17::None::the/DT FBIH/NN among/IN adult/JJ population/NN aged/JJ 25/CD -/: 64/CD years/NNS for/IN assessment/NN and/CC distribution/NN of/IN major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS (/( CVD/NN )/) ,/, preferably/RB hypertension/NN ,/, obesity/NN and/CC 
2137_2137_15_18_19_20::None::its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
342702_0_15_16_10_11::None::inflammatory/JJ and/CC immune/JJ mechanisms/NNS in/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) have/VBP fuelled/VBN 
1075_1075_11_12_22_23::None::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
265539_2_19_20_11_12::None::disease/NN of/IN the/DT CNS/NN During/IN the/DT last/JJ several/JJ decades/NNS ,/, experimental/JJ models/NNS of/IN MS/NN have/VBP 
594019_6_15_16_0_1::None::Females/NNS who/WP began/VBD running/VBG at/IN or/CC before/IN age/NN 10/CD were/VBD more/RBR likely/JJ to/TO report/VB a/DT diagnosis/NN of/IN hypothyroidism/NN versus/CC 
1771_1771_11_14_15_16::POS_ACTION_MEMBER::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
186443_2_0_1_19_20::None::Patients/NNS diagnosed/VBD with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) ,/, were/VBD compared/VBN to/TO matched/VBN non/JJ 
130_130_4_5_6_7::POS_ACTION_BIND::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC 
465207_3_4_5_6_7::medicine.disease.risk_factors::reported/VBN prevalence/NN of/IN osteoporosis/NN among/IN postmenopausal/JJ women/NNS in/IN Brazil/NNP 
231772_0_5_6_16_17::None::degradation/NN of/IN three/CD neonicotinoid/JJ insecticides/NNS (/( NIs/NNS )/) ,/, thiamethoxam/NN (/( TH/NN )/) ,/, imidacloprid/NN (/( IM/NN )/) 
1246_1246_31_32_29_31::None::IV/CD collagen/NN ,/, actin-binding/JJ protein/NN cofilin/NN ,/, profilin/NN and/CC 
1616_1616_35_36_34_35::None::for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT other/JJ 
411_411_13_14_20_21::POS_ACTION_BIND::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
157_157_14_15_8_9::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT 
609_609_19_20_21_22::None::encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
164393_5_34_35_1_2::None::Participants/NNS reported/VBD nicotine/NN craving/NN ,/, nicotine/NN withdrawal/NN symptoms/NNS ,/, and/CC substance/NN use/NN in/IN the/DT week/NN following/VBG a/DT uniform/JJ quit/VBD attempt/NN of/IN the/DT TAU/NN +/CC SCT/NN group/NN ,/, and/CC self/NN -/: reported/VBN smoking/NN 7/CD -/: day/NN point/NN prevalence/NN abstinence/NN 
712_712_15_16_27_28::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
984_984_20_21_33_34::None::the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
250_250_14_15_7_8::POS_ACTION_BIND::of/IN N-cadherin/NN and/CC alpha-catenin/NN which/WDT bind/VBP to/TO either/CC beta-catenin/NN or/CC plakoglobin/NN in/IN a/DT mutually/RB 
767824_2_15_16_22_23::None::concentrations/NNS as/IN a/DT potential/JJ predictor/NN of/IN reduced/VBN depression/NN symptoms/NNS in/IN obese/JJ adolescents/NNS during/IN long/JJ 
784_784_21_22_8_9::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
507093_0_22_23_20_21::None::highly/RB prevalent/JJ in/IN Hispanics/NNPS //: Latinos/NNPS ./. 
22_22_0_1_54_55::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
70627_9_18_19_0_1::medicine.drug.active_moieties::Cortisol/NN response/NN to/TO stress/NN differed/VBD according/VBG to/TO group/NN :/: in/IN the/DT ADHD/NNP group/NN ,/, 20min/JJ post/NN -/: test/NN cortisol/NN levels/NNS were/VBD significantly/RB 
712_712_27_28_15_16::POS_ACTION_UPREGULATE::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
307348_1_33_35_22_23::None::wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, mood/NN or/CC anxiety/NN disorders/NNS ,/, motor/NN impairments/NNS 
1069_1069_46_47_26_27::POS_ACTION_ATTACH::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
456_456_2_3_15_16::NEG_ACTION_CORELATE::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
3197_0_0_1_3_4::None::Tenofovir/NNP alafenamide/NN (/( TAF/NN )/) is/VBZ an/DT 
1069_1069_21_22_29_30::POS_ACTION_CONTAIN::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
1037_1037_27_28_24_26::None::RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
685_685_30_31_6_7::None::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
1434_1434_75_76_75_76::None::histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
930063_2_25_26_2_3::None::While/IN IV/CD thrombolysis/NN has/VBZ been/VBN shown/VBN to/TO decrease/VB morbidity/NN and/CC mortality/NN from/IN acute/JJ ischemic/JJ stroke/NN ,/, it/PRP is/VBZ limited/VBN in/IN both/DT its/PRP$ efficacy/NN in/IN certain/JJ types/NNS of/IN stroke/NN ,/, 
1140_1140_24_25_22_23::POS_ACTION_INTERACT::of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
492455_3_39_40_46_47::None::-/: Present/JJ and/CC Lifetime/NN version/NN (/( K/NN -/: SADS/NN -/: PL/NN )/) ,/, DSM/NNP 
245_245_10_11_0_1::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
1652_1652_45_46_18_19::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
13078_0_3_4_0_1::None::IL/NN -/: 10/CD gene/NN polymorphism/NN and/CC influence/NN 
1052_1052_6_8_12_13::POS_ACTION_BIND::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT 
609813_2_33_34_11_12::None::with/IN plants/NNS ,/, outline/NN steps/NNS necessary/JJ to/TO develop/VB invasive/JJ species/NNS control/VBP strategies/NNS that/WDT are/VBP based/VBN on/IN those/DT relationships/NNS ,/, and/CC use/VB the/DT invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ 
2131_2131_23_24_10_11::None::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
307_307_6_7_12_13::None::truncates/VBZ that/IN inhibit/VBP actin/NN depolymerization/NN by/IN severing/VBG activity/NN of/IN gelsolin/NN and/CC cofilin/NN ./. 
1061_1061_25_27_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
798_798_13_14_11_12::None::EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP smooth-sided/JJ bundles/NNS 
483185_4_43_44_49_50::None::changes/NNS in/IN the/DT chromosome/NN based/VBN on/IN an/DT assessment/NN of/IN telomere/NN length/NN in/IN single/JJ 
1082_1082_35_36_11_12::None::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
211391_8_17_18_27_29::None::Nile/NNP ,/, and/CC tick/VB -/: borne/VBN encephalitis/NN (/( TBE/NN )/) viruses/NNS pose/VBP substantial/JJ public/JJ health/NN problems/NNS in/IN different/JJ 
896731_2_2_3_1_2::medicine.disease.symptoms::An/DT acute/JJ MI/NNP model/NN was/VBD induced/VBN 
221936_3_30_32_33_34::people.cause_of_death.includes_causes_of_death::and/CC a/DT clustered/VBN cardiovascular/JJ disease/NN (/( CVD/NN )/) risk/NN index/NN 
872_872_11_12_6_7::POS_ACTION_BIND::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
113845_3_17_18_28_29::None::,/, lack/NN of/IN swelling/VBG ,/, bleeding/VBG ,/, pain/NN ,/, scar/NN tissue/NN formation/NN and/CC overall/JJ satisfaction/NN were/VBD observed/VBN in/IN 
1527_1527_3_4_5_8::None::The/DT interactions/NNS of/IN actin/NN with/IN thymosin/NN beta/NN 4/CD ,/, actobindin/NN and/CC 
128605_11_37_38_17_18::medicine.disease.treatments::driver/NN of/IN radio/NN chemotherapy/NN resistance/NN ,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN in/IN rectal/JJ cancer/NN ./. 
1373_1373_13_14_4_5::POS_ACTION_MUTUALCOMPLEX::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
799_799_16_17_11_12::POS_ACTION_Causal::linked/VBN to/TO the/DT actin/NN cytoskeleton/NN via/IN the/DT protein/NN talin/NN ./. 
1075_1075_22_23_11_12::POS_ACTION_PHOSPHORYLATE::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
485087_11_0_1_28_29::None::Once/RB ECMO/NNP has/VBZ been/VBN commenced/VBN ,/, if/IN the/DT tachyarrhythmia/NN remains/VBZ difficult/JJ to/TO control/VB with/IN antiarrhythmic/JJ drugs/NNS ,/, RFA/NN should/MD be/VB strongly/RB considered/VBN ,/, to/TO avoid/VB the/DT risk/NN of/IN tachycardia/NN recurrence/NN following/VBG ECMO/NN 
1069_1069_26_27_24_25::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
516597_4_8_9_16_17::None::severe/JJ isolated/VBN head/NN injuries/NNS :/: 337/CD from/IN OEF/NN ,/, 268/CD from/IN OIF/NN ,/, and/CC 42/CD 
652_652_11_12_8_9::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) 
654472_6_22_23_52_53::None::reported/VBN non/JJ -/: ocular/JJ pain/NN measures/NNS (/( numerical/JJ rating/NN scale/NN and/CC pain/NN history/NN )/) ,/, (/( B/NN )/) depression/NN and/CC (/( C/NN )/) PTSD/NN were/VBD significant/JJ and/CC moderate/JJ in/IN strength/NN (/( Pearson/NNP whosewhat/NN coefficient/NN 0.24/CD to/TO 0.60/CD 
109645_7_19_20_17_18::None::a/DT 6.36/CD %/NN proportion/NN (/( CI/NN 4.67/CD -/: 8.2/CD 
1672_1672_10_11_8_9::POS_ACTION_MEMBER::belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN 
686_686_33_34_23_24::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
980_980_18_19_5_6::None::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
607093_2_33_34_46_48::biology.organism_classification.lower_classifications::to/TO the/DT genus/NN Homo/NN but/CC documents/NNS a/DT pattern/NN of/IN morphology/NN not/RB seen/VBN in/IN eastern/JJ African/JJ early/JJ Homo/NN erectus/NN ./. 
296387_0_29_30_0_2::None::Three/CD weeks/NNS after/IN Typhoon/NNP Haiyan/NNP ,/, an/DT increasing/VBG number/NN of/IN acute/JJ gastroenteritis/NN cases/NNS were/VBD reported/VBN in/IN Kananga/NNP ,/, Leyte/NNP ,/, an/DT area/NN where/WRB evacuated/VBN residents/NNS had/VBD returned/VBN home/RB two/CD days/NNS after/IN the/DT disaster/NN 
821060_0_30_34_24_25::medicine.medical_treatment.used_to_treat::-/: versus/CC -/: leukemia/NN (/( GVL/NN )/) effect/NN of/IN allogeneic/JJ stem/NN cell/NN transplantation/NN (/( allo/NN -/: 
334920_0_12_13_20_21::None::interaction/NN of/IN the/DT nucleocapsid/JJ protein/NN with/IN a/DT packaging/NN signal/NN in/IN the/DT viral/JJ RNA/NN as/IN important/JJ 
405577_1_12_15_16_17::medicine.drug_ingredient.active_moiety_of_drug::serine/NN protease/NN ,/, activated/VBN protein/NN C/NN (/( APC/NN )/) ./. 
424911_2_84_86_10_11::None::complexes/NNS such/JJ as/IN fac/NN -/: Ir/NN (/( ppy/NN )/) 3/CD (/( ppy/NN =/JJ 2/CD -/: phenylpyridine/NN )/) and/CC fac/SYM -/: Ir/NN (/( tpy/NN )/) 3/CD (/( tpy/NN =/JJ 2/CD -/: (/( 4/LS ''/'' -/: tolyl/NN )/) pyridine/NN )/) possess/VBP C3/NN -/: symmetric/JJ structures/NNS and/CC excellent/JJ photophysical/JJ properties/NNS as/IN phosphorescence/NN materials/NNS ,/, which/WDT make/VBP them/PRP important/JJ candidates/NNS for/IN use/NN in/IN biological/JJ applications/NNS such/JJ as/IN chemosensors/NNS ,/, biolabeling/NN ,/, living/VBG cell/NN staining/NN ,/, in/FW vivo/FW tumor/NN imaging/NN ,/, and/CC anticancer/JJ agents/NNS ./. 
607_607_8_9_19_20::None::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC 
1652_1652_18_19_20_21::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS 
2107_2107_7_8_39_40::POS_REG(0)_MODIFY::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
297982_0_1_3_4_5::medicine.drug_ingredient.active_moiety_of_drug::Nanosized/JJ titanium/NN dioxide/NN (/( TiO2/NN )/) particles/NNS belong/VBP 
2222_2222_39_40_15_16::NEG_ACTION_COLOCALIZE::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
26717_2_48_49_67_68::None::,/, diabetes/NN ,/, smoking/NN ,/, systolic/JJ blood/NN pressure/NN ,/, lipid/NN levels/NNS ,/, albumin/NN -/: creatinine/NN ratio/NN ,/, physical/JJ activity/NN ,/, C/NN -/: reactive/JJ protein/NN ,/, body/NN 
18_18_4_5_6_7::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
113845_3_21_22_17_18::medicine.symptom.symptom_of::,/, lack/NN of/IN swelling/VBG ,/, bleeding/VBG ,/, pain/NN ,/, scar/NN tissue/NN 
565841_0_5_6_9_10::None::and/CC epidemiological/JJ studies/NNS demonstrated/VBD an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
834587_19_8_9_17_18::None::option/NN in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ resulted/VBD in/IN equivalent/JJ 
265345_3_21_22_15_18::people.cause_of_death.includes_causes_of_death::haematuria/NN -/: associated/VBN acute/JJ kidney/NN injury/NN in/IN immunoglobulin/NN A/NN nephropathy/NN ./. 
119285_0_17_18_32_33::None::sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) by/IN the/DT reaction/NN of/IN ozone/NN (/( O3/NN )/) with/IN peroxymonosulfate/NN (/( PMS/NN ;/: HSO5/NN -/: 
590053_1_21_23_12_13::None::nausea/NN ,/, and/CC influenza/NN -/: like/IN symptoms/NNS ,/, such/JJ as/IN fever/NN and/CC joint/JJ pain/NN ./. 
591709_2_22_23_29_30::None::COX/NNP sequences/NNS in/IN Mollusca/NNP ,/, Crustacea/NNP ,/, and/CC Insecta/NNP ,/, assessing/VBG COX/NNP evolution/NN across/IN 
1553_1553_32_33_38_39::None::daltons/NNS )/) ,/, fimbrin/NN (/( 68,000/CD daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS 
183879_18_6_7_9_10::None::venlafaxine/NN +/CC bright/JJ light/NN therapy/NN treatment/NN strategies/NNS significantly/RB reversed/VBD the/DT 
884_884_14_15_12_13::POS_ACTION_BIND::,/, complexes/NNS of/IN beta-catenin/NN with/IN alpha-catenin/NN and/CC APC/NN were/VBD 
255731_2_36_37_12_13::None::comprehensively/RB investigated/VBD the/DT abundance/NN and/CC diversity/NN of/IN STPs/NNS encoded/VBN in/IN 119/CD actinobacterial/JJ genomes/NNS ,/, based/VBN on/IN the/DT data/NNS stored/VBN in/IN the/DT Microbial/JJ Signal/NN Transduction/NN (/( MiST/NN )/) database/NN ./. 
1843_1843_31_32_19_20::POS_ACTION_LOCALIZE::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
92153_1_12_13_24_26::medicine.medical_treatment.used_to_treat::overall/JJ management/NN and/CC antiarrhythmic/JJ therapy/NN used/VBN in/IN the/DT current/JJ general/JJ population/NN of/IN patients/NNS with/IN nonvalvular/JJ atrial/JJ fibrillation/NN in/IN Spain/NNP ./. 
2222_2222_13_14_11_12::POS_ACTION_COLOCALIZE::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, 
93_93_22_23_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
326872_11_15_16_12_13::None::targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO 
719083_0_8_9_2_3::medicine.symptom.symptom_of::Frequency/NN of/IN Meningitis/NN in/IN Children/NNP Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: 
756738_0_9_10_16_17::None::common/JJ non/JJ -/: cardiovascular/JJ causes/NNS of/IN death/NN in/IN patients/NNS on/IN chronic/JJ renal/JJ replacement/NN therapy/NN 
747_747_27_28_25_26::POS_ACTION_BIND::and/CC association/NN of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN 
1128_1128_11_14_4_5::None::talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
723866_2_1_2_3_4::biology.organism_classification.lower_classifications::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN 
1628_1628_31_33_27_28::None::the/DT ability/NN of/IN Munc-18-2/NN to/TO associate/VB with/IN syntaxin/NN 3/CD in/FW vitro/FW ./. 
395_395_7_8_9_10::None::verprolin-homology/JJ domain/NN in/IN N-WASP/NN to/TO actin/NN is/VBZ essential/JJ for/IN 
520523_1_36_37_17_18::biology.organism_classification.lower_classifications::tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW )/) ,/, apricot/NN (/( Prunus/FW armeniaca/FW )/) ,/, peach/NN (/( Prunus/FW persica/FW )/) ,/, and/CC plum/NN (/( Prunus/NNP domestica/NNP 
549_549_20_21_11_12::None::to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP from/IN interacting/VBG with/IN MSH3/NN and/CC MSH6/NN ./. 
93_93_54_55_28_29::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
556_556_24_25_7_9::NEG_ACTION_INTERACT::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
225720_6_4_6_25_26::None::also/RB show/VBP that/IN primary/JJ tumors/NNS can/MD be/VB modeled/VBN in/IN immunocompetent/JJ mice/NNS by/IN microinjecting/VBG CCR9/NN -/: expressing/VBG cancer/NN cell/NN lines/NNS into/IN early/JJ -/: stage/NN mouse/NN blastocysts/NNS ,/, which/WDT induces/VBZ 
519_519_33_34_32_33::POS_ACTION_MEMBER::)/) -/: specific/JJ Act88F/NN actin/NN gene/NN ./. 
637036_2_17_18_11_12::None::the/DT course/NN of/IN disease/NN is/VBZ recommended/VBN ;/: however/RB ,/, patients/NNS live/VBP with/IN disabling/VBG 
1608_1608_26_27_24_25::None::protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
393_393_12_15_5_7::None::isolated/VBN myofibrils/NNS with/IN alkaline/NN proteinase/NN resulted/VBD in/IN the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
93665_0_16_18_0_1::None::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN 
1701_1701_11_12_43_46::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN 
170709_1_17_18_11_12::None::a/DT breast/NN cancer/NN cell/NN overexpressing/VBG the/DT Her2/NN receptor/NN ,/, trastuzumab/NN (/( Herceptin/NN )/) 
1532_1532_17_18_29_30::POS_ACTION_CORELATE::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD 
2148_2148_52_53_4_5::None::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
1771_1771_15_16_11_14::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
1055_1055_19_22_0_1::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
388589_2_44_45_38_39::None::among/IN the/DT subgroups/NNS diabetes/NN and/CC non/JJ -/: diabetes/NN ,/, age/NN gtgt/NN =/JJ 65/CD 
728820_2_16_17_11_12::medicine.disease.symptoms::LVP/NN for/IN lower/JJR urinary/JJ tract/NN symptoms/NNS secondary/JJ to/TO BPH/NNP from/IN 2005/CD to/TO 
491928_0_5_6_11_12::medicine.risk_factor.diseases::premorbid/JJ childhood/NN and/CC adolescent/JJ functioning/VBG in/IN schizophrenia/NN -/: spectrum/NN psychoses/NNS :/: A/DT first/JJ 
660282_0_5_6_15_16::None::the/DT influence/NN of/IN timing/NN of/IN salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN outcomes/NNS after/IN prostatectomy/NN for/IN prostate/NN cancer/NN 
792558_0_3_4_8_9::None::Polymorphonuclear/JJ neutrophils/NNS (/( PMNs/NNS )/) ,/, the/DT main/JJ effectors/NNS of/IN the/DT innate/JJ 
112_112_18_19_0_1::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
338450_1_8_9_17_19::None::the/DT treatment/NN of/IN pancreatic/JJ cancer/NN is/VBZ dependent/JJ on/IN disease/NN stage/NN and/CC patient/NN performance/NN status/NN but/CC ,/, in/IN 
18_18_21_22_18_20::None::homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
381796_0_9_12_18_22::medicine.disease.treatments::in/IN Patients/NNS with/IN Obstructive/JJ Sleep/NNP Apnea/NNP Not/RB Responsive/JJ to/TO or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
290049_2_3_4_9_11::None::The/DT identification/NN of/IN bats/NNS as/IN possible/JJ additional/JJ reservoir/NN for/IN influenza/NN A/NN viruses/NNS raises/VBZ questions/NNS 
369607_2_27_28_10_11::None::heparin/NN among/IN various/JJ anions/NNS and/CC competitors/NNS of/IN heparin/NN including/VBG chondroitin/NN 4/CD -/: sulfate/NN (/( ChS/NN )/) and/CC hyaluronic/JJ acid/NN (/( HA/NN )/) ./. 
808734_0_23_24_9_10::medicine.symptom.symptom_of::patients/NNS with/IN chronic/JJ hepatitis/NN C/NN (/( CHC/NN )/) and/CC is/VBZ associated/VBN with/IN the/DT increased/VBN risk/NN of/IN liver/NN fibrosis/NN and/CC carcinogenesis/NN ./. 
1534_1534_34_35_16_17::None::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
219974_13_2_3_16_17::None::Non/SYM -/: cardiovascular/JJ causes/NNS of/IN death/NN are/VBP responsible/JJ for/IN almost/RB half/DT of/IN later/JJ deaths/NNS in/IN cardiac/JJ patients/NNS ./. 
1771_1771_11_14_19_20::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
715810_0_24_25_15_16::None::against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN anxiety/NN ,/, and/CC memory/NN improvement/NN ./. 
194621_0_18_19_22_23::None::and/CC //: or/CC antioxidants/NNS compounds/NNS and/CC reduced/VBD sodium/NN intake/NN have/VBP been/VBN 
713_713_14_15_9_10::POS_ACTION_BIND::cofilin/NN and/CC its/PRP$ actin/NN binding/NN peptide/NN compete/VBP with/IN gelsolin/NN segments/NNS 2-3/CD for/IN 
1491_1491_16_17_6_7::POS_ACTION_DEPOLYMERIZE::assay/NN using/VBG an/DT actin/NN cross-linking/NN protein/NN and/CC the/DT nucleation/NN assay/NN also/RB suggested/VBD that/IN cofilin/NN shortens/VBZ the/DT actin/NN 
436497_1_5_6_7_8::medicine.symptom.symptom_of::the/DT correlations/NNS between/IN impulsivity/NN and/CC bulimic/JJ symptoms/NNS ,/, and/CC 
2014_2014_23_24_30_31::POS_ACTION_SIMILAR::mutants/NNS defective/JJ in/IN rhp51/NN and/CC rhp54/NN (/( homologues/NNS of/IN S.cerevisiae/NNP RAD51/NN and/CC RAD54/NN ,/, 
28475_4_68_69_33_34::None::analysis/NN revealed/VBD the/DT presence/NN of/IN a/DT selenocysteine/NN -/: containing/VBG TGR/NN and/CC absenceof/JJ conventional/JJ TR/NN and/CC GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) 
389319_8_12_13_1_2::None::Liver/NN tissue/NN was/VBD assessed/VBN for/IN inflammatory/JJ cytokine/NN expression/NN and/CC radiation/NN -/: induced/VBN SEC/NNP injury/NN based/VBN on/IN 
790_790_33_34_29_33::None::,/, including/VBG the/DT cyclin/NN dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, which/WDT blocks/VBZ 
17565_0_2_5_2_3::medicine.disease.symptoms::Rupture/NN of/IN abdominal/JJ aortic/JJ aneurysms/NNS causes/VBZ 
1908_1908_7_8_19_20::None::that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
513_513_12_13_9_10::POS_ACTION_INTERACT::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
2222_2222_21_22_37_38::None::,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
1850_1850_8_9_23_24::None::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
495841_5_24_26_16_17::people.cause_of_death.includes_causes_of_death::SK/NN -/: Mel2/NN melanoma/NN cells/NNS and/CC p53/NN -/: deficient/JJ H1299/NN lung/NN cancer/NN cells/NNS as/RB well/RB ,/, 
1052_1052_37_38_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1345_1345_3_4_12_13::None::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
1957_1957_36_37_15_16::None::EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
1737_1737_13_15_52_54::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN 
372073_0_11_12_28_29::None::cultures/NNS prepared/VBN from/IN embryonic/JJ mouse/NN mesencephala/NN were/VBD used/VBN to/TO investigate/VB the/DT neuroprotective/JJ effect/NN of/IN cabergoline/NN ,/, an/DT ergoline/NN D2/NN receptor/NN agonist/NN ,/, against/IN the/DT 
1119_1119_11_12_5_6::None::LIM-kinase/NN 1/CD inactivates/VBZ cofilin/NN ,/, leading/VBG to/TO accumulation/NN of/IN actin/NN filaments/NNS ./. 
1486_1486_41_44_35_40::None::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
259511_0_30_31_9_11::None::male/NN with/IN past/JJ medical/JJ history/NN of/IN benign/JJ prostatic/JJ hyperplasia/NN presented/VBN to/TO the/DT emergency/NN department/NN with/IN complaints/NNS of/IN decreased/VBN urinary/JJ flow/NN ,/, inability/NN to/TO fully/RB empty/VB his/PRP$ bladder/NN ,/, 
93_93_54_55_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
18_18_6_7_21_22::POS_ACTION_INTERACT::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
1069_1069_29_30_46_47::POS_ACTION_ATTACH::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
229284_0_4_5_22_23::None::to/TO methotrexate/NN (/( MTX/NN )/) ,/, the/DT ''/'' anchor/NN drug/NN ''/'' for/IN treating/VBG rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, varies/VBZ among/IN individual/JJ patients/NNS ./. 
747_747_27_28_30_31::POS_ACTION_BIND::of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN relative/JJ to/TO Apc/NN 
91905_5_8_9_25_26::None::marker/NN resource/NN (/( Illumina/NNP Infinium/NNP assay/NN )/) for/IN perennial/JJ ryegrass/NN (/( Lolium/NN perenne/NN )/) was/VBD created/VBN and/CC validated/VBN in/IN a/DT broad/JJ ecotype/JJ collection/NN of/IN 
63_63_59_60_49_50::None::.2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
367_367_28_30_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
1334_1334_30_31_0_1::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN mutant/NN defective/JJ in/IN 
355_355_14_15_25_26::POS_ACTION_Assembly::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
678566_0_28_29_27_28::None::successful/JJ anti/JJ -/: epileptic/JJ drug/NN ./. 
605_605_18_19_23_24::None::products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
497295_0_40_42_21_22::medicine.disease.treatments::taxane/NN -/: based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN up/RB to/TO 60/CD %/NN in/IN HER2/NN -/: positive/JJ breast/NN cancer/NN ./. 
266602_0_0_1_9_10::None::Erythrocyte/NN polyunsaturated/JJ fatty/JJ acid/NN levels/NNS in/IN young/JJ people/NNS at/IN ultra/NN -/: high/JJ risk/NN 
2107_2107_39_40_7_8::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
275299_5_5_6_11_12::medicine.drug.active_moieties::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC 
521445_4_22_23_29_30::None::infection/NN ,/, including/VBG medical/JJ optimization/NN ,/, systematic/JJ approaches/NNS to/TO infection/NN management/NN ,/, and/CC the/DT 
315600_15_26_27_2_3::None::GHA/NN priming/NN chemotherapy/NN ,/, as/RB well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ 
1008_1008_10_11_4_5::None::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
452211_4_31_32_2_3::people.cause_of_death.includes_causes_of_death::Anti/SYM -/: tumor/NN Bcl/NN -/: 2/CD //: survivin/NN siRNAs/NNS loaded/VBN in/IN the/DT anti/JJ -/: EGFR/NN -/: 9Arg/NN -/: lipoplexes/NNS effectively/RB suppressed/VBD transcription/NN of/IN their/PRP$ target/NN genes/NNS ,/, resulting/VBG in/IN an/DT efficient/JJ cancer/NN cell/NN death/NN ./. 
2013_2013_7_9_9_10::POS_ACTION_MEMBER::motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
356156_0_7_8_0_1::None::In/IN 2009/CD ,/, the/DT US/NNP Food/NNP and/CC Drug/NNP Administration/NNP (/( FDA/NNP 
23235_3_30_31_45_47::None::Ag/NN )/) and/CC activity/NN (/( vWF/NN :/: GP1bA/NN )/) ,/, factor/NN VIII/CD (/( FVIII/CD :/: C/NN )/) ,/, lupus/NN anticoagulant/NN ,/, and/CC functional/JJ 
276_276_21_22_4_6::None::site-directed/JJ mutagenesis/NN of/IN profilin/NN II/CD from/IN Dictyostelium/NNP discoideum/NN the/DT point/NN mutations/NNS K114E/NN and/CC W3N/NN were/VBD generated/VBN by/IN PCR/NN thus/RB changing/VBG actin/NN and/CC poly/NN -/: 
36424_0_27_28_29_30::None::MC/NNP )/) Dose/NNP Calculation/NN in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN 
72_72_17_18_0_1::POS_ACTION_SUPPRESS::Aip1p/NN localizes/VBZ to/TO cortical/JJ actin/NN patches/NNS in/IN yeast/NN cells/NNS ,/, and/CC this/DT localization/NN is/VBZ disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS 
367549_2_13_14_1_2::None::Staphylococcus/FW aureus/FW (/( n/NN =/JJ 35/CD from/IN 19/CD herds/NNS )/) ,/, coagulase/NN -/: negative/JJ staphylococci/NNS (/( n/NN 
339_339_13_14_10_11::POS_ACTION_MODIFY::modulation/NN of/IN the/DT actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
556_556_7_9_12_13::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
1737_1737_58_59_13_15::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
1857_1857_9_11_17_18::POS_ACTION_BIND::quantitative/JJ conversion/NN of/IN platelet/NN profilin/NN and/CC gelsolin/NN to/TO high-affinity/JJ complexes/NNS with/IN actin/NN ,/, but/CC these/DT 
193027_2_32_33_37_38::medicine.drug_ingredient.active_moiety_of_drug::with/IN PEGylated/VBN liposomal/JJ doxorubicin/NN (/( PLD/NN )/) //: Doxil/NNP for/IN ovarian/JJ cancer/NN 
8_8_26_27_13_14::NEG_ACTION_Amount::1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN ,/, and/CC alpha-catenin/NN is/VBZ not/RB affected/VBN by/IN the/DT differential/JJ calreticulin/NN expression/NN ./. 
735_735_22_23_24_25::None::cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
567_567_7_9_18_19::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
2_2_9_10_0_1::None::alpha-catenin/NN inhibits/VBZ beta-catenin/NN signaling/NN by/IN preventing/VBG formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN 
923_923_7_8_4_5::None::measurements/NNS indicate/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ the/DT affinity/NN 
652_652_13_14_8_9::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
1861_1861_12_13_2_3::None::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
573581_3_2_3_0_1::None::This/DT study/NN aims/VBZ to/TO investigate/VB the/DT 
63_63_44_45_25_26::POS_ACTION_MEMBER::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, 
574065_1_22_25_20_21::None::European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP 
343970_4_37_38_40_41::medicine.drug.active_moieties::TDN/NN )/) and/CC nitrate/JJ nitrogen/NN (/( NO3/NN (/( -/: )/) 
183879_18_13_14_14_15::medicine.disease.symptoms::significantly/RB reversed/VBD the/DT depressive/JJ mood/NN of/IN patients/NNS with/IN 
88435_3_32_33_15_17::medicine.medical_treatment.used_to_treat::agent/NN chemotherapy/NN or/CC hormonal/JJ therapy/NN ,/, with/IN at/IN least/JJS three/CD distinct/JJ measurable/JJ sites/NNS of/IN disease/NN ,/, were/VBD treated/VBN with/IN concurrent/JJ radiotherapy/NN (/( 35/CD Gy/NN 
380111_3_18_19_16_17::None::Au/SYM -/: H/NN insertion/NN minimum/NN attributed/VBD to/TO the/DT stabilization/NN 
776_776_29_30_26_27::None::of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
980_980_14_15_18_19::None::of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
76585_4_7_8_1_2::None::Exclusion/NN criteria/NNS were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, 
996_996_12_13_5_7::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT 
367_367_24_25_32_33::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
10441_0_13_14_3_4::medicine.disease.symptoms::Distal/JJ symmetric/JJ peripheral/JJ polyneuropathy/NN (/( DSPN/NN )/) is/VBZ a/DT highly/RB prevalent/JJ complication/NN of/IN diabetes/NN ./. 
28_28_0_2_3_4::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN 
154535_13_0_1_15_16::None::Our/PRP$ data/NNS suggest/VBP a/DT complex/JJ interplay/NN among/IN insulin/NN resistance/NN ,/, obesity/NN ,/, and/CC depression/NN in/IN PCOS/NN ,/, warranting/VBG additional/JJ 
1743_1743_4_5_11_12::POS_ACTION_MODULATE::results/NNS suggest/VBP that/IN RAD52/NN may/MD modulate/VB the/DT catalytic/JJ activities/NNS of/IN RAD51/NN protein/NN such/JJ as/IN 
287311_9_1_2_103_104::None::The/DT AUROC/NN values/NNS for/IN VFA/NNP were/VBD higher/JJR than/IN those/DT for/IN BMI/NNP and/CC WHR/NNP For/IN VFA/NNP ,/, the/DT sensitivity/NN and/CC specificity/NN for/IN predicting/VBG CKD/NNP were/VBD 62.66/CD %/NN (/( 95/CD %/NN CI/NN ,/, 61.0/CD -/: 64.3/CD )/) and/CC 64.22/CD %/NN (/( 95/CD %/NN CI/NN ,/, 63.5/CD -/: 64.9/CD )/) ,/, respectively/RB ,/, and/CC 77.65/CD %/NN (/( 95/CD %/NN CI/NN ,/, 76.3/CD -/: 79.0/CD )/) ,/, and/CC 68.81/CD %/NN (/( 95/CD %/NN CI/NN ,/, 68.1/CD -/: 69.5/CD )/) ,/, respectively/RB for/IN predicting/VBG MS/NN Our/PRP$ results/NNS demonstrated/VBD that/IN the/DT VFA/NNP ,/, measured/VBN by/IN BIA/NNP ,/, is/VBZ a/DT simple/JJ method/NN for/IN predicting/VBG the/DT risk/NN of/IN CKD/NN and/CC MS/NN Copyright/NN 2015/CD S/NN Karger/NNP 
240152_0_41_42_28_30::None::industrial/JJ district/NN in/IN northeast/JJ China/NNP and/CC were/VBD analyzed/VBN for/IN contents/NNS of/IN titanium/NN (/( Ti/NN )/) ,/, copper/NN (/( Cu/NN )/) 
1025_1025_27_28_0_1::POS_ACTION_BIND::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
1061_1061_15_16_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, 
986_986_25_26_11_12::None::central/JJ role/NN of/IN beta-catenin/NN in/IN this/DT adhesion/NN complex/NN ,/, as/IN it/PRP binds/VBZ to/TO the/DT cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN 
93_93_54_55_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
1052_1052_6_8_18_20::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
507_507_28_29_3_4::POS_ACTION_BIND::For/IN example/NN ,/, profilin/NN with/IN a/DT deletion/NN of/IN the/DT eight/CD C-terminal/JJ residues/NNS has/VBZ many/JJ of/IN the/DT physical/JJ properties/NNS of/IN a/DT molten/JJ globule/NN ,/, yet/RB remarkably/RB still/RB binds/VBZ to/TO actin/NN ./. 
724990_11_0_1_28_29::None::The/DT results/NNS of/IN the/DT present/JJ study/NN suggest/VBP that/IN use/NN of/IN etoricoxib/NN ,/, especially/RB at/IN low/JJ dose/NN ,/, in/IN patients/NNS with/IN epilepsy/NN may/MD not/RB be/VB detrimental/JJ with/IN regard/NN to/TO seizure/NN control/NN ./. 
1386_1386_18_19_1_2::None::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS 
1486_1486_32_33_35_40::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
872_872_6_7_11_12::None::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
2075_2075_21_23_14_15::POS_ACTION_MEMBER::interact/VB with/IN yeast/NN profilin/NN and/CC tropomyosin/NN ,/, the/DT only/JJ yeast/NN actin-binding/JJ proteins/NNS so/RB far/RB purified/VBN 
569500_0_9_10_7_8::None::activity/NN patterns/NNS after/IN Roux/NNP -/: en/IN Y/NN gastric/JJ bypass/NN 
2148_2148_4_5_52_53::POS_ACTION_BIND::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
148500_0_11_12_12_13::medicine.disease.symptoms::Frequency/NN Oscillations/NNS and/CC Epileptic/JJ Seizures/NNS in/IN a/DT Computational/JJ 
416817_3_45_46_17_18::None::to/TO support/VB longitudinal/JJ data/NN analysis/NN and/CC pragmatic/JJ clinical/JJ trials/NNS in/IN asthma/NN and/CC COPD/NNP This/DT involved/VBD a/DT retrospective/JJ extraction/NN of/IN data/NNS from/IN all/DT registered/VBN practices/NNS in/IN Salford/NNP to/TO identify/VB a/DT cohort/NN of/IN patients/NNS with/IN a/DT diagnosis/NN 
452794_0_10_11_0_1::None::Efficacy/NN and/CC safety/NN of/IN anticoagulation/NN therapy/NN with/IN different/JJ doses/NNS of/IN enoxaparin/NN for/IN portal/JJ vein/NN 
397679_0_3_4_23_24::None::To/TO study/VB the/DT impact/NN of/IN novel/JJ treatments/NNS for/IN elderly/JJ (/( gtgt/NN =/JJ 66/CD yr/NN )/) patients/NNS with/IN multiple/JJ myeloma/NN (/( MM/NN )/) in/IN daily/JJ practice/NN by/IN comparing/VBG 
1338_1338_23_24_23_24::None::nucleotide/NN exchange/NN on/IN actin/NN ,/, and/CC promoting/VBG 
30983_5_1_2_8_9::None::Study/NNP group/NN had/VBD significantly/RB lower/JJR mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN 
1466_1466_3_4_5_6::None::The/DT E-cadherin-associated/JJ proteins/NNS alpha-catenin/NN and/CC beta-catenin/NN were/VBD not/RB significantly/RB 
685_685_14_15_30_31::None::to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
1052_1052_37_38_29_30::None::with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1069_1069_21_22_42_45::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
783888_0_36_37_5_6::medicine.disease.treatments::the/DT use/NN of/IN promethazine/NN 6.25/CD mg/NN intravenous/JJ (/( IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ ambulatory/JJ surgery/NN patients/NNS to/TO control/VB established/JJ postoperative/JJ nausea/NN or/CC vomiting/NN (/( PONV/NN )/) 
470116_0_16_20_10_11::None::and/CC Emphysema/NNP Is/VBZ Associated/VBN with/IN Dyspnea/NN and/CC Hospitalization/NN for/IN Chronic/JJ Obstructive/JJ Pulmonary/JJ Disease/NN ./. 
739076_0_24_25_13_14::None::sleep/NN apnea/NN (/( OSA/NN )/) is/VBZ gaining/VBG popularity/NN ,/, especially/RB in/IN children/NNS with/IN mild/JJ disease/NN ./. 
75_75_1_2_17_18::POS_ACTION_MODIFY::A/DT LIMK2/NN mutant/NN with/IN replacement/NN of/IN threonine/NN 505/CD by/IN valine/NN abolished/VBD LIMK2/NN activities/NNS for/IN cofilin/NN phosphorylation/NN and/CC actin/NN cytoskeletal/JJ changes/NNS ,/, 
1652_1652_31_32_45_46::None::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
856_856_13_14_40_41::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
169857_11_6_9_7_9::medicine.disease.symptoms::patients/NNS with/IN severe/JJ obstructive/JJ sleep/NN apnea/NN ,/, 86.7/CD %/NN 
596785_1_18_19_10_11::None::referred/VBN for/IN surgical/JJ ablation/NN due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ dilatation/NN (/( left/JJ atrium/NN 
524639_5_3_4_14_15::None::A/DT majority/NN of/IN data/NNS indicate/VBP that/IN all/PDT the/DT selective/JJ COX/NNP -/: 2/CD inhibitors/NNS ,/, diclofenac/NN and/CC high/JJ -/: 
1755_1755_13_14_26_27::POS_ACTION_BIND::the/DT interaction/NN with/IN actin/NN and/CC ,/, therefore/RB ,/, may/MD constitute/VB part/NN of/IN the/DT actin-binding/JJ domain/NN of/IN cofilin/NN ./. 
1061_1061_6_7_25_27::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
177255_4_0_1_12_13::None::In/IN this/DT paper/NN the/DT possibility/NN to/TO protect/VB from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN socks/NNS ./. 
1064_1064_8_9_15_16::None::yeast/NN actin-binding/JJ protein/NN Sac6p/NN ,/, which/WDT is/VBZ homologous/JJ to/TO vertebrate/JJ fimbrin/NN (/( Adams/NNP ,/, 
267_267_26_27_24_25::None::on/IN patches/NNS containing/VBG vinculin/NN and/CC talin/NN ;/: thus/RB the/DT 
102783_0_16_17_4_5::medicine.drug.active_moieties::(/( imidazole/NN -/: Cu/NN )/) -/: mediated/VBN C1/NN //: C1N2/NN copolymerization/NN of/IN ethyl/NN diazoacetate/NN involved/VBN copper/NN -/: based/VBN carbene/NN 
86_86_14_15_28_29::POS_ACTION_BIND::all/DT sera/NNS caused/VBD IgG/NN binding/NN to/TO platelet/NN components/NNS of/IN 87-90/CD kD/NN ,/, 140/CD kD/NN (/( identified/VBN as/IN vinculin/NN )/) and/CC 220-240/CD 
693828_2_8_9_15_16::medicine.symptom.symptom_of::conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ 
292_292_0_1_11_14::None::CD26/NN ,/, a/DT T/NN cell/NN activation/NN Ag/NN ,/, also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB 
113339_0_19_20_2_4::biology.organism_classification.lower_classifications::To/TO identity/NN Plasmodium/NN ovale/NN infection/NN by/IN 18S/NNP rRNA/NN gene/NN nested/JJ PCR/NN Whole/JJ blood/NN and/CC filter/NN paper/NN blood/NN samples/NNS of/IN malaria/NN patients/NNS in/IN Shandong/NNP 
1087_1087_10_12_25_26::POS_ACTION_ASSEMBLE::profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
2013_2013_9_10_0_1::POS_ACTION_BIND::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
118239_0_10_11_45_46::None::on/IN a/DT mesostructured/JJ ceria/NN -/: supported/VBN gold/NN (/( Au/NN //: meso/SYM -/: CeO2/NN )/) catalyst/NN was/VBD developed/VBN for/IN the/DT synthesis/NN of/IN various/JJ aromatic/JJ azo/NN compounds/NNS by/IN the/DT reductive/JJ coupling/NN of/IN the/DT corresponding/JJ nitroaromatics/NNS ,/, using/VBG CO/NNP as/IN the/DT sole/JJ deoxygenative/JJ reagent/NN ,/, 
133249_2_16_17_1_3::medicine.disease.risk_factors::Although/IN cigarette/NN smoke/NN increases/VBZ TLR4/NN expression/NN ,/, TLR4/NN signaling/NN is/VBZ altered/VBN in/IN smokers/NNS and/CC in/IN smokers/NNS COPD/NN patients/NNS ./. 
280859_11_5_6_6_7::None::and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN 
131579_0_16_17_50_51::None::for/IN locally/RB advanced/JJ resectable/JJ oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN ,/, 24/CD patients/NNS with/IN T3/NN or/CC T4a/NN oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN were/VBD randomly/RB assigned/VBN to/TO surgery/NN alone/RB or/CC Docetaxel/NNP ,/, Cisplatin/NNP ,/, and/CC 5/LS -/: FU/NN (/( TPF/NN )/) induction/NN chemotherapy/NN 
102233_0_2_3_0_4::medicine.symptom.symptom_of::Complex/JJ regional/JJ pain/NN syndrome/NN (/( CRPS/NN )/) 
237_237_5_6_9_10::None::causes/VBZ phosphorylation/NN of/IN talin/NN and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS 
342702_0_37_38_20_21::None::have/VBP fuelled/VBN the/DT development/NN of/IN targeted/VBN therapies/NNS that/WDT block/VBP cytokine/NN networks/NNS and/CC pathogenic/JJ immune/JJ cells/NNS ,/, leading/VBG to/TO a/DT considerable/JJ improvement/NN in/IN the/DT management/NN 
456_456_2_3_17_18::NEG_ACTION_CORELATE::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
1219_1219_20_21_11_12::None::enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
218696_6_22_24_17_18::None::)/) ,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, co/SYM -/: 
275299_5_24_25_5_6::None::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC calcium/NN signaling/NN pathways/NNS as/IN revealed/VBN by/IN gene/NN ontology/NN (/( GO/NN )/) and/CC Kyoto/NNP 
759_759_12_13_20_24::POS_REG(-)_INCREASE::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
1977_1977_16_17_22_23::POS_ACTION_BIND::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
196539_13_14_16_3_4::people.cause_of_death.includes_causes_of_death::The/DT association/NN between/IN cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ risk/NN factors/NNS ./. 
1761_1761_23_25_15_16::None::HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
1345_1345_6_7_3_4::POS_ACTION_SIMILAR::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN 
2064_2064_28_29_40_41::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
184609_0_17_19_20_21::None::NO/NN )/) by/IN NO/NN synthase/NN (/( NOS/NN )/) takes/VBZ place/NN 
665_665_14_17_19_20::POS_ACTION_MEMBER::antibodies/NNS to/TO the/DT actin/NN binding/NN proteins/NNS Abp1p/NN and/CC cofilin/NN ./. 
20599_4_45_49_8_9::None::a/DT double/JJ -/: blind/JJ ,/, phase/NN 2/CD study/NN in/IN patients/NNS with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC with/IN high/JJ or/CC low/JJ doses/NNS of/IN patritumab/NN ,/, a/DT monoclonal/JJ antibody/NN targeted/VBN against/IN human/JJ epidermal/JJ growth/NN factor/NN receptor/NN 3/CD (/( HER3/NN 
429251_0_6_7_4_5::medicine.drug.active_moieties::evidence/NN suggests/VBZ that/IN dopamine/NN (/( DA/NN )/) is/VBZ involved/VBN 
710191_0_20_21_14_15::None::are/VBP both/DT poor/JJ prognostic/JJ factors/NNS with/IN synergistic/JJ effect/NN on/IN locally/RB advanced/JJ head/NN and/CC 
628556_0_14_15_9_10::medicine.medical_treatment.used_to_treat::Head/NNP and/CC Neck/NNP Cancer/NNP :/: Implications/NNS for/IN Adaptive/JJ Radiotherapy/NN ./. 
93_93_50_51_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
2014_2014_30_31_23_24::None::mutants/NNS defective/JJ in/IN rhp51/NN and/CC rhp54/NN (/( homologues/NNS of/IN S.cerevisiae/NNP RAD51/NN and/CC RAD54/NN ,/, 
1866_1866_7_8_5_6::POS_ACTION_RELATE::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, 
702752_2_16_19_28_30::None::inhibitor/NN ,/, in/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, and/CC differentiation/NN using/VBG isolated/VBN murine/JJ splenic/JJ T/NN cells/NNS from/IN C57BL/NN //: 
865150_0_22_23_4_5::medicine.medical_treatment.used_to_treat::-/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN death/NN worldwide/RB due/JJ its/PRP$ resistance/NN to/TO chemotherapy/NN and/CC aggressive/JJ tumor/NN 
350981_0_10_11_12_13::None::of/IN Mind/NNP and/CC Body/NNP -/: The/NNP ALPIM/NNP (/( Anxiety/NN 
1474_1474_29_31_9_10::None::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
30174_0_33_34_12_13::None::During/IN Anti/NNP -/: Cancer/NNP Treatment/NNP Period/NN in/IN Elderly/NNP Lung/NN Cancer/NN Patients/NNS on/IN Community/NN -/: Acquired/VBN Pneumonia/NNP Hospitalization/NNP :/: A/NNP Nationwide/NNP Population/NNP -/: Based/VBD Cohort/NNP Study/NNP ./. 
459318_0_18_19_2_3::medicine.drug.active_moieties::Synthesis/NN of/IN copper/NN micro/JJ -/: rods/NNS with/IN layered/JJ nano/NN -/: structure/NN by/IN thermal/JJ decomposition/NN of/IN the/DT coordination/NN complex/NN Cu/NN (/( BTA/NN )/) 
1771_1771_1_2_11_14::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, 
1923_1923_52_53_52_53::None::)/) than/IN cys-374-labeled/JJ actin/NN (/( Kd/NN >/JJR 
702304_0_6_7_16_19::None::high/JJ risk/NN for/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( ASCVD/NN )/) and/CC are/VBP considered/VBN a/DT coronary/JJ heart/NN disease/NN risk/NN equivalent/NN ./. 
317242_0_20_21_39_40::None::granulation/NN and/CC immunohistochemical/JJ hormone/NN expression/NN ,/, such/JJ as/IN growth/NN hormone/NN (/( GH/NN )/) ,/, prolactin/NN ,/, adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) ,/, thyroid/NN stimulating/NN hormone/NN (/( 
640_640_25_26_25_26::None::can/MD not/RB increase/VB profilin/NN 's/POS affinity/NN for/IN 
608_608_18_19_23_24::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
151537_7_39_40_30_31::None::(/( lymphoma/NN ,/, leukaemia/NN )/) ,/, bladder/NN cancer/NN ,/, intracranial/JJ neoplasms/NNS (/( meningioma/NN ,/, glioma/NN )/) 
831385_3_33_34_11_12::None::relation/NN to/TO the/DT artemisinin/NN inhibitory/JJ effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN is/VBZ more/RBR susceptible/JJ to/TO CPA/NNP Here/RB ,/, we/PRP 
1532_1532_31_33_31_33::POS_ACTION_CORELATE::displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD complexes/NNS when/WRB overexpressed/VBN 
492455_9_0_1_21_22::None::The/DT MASC/NNP has/VBZ probably/RB a/DT more/RBR limited/JJ function/NN in/IN screening/VBG for/IN AD/NN among/IN a/DT highly/RB comorbid/JJ inpatient/JJ sample/NN of/IN severely/RB affected/VBN adolescents/NNS ./. 
492693_2_58_59_47_48::None::with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB 
218394_4_16_17_0_1::None::To/TO determine/VB the/DT effect/NN of/IN prehospital/JJ thrombolysis/NN for/IN acute/JJ ischemic/JJ stroke/NN administered/VBN in/IN specialized/VBN ambulances/NNS on/IN delay/NN in/IN thrombolytic/JJ administration/NN 
320864_0_11_12_37_38::medicine.disease.risk_factors::of/IN maintaining/VBG a/DT high/JJ Hb/NN target/NN range/NN through/IN erythropoiesis/NN -/: stimulating/VBG agent/NN therapy/NN on/IN the/DT renal/JJ outcome/NN with/IN respect/NN to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) stage/NN and/CC concurrent/JJ diabetes/NN condition/NN in/IN patients/NNS 
250192_5_0_1_23_25::None::Celecoxib/NNP was/VBD as/IN effective/JJ as/IN naproxen/NN in/IN reducing/VBG OA/NN pain/NN (/( least/JJS squares/NNS mean/VBP change/NN from/IN baseline/NN in/IN visual/JJ analogue/NN scale/NN score/NN [/( standard/JJ error/NN ]/) -/: 37.1/CD 
2131_2131_23_24_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
350850_8_15_16_22_23::medicine.risk_factor.diseases::the/DT presence/NN of/IN diabetes/NN (/( P/NN =/JJ 0.006/CD )/) ,/, hypertension/NN (/( P/NN &/CC 
784_784_12_13_21_22::None::,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
2074_2074_12_13_16_17::POS_ACTION_COLOCALIZE::the/DT nucleocapsid/NN (/( N/NN )/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) 
1866_1866_9_10_3_4::POS_ACTION_Change::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
1851_1851_17_18_21_22::POS_ACTION_SIMILAR::been/VBN identified/VBN :/: Armadillo/NN (/( homolog/NN of/IN beta-catenin/NN )/) ,/, Drosophila/FW 
274753_0_27_28_1_2::None::Electronic/JJ cigarettes/NNS (/( e/SYM -/: cigarettes/NNS )/) are/VBP a/DT relatively/RB recent/JJ phenomenon/NN ,/, serving/VBG dual/JJ roles/NNS as/IN an/DT alternative/JJ vehicle/NN for/IN nicotine/NN delivery/NN and/CC a/DT smoking/NN -/: cessation/NN tool/NN ./. 
503061_9_11_12_7_8::None::study/NN shows/VBZ that/IN NXT/NNP can/MD inhibit/VB the/DT development/NN of/IN diabetic/JJ retinopathy/NN 
1037_1037_21_22_27_28::None::the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
492693_2_71_72_116_117::None::as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS above/IN 4.9/CD K/NN The/DT observation/NN of/IN a/DT double/JJ -/: dome/NN superconducting/JJ phase/NN may/MD provide/VB a/DT hint/NN for/IN pursuing/VBG the/DT superconducting/VBG coupling/NN -/: mechanism/NN of/IN 
1380_1380_36_37_26_27::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
1652_1652_18_19_43_44::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
1156_1156_7_8_10_11::POS_ACTION_MUTUALCOMPLEX::with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN ,/, all/DT components/NNS 
201815_2_6_7_16_17::None::we/PRP established/VBD a/DT silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS 
759_759_17_19_20_24::None::increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
1069_1069_29_30_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
93_93_24_26_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
1219_1219_20_21_0_1::None::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
1652_1652_20_21_45_46::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
1434_1434_75_76_11_12::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
229_229_11_12_15_16::None::(/( flk-1/NN //: KDR/NN )/) tyrosine-autophosphorylation/NN by/IN VEGF/NN which/WDT was/VBD maximal/JJ 
1373_1373_11_12_4_5::None::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
76705_14_16_17_13_14::None::rise/NN showed/VBD a/DT high/JJ prevalence/NN of/IN CVE/NN but/CC not/RB stroke/NN 
703552_5_16_17_37_38::medicine.symptom.symptom_of::the/DT effect/NN of/IN hyperglycemia/NN on/IN expression/NN of/IN IL/NN -/: 1/CD family/NN members/NNS in/IN retinal/JJ layers/NNS ,/, using/VBG an/DT in/FW vivo/FW model/NN of/IN type/NN 1/CD diabetes/NN ./. 
125255_5_24_25_12_13::None::well/RB as/IN several/JJ pathophysiological/JJ alterations/NNS such/JJ as/IN hypertension/NN ,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: 
333090_0_0_1_1_2::None::Prevalence/NN estimates/NNS for/IN depression/NN and/CC 
1466_1466_5_6_3_4::None::The/DT E-cadherin-associated/JJ proteins/NNS alpha-catenin/NN and/CC beta-catenin/NN were/VBD not/RB significantly/RB 
2137_2137_4_5_15_18::POS_ACTION_BIND::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
1178_1178_14_15_14_15::None::does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
919_919_12_13_20_21::POS_ACTION_Assembly::E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
1742_1742_4_5_15_16::POS_ACTION_MODIFY::results/NNS suggest/VBP that/IN profilin/NN may/MD be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN glomerulonephritis/NN by/IN reorganizing/VBG actin/NN cytoskeleton/NN ./. 
537_537_18_19_6_7::POS_ACTION_COEXPRESS::inactivating/VBG effect/NN of/IN calmodulin/NN can/MD be/VB prevented/VBN by/IN coexpressing/VBG a/DT region/NN of/IN the/DT cytoskeletal/JJ protein/NN alpha-actinin2/NN known/VBN to/TO interact/VB 
1169_1169_26_27_13_16::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
112017_4_4_5_1_2::None::The/DT patients/NNS had/VBD situational/JJ disorders/NNS ,/, with/IN a/DT 
919_919_20_21_14_15::None::either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
178051_0_38_39_39_40::None::measured/VBN by/IN the/DT modified/VBN Rankin/NNP scale/NN ./. 
833154_0_0_1_8_9::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN department/NN ./. 
447089_0_10_11_7_9::medicine.drug_ingredient.active_moiety_of_drug::we/PRP showed/VBD that/IN adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) promoted/VBD erythroblast/NN 
683800_2_32_33_23_24::None::extant/JJ squamates/NNS (/( lizards/NNS and/CC snakes/NNS )/) but/CC is/VBZ poorly/RB understood/VBN in/IN archosaurs/NNS (/( crocodylians/NNS and/CC 
4599_8_13_14_43_44::medicine.medical_treatment.used_to_treat::male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ offspring/NN born/VBN after/IN assisted/JJ reproduction/NN and/CC the/DT risk/NN of/IN perpetuating/VBG infertility/NN in/IN future/JJ generation/NN 
669_669_21_22_16_17::None::talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS at/IN 
93_93_50_51_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
331938_2_30_31_17_18::None::,/, increase/VBP the/DT coronary/JJ blood/NN supply/NN ,/, improve/VB ischemic/JJ myocardial/JJ metabolism/NN ,/, scavenge/VB free/JJ radicals/NNS and/CC protect/VB myocardial/JJ ultrastructure/NN ./. 
445433_1_3_4_38_39::None::Indeed/RB ,/, a/DT neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ and/CC central/JJ nervous/JJ system/NN has/VBZ been/VBN described/VBN in/IN animals/NNS and/CC humans/NNS ,/, and/CC recently/RB several/JJ non/JJ -/: histaminergic/JJ pathways/NNS for/IN itch/NN have/VBP been/VBN discovered/VBN in/IN rodents/NNS that/WDT support/VBP a/DT 
226276_6_37_38_23_24::medicine.disease.symptoms::psychotic/JJ pre/JJ -/: delusional/JJ symptoms/NNS that/WDT acutely/RB worsen/VBP in/IN the/DT ramp/NN -/: up/IN to/TO full/JJ -/: blown/VBN psychosis/NN ,/, and/CC as/IN 
374_374_4_5_6_7::None::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC 
1440_1440_4_5_12_13::POS_ACTION_Assembly::C-terminal/JJ region/NN of/IN ORC3/NN was/VBD ,/, however/RB ,/, necessary/JJ to/TO bring/VB ORC4/NN and/CC ORC5/NN into/IN 
370669_2_9_10_12_13::None::of/IN high/JJ cardiovascular/JJ mortality/NN in/IN maintenance/NN hemodialysis/NN (/( MHD/NN )/) 
333054_4_0_1_14_15::medicine.disease.risk_factors::It/PRP is/VBZ concluded/VBN that/IN the/DT young/JJ rind/JJ region/NN was/VBD more/RBR directly/RB affected/VBN by/IN water/NN stress/NN and/CC ,/, depending/VBG 
313728_4_36_37_7_8::people.cause_of_death.includes_causes_of_death::metabolic/JJ needs/NNS of/IN tumor/NN cells/NNS has/VBZ led/VBN to/TO the/DT proposal/NN of/IN a/DT new/JJ metabolic/JJ treatment/NN for/IN various/JJ cancers/NNS including/VBG GBMs/NNS that/WDT may/MD enhance/VB the/DT effectiveness/NN of/IN the/DT SOC/NNP The/DT goal/NN of/IN metabolic/JJ cancer/NN therapy/NN is/VBZ to/TO 
332464_0_4_5_18_20::None::-/: density/NN lipoprotein/NN cholesterol/NN (/( LDL/NN -/: C/NN )/) reduction/NN with/IN statins/NNS is/VBZ the/DT cornerstone/NN of/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) 
1464_1464_8_9_22_23::None::are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ activation/NN are/VBP highly/RB related/VBN to/TO the/DT adenoviral/JJ E1A-associated/JJ cellular/JJ protein/NN p300/NN (/( refs/NNS 2/CD 
1004_1004_23_24_21_22::None::proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ,/, while/IN one/CD 
553793_3_32_34_10_11::None::QOL/NN in/IN elderly/JJ patients/NNS with/IN AF/NN receiving/VBG oral/JJ anticoagulants/NNS and/CC compare/VB QOL/NN of/IN patients/NNS treated/VBN with/IN vitamin/NN K/NN antagonists/NNS (/( VKA/NN )/) and/CC DOAC/NN This/DT prospective/JJ study/NN included/VBD patients/NNS of/IN 
620873_8_0_1_12_14::None::In/IN conclusion/NN ,/, mice/NNS administered/VBN formulations/NNS of/IN a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN silicone/NN oil/NN microdroplets/NNS ,/, glass/NN 
526397_0_3_4_27_28::None::This/DT longitudinal/JJ study/NN aims/VBZ to/TO compare/VB long/JJ -/: term/NN work/NN disability/NN and/CC absenteeism/NN between/IN anxiety/NN and/CC depressive/JJ disorders/NNS focusing/VBG on/IN the/DT effects/NNS of/IN different/JJ course/NN trajectories/NNS (/( remission/NN ,/, recurrence/NN and/CC 
241804_0_11_14_8_9::None::is/VBZ a/DT major/JJ complication/NN of/IN delayed/VBN tissue/NN plasminogen/NN activator/NN (/( t/NN -/: 
365_365_8_10_30_31::POS_ACTION_Causal::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
768572_0_11_12_1_2::None::The/DT utility/NN of/IN intravenous/JJ tissue/NN plasminogen/NN activator/NN (/( IV/CD t/NN -/: PA/NN )/) in/IN improving/VBG 
194621_0_12_13_7_8::None::lifestyle/NN ,/, the/DT technology/NN of/IN active/JJ and/CC biodegradable/JJ packaging/NN with/IN antimicrobial/JJ and/CC 
590_590_29_31_33_34::None::related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN 
467_467_4_6_2_3::None::Expression/NN of/IN c-Myc/NN or/CC cyclin/NN D1/NN was/VBD sufficient/JJ to/TO 
932_932_5_6_1_2::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
512613_1_42_43_12_14::medicine.disease.symptoms::affectivity/JJ symptoms/NNS (/( depressed/JJ mood/NN ,/, anxious/JJ mood/NN ,/, worry/NN )/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS ;/: more/JJR moderately/RB with/IN symptoms/NNS of/IN social/JJ phobia/NN ,/, affective/JJ lability/NN ,/, panic/NN ,/, posttraumatic/JJ stress/NN disorder/NN ,/, lassitude/NN ,/, 
671646_0_10_11_10_12::None::the/DT treatment/NN of/IN spinal/JJ tuberculosis/NN (/( TB/NN )/) 
1810_1810_20_21_0_1::POS_ACTION_CORELATE::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
1460_1460_8_9_3_4::POS_REG(0)_LOCALIZE::The/DT distribution/NN of/IN actin/NN filaments/NNS is/VBZ altered/VBN by/IN profilin/NN overexpression/NN ./. 
461685_1_18_19_3_4::None::Impaired/JJ glucagon/NN secretion/NN predisposes/VBZ some/DT patients/NNS with/IN type/NN 1/CD diabetes/NN mellitus/NN (/( T1DM/NN )/) to/TO hypoglycaemia/NN ;/: whereas/IN hyperglycaemia/NN in/IN patients/NNS with/IN 
755_755_4_5_9_10::None::cultured/VBN cells/NNS ,/, cofilin/NN ,/, as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN 
1233_1233_19_24_30_31::POS_ACTION_MEMBER::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
670_670_19_20_14_15::None::that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
1646_1646_13_14_2_3::None::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ for/IN actin/NN filament/NN binding/NN and/CC 
367_367_24_25_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
513747_5_101_102_106_107::None::childhood/NN prevalence/NN of/IN hypertension/NN ,/, renal/JJ denervation/NN for/IN resistant/JJ hypertension/NN and/CC the/DT 
899821_0_8_9_3_4::None::High/JJ risk/NN (/( oncogenic/JJ )/) human/JJ papillomavirus/NN (/( HPV/NN )/) infection/NN causes/VBZ 
231123_0_19_20_2_3::None::Nilotinib/NNP in/IN patients/NNS with/IN systemic/JJ mastocytosis/NN :/: analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN 
1760_1760_3_4_1_3::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP 
28_28_11_13_0_2::POS_ACTION_MEMBER::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
873835_0_43_46_14_15::None::that/WDT has/VBZ gained/VBN popularity/NN in/IN the/DT last/JJ couple/NN of/IN decades/NNS as/IN a/DT possible/JJ alternative/NN to/TO a/DT meniscectomy/NN to/TO provide/VB significant/JJ pain/NN relief/NN ,/, improve/VB function/NN ,/, and/CC prevent/VB the/DT early/JJ onset/NN of/IN degenerative/JJ joint/JJ disease/NN (/( DJD/NN )/) 
242294_6_31_32_8_9::None::A/NN )/) ,/, inter/NN -/: molecular/JJ O/NN -/: H/NN O/NN ,/, C/NN -/: H/NN O/NN and/CC C/NN -/: Hpi/NN inter/NN -/: actions/NNS link/VBP the/DT independent/JJ benzoates/NNS alternately/RB ,/, forming/VBG a/DT 
567_567_14_15_10_11::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
715810_0_3_4_25_26::None::The/DT root/NN of/IN Polygala/NN tenuifolia/NN Willdenow/NNP has/VBZ been/VBN used/VBN for/IN the/DT treatment/NN against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN anxiety/NN ,/, and/CC memory/NN improvement/NN ./. 
865_865_33_35_7_8::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
315603_0_8_9_19_20::medicine.medical_treatment.used_to_treat::,/, Nilotinib/NNP and/CC Imatinib/NNP in/IN Newly/RB Diagnosed/VBN Patients/NNS with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT Three/CD 
214618_2_0_1_3_4::None::Detection/NN of/IN a/DT rise/NN and/CC a/DT fall/NN 
662630_5_12_13_25_27::None::found/VBN with/IN Black/JJ adolescents/NNS reporting/VBG lower/JJR withdrawal/NN discomfort/NN scores/NNS and/CC experiencing/VBG less/RBR severe/JJ depressed/JJ mood/NN ,/, difficulty/NN sleeping/VBG ,/, nervousness/NN //: 
984_984_9_10_20_21::None::different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
735_735_22_23_3_4::None::In/IN contrast/NN ,/, act1-159/NN partially/RB suppresses/VBZ the/DT temperature/NN sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, 
494835_0_30_31_37_39::medicine.risk_factor.diseases::finasteride/NN alone/RB in/IN men/NNS with/IN prostatic/JJ enlargement/NN secondary/JJ to/TO benign/JJ prostatic/JJ hyperplasia/NN ./. 
93_93_28_29_54_55::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
244614_0_48_49_9_10::medicine.drug_ingredient.active_moiety_of_drug::prepared/VBN by/IN reacting/VBG Cr/NN (/( EH/NN )/) 3/CD (/( EH/NN =/JJ 2/CD -/: ethylhexanoate/NN )/) ,/, 2,5/CD -/: dimethylpyrrole/NN (/( Me2C4H2NH/NN )/) ,/, Et3Al/NN ,/, and/CC Et2AlCl/NN in/IN an/DT aromatic/JJ hydrocarbon/NN solvent/JJ was/VBD improved/VBN to/TO obtain/VB a/DT congener/NN composed/VBN of/IN a/DT new/JJ chromium/NN precursor/NN (/( EH/NN 
312260_0_1_2_8_9::None::The/DT procedure/NN of/IN reconstruction/NN after/IN the/DT removal/NN of/IN cranial/JJ fibrous/JJ dysplasia/NN (/( 
185_185_2_3_4_5::None::Associations/NNS of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, 
676724_2_37_38_47_48::None::like/IN disease/NN (/( D1/NN )/) was/VBD provoked/VBN by/IN STZ/NN without/IN NA/NNP Non/NNP -/: diabetic/JJ mice/NNS received/VBD vehicle/NN 
241804_0_7_8_17_18::None::)/) is/VBZ a/DT major/JJ complication/NN of/IN delayed/VBN tissue/NN plasminogen/NN activator/NN (/( t/NN -/: PA/NN )/) treatment/NN in/IN 
443637_7_20_21_12_13::None::tumorigenic/JJ model/NN of/IN HCC/NNP These/DT findings/NNS provide/VBP in/FW vitro/FW evidence/NN that/IN sorafenib/NN suppresses/VBZ HGF/NN -/: 
367_367_32_33_28_30::None::and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
202687_5_26_27_2_3::None::In/IN these/DT reactions/NNS ,/, the/DT ortho/NN C/NN -/: H/NN bond/NN of/IN two/CD different/JJ phenols/NNS and/CC the/DT ortho/NN and/CC para/NN C/NN -/: H/NN bond/NN of/IN phenols/NNS were/VBD coupled/VBN together/RB ./. 
1686_1686_25_28_51_53::POS_ACTION_Dynamics::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
243_243_30_32_3_4::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
255731_2_10_11_27_28::None::,/, we/PRP comprehensively/RB investigated/VBD the/DT abundance/NN and/CC diversity/NN of/IN STPs/NNS encoded/VBN in/IN 119/CD actinobacterial/JJ genomes/NNS ,/, based/VBN on/IN the/DT data/NNS stored/VBN in/IN the/DT Microbial/JJ 
907653_2_19_20_21_22::None::-/: based/VBN patient/NN provider/NN communication/NN service/NN (/( IPPC/NN )/) 
566758_0_2_3_11_12::None::Accelerometer/SYM -/: derived/VBN sedentary/JJ and/CC physical/JJ activity/NN time/NN in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 
1233_1233_30_31_26_27::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
574337_0_2_3_11_12::None::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN the/DT main/JJ etiologies/NNS of/IN cervical/JJ cancer/NN 
492693_2_39_40_92_93::None::re/SYM -/: appeared/VBD rapidly/RB above/IN 13/CD GPa/NN ,/, with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB accompanied/VBN by/IN a/DT structural/JJ transition/NN ,/, as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS 
322082_9_26_27_1_2::None::580/CD pg/NN //: ml/NN ,/, p/NN =/JJ 0.03/CD )/) but/CC not/RB cystatin/NN C/NN Patients/NNS with/IN chronic/JJ kidney/NN disease/NN demonstrated/VBD higher/JJR NGAL/NN levels/NNS compared/VBN with/IN subjects/NNS with/IN preserved/JJ renal/JJ function/NN (/( 
265468_0_5_7_8_9::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS 
502525_12_6_7_30_32::None::-/: CCP/NN and/CC CRP/NN are/VBP associated/VBN with/IN increased/VBN cIMT/NN and/CC cardiovascular/JJ risk/NN supporting/VBG a/DT clinical/JJ role/NN of/IN the/DT measurement/NN of/IN cIMT/NN in/IN RA/NN in/IN predicting/VBG and/CC preventing/VBG cardiovascular/JJ events/NNS ./. 
499291_35_18_19_8_9::medicine.symptom.symptom_of::of/IN women/NNS with/IN PCOS/NN appear/VBP to/TO be/VB significantly/RB different/JJ depending/VBG on/IN ethnicity/NN ,/, obesity/NN and/CC age/NN ./. 
159463_2_14_15_2_3::None::Actually/RB ,/, premenopausal/JJ women/NNS have/VBP a/DT significantly/RB lower/JJR risk/NN for/IN cardiovascular/JJ disease/NN comparing/VBG to/TO postmenopausal/JJ women/NNS or/CC age/NN 
932_932_5_6_3_4::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
1089_1089_9_10_20_21::None::studies/NNS demonstrated/VBD that/IN Stat1/NN could/MD directly/RB interact/VB with/IN TNFR1/NN and/CC TRADD/NN but/CC not/RB with/IN FADD/NN ./. 
406221_0_7_8_0_1::None::Antibiotic/JJ and/CC oral/JJ corticosteroid/NN prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ 
675416_11_0_1_10_11::None::The/DT following/VBG five/CD biomarkers/NNS will/MD be/VB discussed/VBN :/: proadrenomedullin/NN for/IN prognostic/JJ triage/NN assessment/NN and/CC 
322750_1_21_22_51_52::None::N/NN )/) ,/, ammonium/NN (/( NH4/NN -/: N/NN )/) ,/, phosphate/NN (/( PO4/NN -/: P/NN )/) ,/, dissolved/VBN organic/JJ carbon/NN (/( DOC/NN )/) ,/, methane/NN (/( CH4/NN )/) ,/, and/CC dinitrogen/NN oxide/NN (/( N2O/NN )/) ./. 
311864_8_23_24_38_39::None::suffering/VBG from/IN IgG/NN subclass/NN deficiency/NN without/IN autoimmunity/NN and/CC //: or/CC coagulation/NN disorders/NNS ,/, likely/JJ restoring/VBG idiotype/NN -/: antiidiotype/JJ network/NN ;/: showing/VBG evidence/NN 
306064_4_29_30_0_1::medicine.drug_ingredient.active_moiety_of_drug::Denosumab/NNP has/VBZ recently/RB been/VBN reported/VBN to/TO be/VB effective/JJ for/IN unresectable/JJ GCTB/NN ;/: however/RB ,/, there/EX is/VBZ only/RB one/CD report/NN of/IN its/PRP$ effect/NN on/IN GCRG/NNP Moreover/RB ,/, the/DT effect/NN of/IN denosumab/NN on/IN GCRG/NN of/IN 
513_513_17_19_12_13::None::PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
346198_0_1_2_10_11::medicine.drug.active_moieties::Microbial/JJ caffeine/NN removal/NN is/VBZ a/DT green/JJ solution/NN for/IN treatment/NN of/IN caffeinated/VBN products/NNS and/CC agro/NN 
468565_7_9_10_10_11::None::ended/VBD ,/, indicating/VBG rapid/JJ physiological/JJ recovery/NN from/IN the/DT 
1866_1866_7_8_9_10::None::and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
235372_5_10_12_25_26::None::BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN ,/, length/NN of/IN time/NN on/IN oral/JJ contraceptives/NNS ,/, age/NN at/IN menarche/NN and/CC calcium/NN intake/NN 
95_95_9_10_5_6::None::contain/VBP only/RB 1/CD profilin/NN for/IN every/DT 5-10/CD actin/NN molecules/NNS ,/, these/DT 
241510_0_4_5_28_29::medicine.disease.treatments::patients/NNS with/IN ischemic/JJ cardiomyopathy/NN the/DT size/NN of/IN bipolar/JJ low/JJ voltage/NN areas/NNS (/( LVA/NN )/) in/IN electroanatomical/JJ maps/NNS (/( EAM/NN )/) was/VBD associated/VBN with/IN poorer/JJR outcomes/NNS after/IN catheter/NN ablation/NN (/( CA/NNP )/) 
1258_1258_3_4_32_33::None::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) 
1683_1683_15_16_10_12::POS_ACTION_BIND::the/DT profilin/NN and/CC DNase/NN I/CD binding/NN sites/NNS on/IN actin/NN ./. 
1486_1486_35_40_60_61::POS_ACTION_STIMULATE::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
467441_4_14_15_18_19::None::of/IN Copper/NN //: Zinc/NNP Superoxide/NN dismutase/NN (/( Cu/NN //: Zn/NN -/: 
1087_1087_25_26_7_9::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
30983_5_8_9_13_14::medicine.medical_treatment.used_to_treat::mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN of/IN menopausal/JJ symptoms/NNS than/IN control/JJ 
749205_0_14_15_23_24::medicine.medical_treatment.used_to_treat::Neuroendocrine/JJ Factors/NNS Predict/VB SSRIs/NNS Treatment/NN Outcome/NN in/IN the/DT Chinese/JJ Population/NNP with/IN Major/NNP Depression/NNP ./. 
446387_0_48_49_8_9::None::old/JJ man/NN with/IN metastatic/JJ castration/NN -/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT adenovirus/NN vector/NN carrying/VBG the/DT human/JJ REIC/NN //: Dkk/SYM -/: 3/CD gene/NN (/( Ad/NN -/: REIC/NN )/) ,/, following/VBG chemotherapy/NN ./. 
1380_1380_24_25_34_35::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, 
1526_1526_12_13_10_11::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN 
1850_1850_23_24_10_11::None::the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
849947_0_0_1_6_7::None::Congenital/JJ peritoneopericardial/JJ diaphragmatic/JJ hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
2222_2222_11_12_19_20::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
346_346_24_25_16_17::POS_ACTION_BIND::of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT binding/NN of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
1711_1711_19_20_16_19::None::related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
1434_1434_7_8_14_15::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
280_280_14_15_13_14::None::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB 
25979_5_5_7_5_6::people.cause_of_death.includes_causes_of_death::60,211/CD participants/NNS without/IN cardiovascular/JJ disease/NN at/IN baseline/NN 
1648_1648_7_8_44_45::None::that/IN the/DT mutated/VBN cofilin/NN possessing/VBG KTLKK/NNP instead/RB of/IN KKRKK/NNP did/VBD not/RB translocate/VB into/IN the/DT nuclei/NNS in/IN response/NN to/TO heat/NN shock/NN whereas/IN a/DT recombinant/JJ cofilin/NN with/IN the/DT unaltered/JJ sequence/NN of/IN KKRKK/NNP responded/VBD to/TO heat/NN shock/NN and/CC formed/VBD intranuclear/JJ rods/NNS together/RB with/IN actin/NN ./. 
423051_1_21_22_13_14::None::in/IN RA/NN are/VBP confounded/VBN not/RB only/RB by/IN traditional/JJ risk/NN factors/NNS (/( TRF/NN )/) but/CC also/RB 
340516_1_20_21_11_12::None::2011/CD ,/, we/PRP estimated/VBD the/DT frequency/NN of/IN antibiotics/NNS prescribing/VBG for/IN URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS 
426593_3_20_21_17_18::None::-/: probability/NN pain/NN reduction/NN ,/, the/DT objective/JJ response/NN was/VBD poor/JJ 
2222_2222_19_20_21_22::POS_ACTION_COLOCALIZE::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
1286_1286_8_9_12_13::None::chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
1289_1289_11_12_7_8::POS_ACTION_INTERACT::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
565_565_28_29_4_7::None::we/PRP demonstrate/VBP that/IN type/NN XIII/CD collagen/NN is/VBZ concentrated/VBN in/IN cultured/VBN skin/NN fibroblasts/NNS and/CC several/JJ other/JJ human/JJ mesenchymal/JJ cell/NN lines/NNS in/IN the/DT focal/JJ adhesions/NNS at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, 
658012_2_1_2_25_26::None::We/PRP report/VBP a/DT case/NN of/IN a/DT 66/CD -/: year/NN -/: old/JJ male/NN who/WP had/VBD undergone/VBN PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB and/CC who/WP presented/VBD at/IN our/PRP$ hospital/NN 
967935_1_8_10_3_4::None::We/PRP analyzed/VBD the/DT chromosomal/JJ distribution/NN and/CC evolution/NN of/IN repeated/VBN sequences/NNS in/IN Triatominae/FW genomes/NNS 
1006_1006_14_15_11_13::None::microfilaments/NNS and/CC two/CD actin-binding/JJ proteins/NNS :/: gelsolin/NN and/CC profilin/NN ./. 
2222_2222_19_20_13_14::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
663522_15_9_10_36_38::None::prostate/NN cancer/NN detection/NN rate/NN stratified/VBN by/IN the/DT severity/NN of/IN LUTS/NNP Patients/NNPS undergoing/VBG prostate/NN biopsy/NN have/VBP ,/, with/IN a/DT high/JJ probability/NN ,/, LUTS/NNP Approximately/RB 50/CD %/NN suffer/VBP from/IN some/DT degree/NN of/IN erectile/JJ dysfunction/NN and/CC 24/CD %/NN 
416351_15_1_2_6_7::None::Having/VBG personal/JJ or/CC family/NN history/NN of/IN hypertension/NN ,/, older/JJR age/NN 
1782_1782_20_22_23_24::None::the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
739338_5_23_24_15_16::None::a/DT history/NN of/IN smoking/NN and/CC diabetes/NN ,/, but/CC there/EX was/VBD no/DT difference/NN in/IN stroke/NN severity/NN 
1539_1539_1_3_13_14::None::The/DT K114E/NN profilin/NN exhibited/VBD a/DT profound/JJ decrease/NN in/IN its/PRP$ ability/NN to/TO interact/VB with/IN actin/NN ,/, whereas/IN binding/VBG 
1439_1439_16_17_26_27::POS_ACTION_BIND::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
352442_4_7_9_28_30::None::,/, the/DT calculated/JJ association/NN constants/NNS are/VBP 10.1/CD M/NN (/( -/: 1/LS )/) (/( lidocainium/NN docusate/NN )/) ;/: 0.77/CD M/NN (/( -/: 1/LS )/) (/( sodium/NN chloride/NN )/) ;/: 0.086/CD 
365169_1_22_23_5_6::None::a/DT cascade/NN of/IN complications/NNS -/: active/JJ pulmonary/JJ tuberculosis/NN despite/IN recent/JJ isoniazid/NN prophylactic/NN therapy/NN ,/, non/JJ -/: tuberculous/JJ mycobacterial/JJ disease/NN ,/, chronic/JJ airways/NNS obstruction/NN ,/, 
18_18_4_5_18_20::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
464783_0_0_1_19_20::None::This/DT review/NN describes/VBZ the/DT recent/JJ developments/NNS in/IN the/DT pathobiology/NN of/IN endothelial/JJ dysfunction/NN (/( ED/NN )/) in/IN the/DT context/NN of/IN cirrhosis/NN with/IN portal/JJ hypertension/NN 
225032_8_17_18_8_9::None::two/CD -/: dimensional/JJ culture/NN ,/, three/CD -/: dimensional/JJ culture/NN system/NN could/MD give/VB rise/VB to/TO an/DT up/RB 
302982_3_9_10_2_3::None::In/IN dyssomnia/NN group/NN ,/, (/( 1/LS )/) Glucagon/NNP ,/, glucagon/NNP //: insulin/NN ratio/NN 
495841_5_7_8_5_6::None::and/CC 26/CD displayed/VBD strong/JJ ,/, equipotent/JJ activities/NNS against/IN vemurafenib/NN 
512095_3_29_30_46_47::medicine.medical_treatment.used_to_treat::on/IN post/NN -/: operative/JJ MAG/NN -/: 3/CD scan/VB ,/, and/CC //: or/CC a/DT reduction/NN in/IN renal/JJ function/NN of/IN the/DT obstructed/VBN kidney/NN to/TO &/CC lt/NN 
312260_0_12_13_3_4::None::The/DT procedure/NN of/IN reconstruction/NN after/IN the/DT removal/NN of/IN cranial/JJ fibrous/JJ dysplasia/NN (/( FD/NN )/) must/MD be/VB 
2064_2064_49_50_28_29::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
15883_8_5_6_1_2::None::The/DT MRI/NNP remains/VBZ the/DT best/JJS tool/NN to/TO detect/VB and/CC 
2064_2064_49_50_40_41::POS_ACTION_CORELATE::,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
723866_2_8_9_1_2::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN from/IN India/NNP ./. 
96855_6_18_19_14_15::None::all/DT five/CD underwent/VBD burn/VBP excision/NN and/CC microsurgical/JJ reconstruction/NN using/VBG distant/JJ flaps/NNS 
95037_9_21_22_12_13::medicine.disease.risk_factors:://: 136/CD control/NN elderly/JJ (/( 40.0/CD %/NN )/) ,/, 21/CD //: 29/CD AD/NN (/( 72.4/CD %/NN 
596639_0_22_23_15_17::None::,/, several/JJ simultaneously/RB flowering/VBG plant/NN species/NNS depend/VBP on/IN the/DT same/JJ pollinator/NN ./. 
245_245_10_11_2_3::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
189641_0_10_11_22_23::None::energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD diabetes/NN has/VBZ developed/VBN into/IN a/DT major/JJ health/NN concern/NN worldwide/RB 
1782_1782_27_28_11_12::None::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
243_243_0_2_3_4::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT 
515725_7_3_4_36_37::None::Individuals/NNS with/IN chronic/JJ mental/JJ and/CC physical/JJ conditions/NNS (/( fatigue/NN ,/, insomnia/NN ,/, anxiety/NN ,/, depression/NN ,/, diabetes/NN ,/, breathing/NN problems/NNS ,/, high/JJ blood/NN pressure/NN ,/, heart/NN disease/NN ,/, stroke/NN and/CC cancer/NN )/) were/VBD more/RBR likely/JJ to/TO report/VB the/DT lowest/JJS levels/NNS 
1688_1688_5_6_13_14::POS_ACTION_Change::suggest/VBP that/IN nuclear/JJ profilin/NN can/MD mediate/VB a/DT stimulus-response/JJ action/NN on/IN the/DT actin/NN cytoskeleton/NN which/WDT is/VBZ 
93_93_22_23_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
1095_1095_35_36_17_18::POS_ACTION_LOCALIZE::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
790_790_29_33_33_34::POS_ACTION_MEMBER::,/, including/VBG the/DT cyclin/NN dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, which/WDT blocks/VBZ 
1633_1633_25_26_15_16::POS_ACTION_MEMBER::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: 
287311_9_1_2_21_22::None::The/DT AUROC/NN values/NNS for/IN VFA/NNP were/VBD higher/JJR than/IN those/DT for/IN BMI/NNP and/CC WHR/NNP For/IN VFA/NNP ,/, the/DT sensitivity/NN and/CC specificity/NN for/IN predicting/VBG CKD/NNP were/VBD 62.66/CD 
1094_1094_14_15_16_17::None::three/CD subunits/NNS ,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, 
305802_4_3_4_30_31::None::Dantrolene/NN reduced/VBD the/DT number/NN of/IN premature/JJ ventricular/JJ complexes/NNS (/( PVCs/NNS )/) on/IN average/NN by/IN 74/CD %/NN (/( range/NN 33/CD -/: 97/CD )/) in/IN four/CD patients/NNS with/IN N/NN -/: terminal/JJ or/CC central/JJ mutations/NNS in/IN the/DT 
2222_2222_23_24_39_40::None::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
658012_2_25_26_0_1::None::We/PRP report/VBP a/DT case/NN of/IN a/DT 66/CD -/: year/NN -/: old/JJ male/NN who/WP had/VBD undergone/VBN PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB and/CC who/WP presented/VBD at/IN our/PRP$ hospital/NN 
315603_0_14_15_22_23::None::Diagnosed/VBN Patients/NNS with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT Three/CD -/: year/NN Retrospective/JJ 
125639_3_21_22_6_7::None::UV/NN -/: visible/JJ absorption/NN and/CC electron/NN paramagnetic/JJ resonance/NN (/( EPR/NN )/) analysis/NN suggested/VBD that/IN the/DT enzyme/NN had/VBD the/DT typical/JJ copper/NN sites/NNS ,/, 
1782_1782_1_6_7_8::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT 
272493_8_6_8_15_16::None::,/, among/IN 13/CD NMDA/NN receptor/NN IgG/NN -/: positive/JJ patients/NNS ,/, 12/CD had/VBD encephalitis/NN ;/: their/PRP$ psychiatric/JJ 
2003_2003_33_34_26_27::None::]/) for/IN binding/VBG profilin/NN ,/, an/DT actin-regulatory/JJ protein/NN that/WDT stimulates/VBZ actin/NN filament/NN assembly/NN ./. 
216790_2_2_3_4_5::None::In/IN this/DT study/NN ,/, sulfated/JJ (/( 1/LS -/: 
1169_1169_41_42_10_11::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
1850_1850_10_11_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
1052_1052_37_38_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
579913_0_3_4_19_20::None::Metabolic/JJ syndrome/NN (/( MetS/NN )/) is/VBZ a/DT cluster/NN of/IN cardiovascular/JJ risk/NN factors/NNS that/WDT includes/VBZ obesity/NN ,/, diabetes/NN ,/, and/CC dyslipidemia/NN ./. 
394705_2_89_92_107_108::None::B/NN having/VBG estimated/VBN glomerular/JJ filtration/NN rates/NNS &/CC gt/NN ;/: 45/CD mL/NN //: min/NN //: 1.73/CD m2/NN ,/, and/CC a/DT significantly/RB lower/JJR incidence/NN of/IN chronic/JJ allograft/NN 
1105_1105_20_24_0_1::None::p21/NN (/( p21WAF1/Cip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN arrest/NN and/CC can/MD inhibit/VB the/DT activity/NN of/IN the/DT proliferating/VBG cell/NN nuclear/JJ antigen/NN (/( PCNA/NN )/) 
236038_0_16_17_17_18::None::and/CC cell/NN -/: matrix/NN adhesion/NN ,/, cell/NN migration/NN 
456903_0_9_10_37_38::None::and/CC short/JJ -/: acting/VBG once/RB daily/JJ prandial/JJ glucagon/NN -/: like/IN peptide/NN -/: 1/CD receptor/NN agonist/NN which/WDT lowers/VBZ glycohemoglobin/NN and/CC body/NN weight/NN by/IN clinically/RB significant/JJ amounts/NNS in/IN patients/NNS with/IN type/NN 2/CD diabetes/NNS treated/VBN with/IN basal/JJ insulin/NN 
258_258_6_7_8_9::POS_ACTION_BIND::and/CC association/NN of/IN beta-catenin/NN with/IN EGFR/NN were/VBD inhibited/VBN by/IN 
369607_2_16_17_27_28::None::of/IN heparin/NN including/VBG chondroitin/NN 4/CD -/: sulfate/NN (/( ChS/NN )/) and/CC hyaluronic/JJ acid/NN (/( HA/NN )/) ./. 
699_699_19_22_22_23::POS_ACTION_MEMBER::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) 
1969_1969_18_19_20_21::None::motility/NN complex/NN containing/VBG VASP/NN and/CC profilin/NN ./. 
2064_2064_8_9_40_41::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
1288_1288_13_14_11_12::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
728764_2_6_8_4_5::None::of/IN chronic/JJ kidney/NN disease/NN included/VBD diabetes/NN mellitus/NN (/( n/NN =/JJ 
322602_4_18_19_6_7::None::heart/NN diseases/NNS were/VBD congenital/JJ heart/NN disease/NN (/( n/NN =/JJ 65/CD ,/, 53.3/CD %/NN )/) and/CC arrhythmia/NN (/( n/NN =/JJ 
996_996_31_34_12_13::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
713526_5_14_16_18_20::None::of/IN comorbid/JJ bipolar/JJ mood/NN disorder/NN and/CC chronic/JJ pain/NN disorders/NNS ./. 
446387_0_26_27_12_13::medicine.medical_treatment.used_to_treat::castration/NN -/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT 
1652_1652_20_21_31_32::POS_ACTION_BIND::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
573489_1_15_16_22_23::medicine.medical_treatment.used_to_treat::plastic/NN and/CC reconstructive/JJ surgeon/NN after/IN the/DT initial/JJ diagnosis/NN of/IN breast/NN cancer/NN ./. 
240658_2_11_12_5_6::None::work/NN ,/, we/PRP demonstrated/VBD that/IN aggression/NN acts/VBZ as/IN an/DT SNC/NN trait/NN in/IN fruit/NN 
661306_5_6_7_2_3::None::Commonly/RB occurring/VBG strains/NNS included/VBD apprehension/NN //: anxiety/NN ,/, frustration/NN ,/, 
2148_2148_52_53_52_53::None::does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
2072_2072_11_14_14_15::POS_ACTION_MEMBER::of/IN the/DT mammalian/JJ actin/NN binding/NN protein/NN cofilin/NN ./. 
2131_2131_21_22_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
327522_2_2_3_6_7::medicine.drug_ingredient.active_moiety_of_drug::CB1/NN inhibits/VBZ GABA/NN release/NN ,/, and/CC GABAergic/JJ dysregulation/NN in/IN the/DT 
807975_0_12_13_14_15::None::pain/NN -/: related/JJ depression/NN of/IN behavior/NN and/CC mesolimbic/JJ dopamine/NN 
663522_15_36_38_24_25::medicine.symptom.symptom_of::,/, with/IN a/DT high/JJ probability/NN ,/, LUTS/NNP Approximately/RB 50/CD %/NN suffer/VBP from/IN some/DT degree/NN of/IN erectile/JJ dysfunction/NN and/CC 24/CD %/NN 
303626_0_19_20_27_28::None::NPs/NNS )/) on/IN chromium/NN (/( Cr/NN )/) fractionation/NN in/IN a/DT soil/NN contaminated/VBN with/IN leather/NN factory/NN 
497295_0_40_41_23_24::None::based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN up/RB to/TO 60/CD %/NN in/IN HER2/NN -/: positive/JJ breast/NN cancer/NN ./. 
275933_7_2_3_28_29::medicine.disease.risk_factors::When/WRB describing/VBG leukemia/NN predisposition/NN due/JJ to/TO hereditary/JJ cancer/NN syndromes/NNS ,/, the/DT following/VBG 6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN 
1006_1006_11_13_14_15::POS_ACTION_MEMBER::microfilaments/NNS and/CC two/CD actin-binding/JJ proteins/NNS :/: gelsolin/NN and/CC profilin/NN ./. 
420079_6_3_6_19_20::None::During/IN pregnancy/NN ,/, acute/JJ kidney/NN injury/NN (/( 5/CD //: 8/CD )/) ,/, anemia/NN (/( 5/CD //: 8/CD )/) ,/, hematuria/NN (/( 8/CD //: 
156299_3_1_2_22_24::None::Between/IN September/NNP 2009/CD and/CC July/NNP 2011/CD ,/, RFA/NN using/VBG two/CD or/CC three/CD radiofrequency/NN (/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN 
125951_3_24_25_34_36::None::dexamethasone/NN )/) can/MD induce/VB apoptosis/NN in/IN cancer/NN cells/NNS and/CC //: or/CC diminish/VB the/DT inflammatory/JJ response/NN during/IN surgery/NN which/WDT 
72723_0_18_19_4_5::None::nephropathy/NN ,/, a/DT consequence/NN of/IN chronic/JJ high/JJ blood/NN pressure/NN ,/, is/VBZ increasingly/RB a/DT cause/NN of/IN end/NN -/: stage/NN renal/JJ diseases/NNS and/CC 
87_87_12_13_37_38::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN 
340516_1_15_16_39_40::medicine.medical_treatment.used_to_treat::the/DT frequency/NN of/IN antibiotics/NNS prescribing/VBG for/IN URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS of/IN acute/JJ nasopharyngitis/NN (/( common/JJ cold/NN )/) ,/, acute/JJ sinusitis/NN ,/, acute/JJ pharyngitis/NN ,/, acute/JJ tonsillitis/NN ,/, acute/JJ laryngitis/NN 
497295_0_28_29_1_2::None::Dual/JJ anti/JJ -/: HER2/NN blockade/NN with/IN trastuzumab/NN //: pertuzumab/NN or/CC trastuzumab/NN //: lapatinib/NN in/IN combination/NN with/IN anthracycline/NN //: taxane/NN -/: based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN 
1771_1771_1_2_19_20::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
341530_0_24_25_2_5::None::Patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) are/VBP at/IN a/DT high/JJ risk/NN for/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) due/JJ to/TO increased/VBN prevalence/NN of/IN traditional/JJ and/CC nontraditional/JJ CVD/NN 
957_957_23_24_12_13::None::heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
1434_1434_11_12_14_15::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
456903_0_13_14_46_47::medicine.medical_treatment.used_to_treat::once/RB daily/JJ prandial/JJ glucagon/NN -/: like/IN peptide/NN -/: 1/CD receptor/NN agonist/NN which/WDT lowers/VBZ glycohemoglobin/NN and/CC body/NN weight/NN by/IN clinically/RB significant/JJ amounts/NNS in/IN patients/NNS with/IN type/NN 2/CD diabetes/NNS treated/VBN with/IN basal/JJ insulin/NN ,/, with/IN limited/JJ risk/NN of/IN hypoglycemia/NN ./. 
417653_2_13_14_5_6::None::are/VBP increased/VBN in/IN plasma/NN of/IN obese/JJ ,/, insulin/NN -/: resistant/JJ and/CC diabetic/JJ individuals/NNS ,/, who/WP 
370155_0_10_11_29_30::None::artery/NN disease/NN (/( CAD/NN )/) ,/, and/CC noncoronary/JJ atherosclerotic/JJ vascular/JJ diseases/NNS (/( NCVDs/NNS )/) have/VBP similar/JJ risks/NNS of/IN cardiovascular/JJ events/NNS and/CC similar/JJ recommendations/NNS for/IN lipid/NN control/NN 
31738_0_2_3_0_1::None::Variation/NN in/IN Medicare/NNP Payments/NNS for/IN Colorectal/JJ 
188913_0_25_26_23_24::medicine.drug_ingredient.active_moiety_of_drug::Ca/NN )/) ,/, iron/NN (/( Fe/NNP )/) ,/, copper/NN 
834587_19_9_11_14_15::medicine.disease.treatments::in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ 
270415_4_7_8_6_7::None::rest/NN MFR/NN were/VBD automatically/RB derived/VBN from/IN PET/NNP Patient/NNP 
185609_1_12_13_33_34::None::patients/NNS ,/, the/DT number/NN of/IN patients/NNS with/IN various/JJ comorbidities/NNS such/JJ as/IN membranous/JJ nephropathy/NN is/VBZ also/RB rising/VBG ,/, and/CC problems/NNS associated/VBN with/IN the/DT administration/NN of/IN chemotherapy/NN to/TO elderly/JJ patients/NNS 
213969_5_64_65_48_49::None::,/, rituximab/NN ,/, tacrolimus/NN ,/, paroxetine/NN ,/, sertraline/NN ,/, fluoxetine/NN ,/, bardoxolone/NN methyl/NN [/( phase/NN II/CD ]/) ;/: and/CC sorafenib/NN ,/, FK506/NN ,/, 
259065_5_16_18_4_5::medicine.risk_factor.diseases::between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN 
1913_1913_7_8_5_6::None::the/DT possibility/NN that/IN TD77/NN disrupts/VBZ actin/NN stress/NN fibers/NNS by/IN 
754436_8_13_14_15_16::None::problems/NNS with/IN their/PRP$ memory/NN and/CC concentration/NN compared/VBN with/IN fewer/JJR 
1055_1055_2_3_19_22::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
664393_0_1_2_9_11::medicine.risk_factor.diseases::Intraoperative/JJ radiotherapy/NN of/IN the/DT breast/NN for/IN early/JJ -/: stage/NN breast/NN cancer/NN :/: ready/JJ for/IN 
173493_0_21_22_0_1::medicine.drug_ingredient.active_moiety_of_drug::Budesonide/NN formoterol/NN (/( BF/NN )/) SpiromaxRegistered/NNP is/VBZ a/DT breath/NN -/: actuated/VBN dry/JJ -/: powder/NN inhaler/NN designed/VBN to/TO deliver/VB similar/JJ combinations/NNS of/IN budesonide/NN and/CC formoterol/NN as/IN 
178597_0_28_29_0_2::None::Clinical/JJ trials/NNS have/VBP shown/VBN that/IN a/DT strategy/NN for/IN haploidentical/JJ transplantation/NN based/VBN on/IN the/DT infusion/NN of/IN high/JJ numbers/NNS of/IN T/NN -/: cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN 
980_980_12_13_14_15::None::the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN 
832646_0_4_5_8_10::medicine.symptom.symptom_of::identity/NN predicts/VBZ lower/JJR anxiety/NN and/CC depression/NN in/IN multiple/JJ sclerosis/NN ./. 
326872_11_15_16_2_3::None::AII/CD amacrine/NN cells/NNS have/VBP been/VBN considered/VBN as/IN the/DT main/JJ targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO 
1790_1790_22_24_25_26::POS_ACTION_MEMBER::interferon-induced/JJ ,/, dsRNA-activated/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
237860_0_8_10_20_21::None::woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN )/) named/VBN Lyuba/NNP was/VBD found/VBN frozen/VBN in/IN the/DT Siberian/JJ tundra/NN permafrost/NN along/IN the/DT Yuribey/NNP 
567_567_10_11_7_9::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT 
201815_2_6_7_22_23::None::we/PRP established/VBD a/DT silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS such/JJ as/IN pioglitazone/NN and/CC metformin/NN ./. 
113665_4_12_13_3_4::None::We/PRP show/VBP that/IN dopamine/NN ,/, acting/VBG through/IN D1/NN receptors/NNS ,/, reduces/VBZ the/DT amplitude/NN and/CC sensitivity/NN of/IN 
1140_1140_22_23_20_21::None::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
543881_0_27_28_18_19::None::leading/VBG to/TO progressive/JJ damage/NN of/IN bone/NN and/CC cartilage/NN with/IN functional/JJ impairment/NN and/CC disability/NN ./. 
735_735_24_25_22_23::None::cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
251166_0_13_15_25_26::people.cause_of_death.includes_causes_of_death::cholesterol/NN levels/NNS for/IN cardiovascular/JJ risk/NN stratification/NN is/VBZ limited/VBN in/IN patients/NNS with/IN coronary/JJ artery/NN disease/NN (/( CAD/NN )/) ./. 
347064_0_17_18_15_18::people.cause_of_death.includes_causes_of_death::for/IN spinal/JJ cord/NN injury/NN ,/, but/CC the/DT 
1052_1052_29_30_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
865150_0_5_6_12_13::None::small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN 
853642_16_11_12_2_3::None::HF/NN and/CC perfusion/NN defects/NNS were/VBD not/RB recognized/VBN with/IN LDCT/NN In/IN COPD/NN patients/NNS and/CC long/JJ -/: 
18085_7_7_9_12_13::None::report/NN of/IN a/DT live/JJ birth/NN of/IN a/DT healthy/JJ child/NN after/IN ICSI/NN -/: 
29775_1_3_5_10_11::None::Despite/IN the/DT significant/JJ anatomical/JJ variation/NN in/IN the/DT hymen/NN and/CC no/DT guarantee/NN that/IN rupture/NN or/CC 
15883_8_5_6_0_1::None::The/DT MRI/NNP remains/VBZ the/DT best/JJS tool/NN to/TO detect/VB and/CC 
228216_0_10_11_3_4::None::Exposing/VBG cells/NNS to/TO folding/JJ stress/NN causes/VBZ a/DT subset/NN of/IN their/PRP$ proteins/NNS to/TO misfold/VB and/CC 
169759_4_19_20_27_29::None::and/CC //: or/CC activity/NN ,/, consistent/JJ with/IN their/PRP$ involvement/NN in/IN the/DT disulfide/NN bonds/NNS found/VBN in/IN the/DT 
844136_3_23_24_24_25::medicine.medical_treatment.used_to_treat::new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
1962_1962_20_22_24_25::POS_ACTION_MEMBER::deficient/JJ in/IN the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
928918_0_9_10_2_3::None::Long/JJ -/: term/NN consequences/NNS of/IN anesthetic/JJ technique/NN after/IN cancer/NN surgery/NN ./. 
162581_4_3_4_11_13::None::We/PRP focused/VBD on/IN esophageal/NN ,/, gastric/JJ ,/, pancreatic/JJ ,/, liver/NN and/CC colorectal/JJ cancers/NNS ./. 
1205_1205_6_7_4_5::None::of/IN the/DT yeast/NN MSH3/NN and/CC MSH6/NN genes/NNS for/IN MSH2-dependent/JJ 
619_619_43_44_21_22::None::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
398949_5_8_10_66_67::None::vitamin/NN C/NN ,/, vitamin/NN E/NN ,/, N/NN -/: acetyl/NN -/: l/NN -/: cysteine/NN )/) provided/VBD partial/JJ protection/NN against/IN cell/NN loss/NN but/CC also/RB promoted/VBD loss/NN of/IN the/DT cholinergic/JJ phenotype/NN in/IN response/NN to/TO TSE/NNP Notably/RB ,/, the/DT antioxidants/NNS themselves/PRP altered/VBD neurodifferentiation/NN ,/, reducing/VBG cell/NN numbers/NNS and/CC promoting/VBG the/DT cholinergic/JJ phenotype/NN at/IN the/DT expense/NN of/IN the/DT dopaminergic/JJ phenotype/NN ,/, an/DT effect/NN that/WDT was/VBD most/RBS prominent/JJ for/IN N/NN -/: 
721_721_13_14_15_16::None::to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC PRP21/NN and/CC 
957_957_12_13_8_11::None::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO 
252268_2_0_1_10_11::None::We/PRP describe/VBP a/DT cohort/NN of/IN rhesus/NN macaques/NNS displaying/VBG SIB/NNP as/IN adults/NNS ,/, in/IN which/WDT 
1678_1678_13_14_13_14::POS_ACTION_ENCODE::of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN 
546055_2_20_21_30_31::medicine.risk_factor.diseases::urinarypeptide/NN -/: based/VBN high/JJ -/: dimensional/JJ classifier/NN ,/, namely/RB CKD273/NN ,/, for/IN predicting/VBG CKD/NNP progression/NN ./. 
323090_6_13_14_15_16::None::,/, liver/NN ,/, colorectal/JJ ,/, breast/NN ,/, and/CC cervical/JJ 
38849_2_7_8_19_20::medicine.disease.risk_factors::human/JJ acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) ,/, they/PRP are/VBP common/JJ in/IN murine/JJ models/NNS of/IN radiation/NN -/: induced/VBN AML/NN 
712_712_24_25_11_12::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
70627_9_11_12_0_1::None::Cortisol/NN response/NN to/TO stress/NN differed/VBD according/VBG to/TO group/NN :/: in/IN the/DT ADHD/NNP group/NN ,/, 20min/JJ 
473887_5_18_19_0_2::None::Palliative/JJ care/NN improves/VBZ symptoms/NNS ,/, most/JJS frequently/RB pain/NN ,/, and/CC improves/VBZ quality/NN of/IN life/NN for/IN patients/NNS and/CC their/PRP$ families/NNS ,/, especially/RB in/IN 
862710_1_26_27_25_26::medicine.medical_treatment.used_to_treat::drug/NN therapy/NN of/IN ALS/NNP Riluzole/NNP ,/, a/DT moderately/RB 
513_513_9_10_12_13::None::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
1095_1095_22_23_11_12::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
1508_1508_5_6_10_11::None::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT 
1507_1507_6_7_22_23::POS_ACTION_CONTAIN::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS ./. 
2131_2131_9_10_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC 
619_619_26_29_21_22::None::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT 
1199_1199_8_9_5_6::POS_REG(-)_POLYMERIZE::the/DT inhibition/NN of/IN actin/NN polymerization/NN by/IN profilin/NN ./. 
201_201_4_5_6_7::POS_ACTION_INTERACT::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS 
608_608_23_24_18_19::POS_ACTION_BIND::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
787228_4_4_5_23_24::medicine.disease.treatments::results/NNS revealed/VBD that/IN COPD/NNP was/VBD significantly/RB associated/VBN with/IN a/DT high/JJ risk/NN of/IN osteoporosis/NN ,/, regardless/RB of/IN whether/IN the/DT patients/NNS with/IN COPD/NN were/VBD corticosteroid/NN users/NNS and/CC irrespective/RB 
23235_3_16_17_23_24::None::70o/JJ HUT/NN for/IN determination/NN of/IN fibrinogen/NN ,/, von/NN Willebrand/NN factor/NN antigen/NN (/( vWF/NN :/: 
1686_1686_47_48_15_18::None::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
445671_0_19_20_4_5::medicine.symptom.symptom_of::muscular/JJ dystrophy/NN (/( DMD/NN )/) ,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN 
416351_15_6_7_1_2::None::Having/VBG personal/JJ or/CC family/NN history/NN of/IN hypertension/NN ,/, older/JJR age/NN 
1206_1206_5_6_3_4::None::Requirement/NN of/IN yeast/NN fimbrin/NN for/IN actin/NN organization/NN and/CC morphogenesis/NN 
279_279_12_13_19_20::None::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC 
712_712_23_24_15_16::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN 
96855_6_14_15_18_19::None::all/DT five/CD underwent/VBD burn/VBP excision/NN and/CC microsurgical/JJ reconstruction/NN using/VBG distant/JJ flaps/NNS 
844136_3_23_24_12_13::None::targets/VBZ cancer/NN -/: specific/JJ expression/NN and/CC limits/NNS toxicity/NN ,/, is/VBZ a/DT new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
365_365_12_15_30_31::None::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
17565_0_13_14_10_11::None::high/JJ morbidity/NN and/CC mortality/NN in/IN the/DT elderly/JJ population/NN ./. 
226308_2_30_31_6_7::None::was/VBD assessed/VBN on/IN CRA/NNP agar/NN and/CC hydrophobicity/NN of/IN 20/CD Salmonella/FW strains/NNS isolated/VBN from/IN poultry/NN and/CC human/JJ and/CC two/CD Salmonella/FW enterica/FW serovar/NN Typhimurium/NN references/NNS strains/NNS was/VBD achieved/VBN by/IN microbial/JJ adhesion/NN to/TO n/NN 
996_996_12_13_29_30::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
98643_2_10_11_29_30::None::rinv/NN were/VBD prescribed/VBN ondansetron/NN rdf/NN 8/CD mg/NN twice/RB daily/RB while/IN on/IN treatment/NN and/CC were/VBD asked/VBN to/TO complete/VB a/DT nausea/NN and/CC vomiting/NN -/: specific/JJ daily/JJ diary/NN ,/, 
1793_1793_14_15_4_5::POS_ACTION_CONTROL::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
757758_7_27_28_33_34::None::illness/NN and/CC longer/JJR duration/NN of/IN time/NN from/IN the/DT first/JJ CDI/NNP to/TO bacteriotherapy/NN (/( 
686_686_23_24_29_30::POS_ACTION_BIND::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
6567_1_26_27_16_17::None::sodium/NN -/: containing/VBG salts/NNS ,/, is/VBZ a/DT behaviour/NN mediated/VBN by/IN a/DT set/NN of/IN evolutionary/JJ conserved/VBN neuronal/JJ systems/NNS 
355_355_14_15_16_17::None::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
1147_1147_22_23_17_18::None::ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG extensive/JJ actin/NN filament/NN accumulation/NN ./. 
63_63_49_50_44_45::None::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
170773_3_22_25_30_31::medicine.disease.risk_factors::of/IN sequela/NN of/IN coronary/JJ artery/NN disease/NN and/CC present/VB the/DT genome/NN -/: wide/JJ association/NN studies/NNS conducted/VBN 
473887_5_3_4_23_24::people.cause_of_death.includes_causes_of_death::Palliative/JJ care/NN improves/VBZ symptoms/NNS ,/, most/JJS frequently/RB pain/NN ,/, and/CC improves/VBZ quality/NN of/IN life/NN for/IN patients/NNS and/CC their/PRP$ families/NNS ,/, especially/RB in/IN the/DT terminal/JJ disease/NN phase/NN ./. 
1087_1087_7_9_10_12::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT 
1289_1289_13_14_11_12::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
1025_1025_0_1_27_28::None::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
367_367_24_25_26_27::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
793106_10_23_24_87_88::None::variables/NNS age/NN ,/, gender/NN ,/, disease/NN duration/NN ,/, tumor/NN size/NN ,/, basal/JJ hormone/NN levels/NNS ,/, relevant/JJ treatment/NN modalities/NNS ,/, and/CC relevant/JJ comorbidities/NNS )/) ,/, with/IN a/DT higher/JJR degree/NN of/IN psychopathology/NN indicating/VBG a/DT lower/JJR QoL/NN (/( depression/NN vs/CC AcroQoL/NN :/: B/NN =/SYM -/: 1.175/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, depression/NN vs/CC SF/NN -/: 36/CD :/: B/NN =/SYM -/: 1.648/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, anxiety/NN vs/CC AcroQoL/NN :/: 
408257_14_6_7_13_14::None::is/VBZ questionable/JJ whether/IN senescence/NN of/IN MM/NN -/: BMMSCs/NNS plays/VBZ a/DT pathological/JJ role/NN in/IN active/JJ 
275901_0_7_8_35_36::None::,/, many/JJ chronic/JJ hepatitis/NN B/NN (/( CHB/NN )/) patients/NNS have/VBP undergone/VBN sequential/JJ treatment/NN with/IN lamivudine/NN (/( LAM/NN )/) ,/, adefovir/NN (/( ADV/NN )/) ,/, and/CC entecavir/NN (/( ETV/NN )/) to/TO manage/VB antiviral/JJ resistance/NN or/CC insufficient/JJ 
76585_4_5_6_13_14::None::were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, aspirin/NN or/CC statin/NN treatment/NN ./. 
515_515_7_8_23_24::POS_ACTION_Causal::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
1532_1532_29_30_17_18::None::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD 
1460_1460_3_4_8_9::None::The/DT distribution/NN of/IN actin/NN filaments/NNS is/VBZ altered/VBN by/IN profilin/NN overexpression/NN ./. 
1754_1754_32_33_7_8::NEG_ACTION_Change::the/DT dysfunction/NN of/IN E-cadherin/NN in/IN these/DT cell/NN lines/NNS is/VBZ due/JJ primarily/RB to/TO its/PRP$ failure/NN to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
1122_1122_8_9_23_24::None::could/MD regulate/VB the/DT actin/NN binding/NN and/CC bundling/VBG properties/NNS of/IN fimbrin/NN ,/, or/CC it/PRP could/MD regulate/VB the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
1258_1258_32_33_3_4::POS_ACTION_BIND::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) 
248192_9_0_1_10_14::None::Provisional/JJ videonystagmography/NN (/( VNG/NN )/) results/NNS were/VBD :/: 40/CD %/NN benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) 
574065_1_39_40_7_8::None::on/IN prostate/NN ,/, renal/JJ and/CC bladder/NN cancer/NN presented/VBN at/IN the/DT 2014/CD congresses/NNS (/( European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP of/IN Clinical/JJ Oncology/NN and/CC American/JJ Society/NNP for/IN Radiation/NNP Oncology/NNP )/) that/WDT received/VBD the/DT best/JJS evaluations/NNS 
960_960_5_6_17_18::None::the/DT previously/RB identified/VBN VRP1/NN ,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN proper/JJ organization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
533311_1_0_1_11_12::None::The/DT study/NN aimed/VBN to/TO identify/VB the/DT depression/NN and/CC anxiety/NN state/NN of/IN diabetic/JJ adolescents/NNS and/CC its/PRP$ 
3836_0_0_1_7_8::medicine.disease.risk_factors::Management/NN of/IN Idiopathic/JJ Pulmonary/JJ Fibrosis/NN in/IN the/DT Elderly/NNP Patient/NN :/: Addressing/VBG 
93_93_24_26_22_23::POS_ACTION_MEMBER::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
18085_7_32_33_33_34::None::trisomy/NN 21/CD and/CC male/JJ factor/NN infertility/NN ./. 
70627_9_24_25_15_16::None::group/NN ,/, 20min/JJ post/NN -/: test/NN cortisol/NN levels/NNS were/VBD significantly/RB higher/JJR than/IN base/NN -/: line/NN cortisol/NN 
244414_9_7_8_3_4::medicine.medical_treatment.used_to_treat::For/IN T4/NN nasopharynx/NN cancer/NN patients/NNS treated/VBN with/IN IMRT/NN and/CC chemotherapy/NN ,/, 
355_355_25_26_12_13::None::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
556761_3_8_9_9_10::None::performed/VBN for/IN a/DT male/JJ cat/NN with/IN UO/NN ,/, 
628556_0_3_4_8_9::None::Decision/NN Trees/NNP Predicting/VBG Tumor/NN Shrinkage/NN for/IN Head/NNP and/CC Neck/NNP Cancer/NNP :/: Implications/NNS 
607_607_8_9_23_24::None::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
1508_1508_5_6_16_18::POS_ACTION_ENCODE::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
1713_1713_12_13_10_11::None::relevant/JJ ligands/NNS of/IN profilin/NN ,/, actin/NN and/CC proline-rich/JJ peptides/NNS 
380023_1_11_12_9_10::None::not/RB routinely/RB screen/NN patients/NNS for/IN anxiety/NN and/CC depression/NN ,/, 
779_779_49_52_26_27::POS_ACTION_COOCCUR::inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
778878_10_18_19_5_6::None::with/IN non/JJ -/: CF/NN bronchiectasis/NN ,/, long/JJ -/: term/NN inhaled/VBD antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN 
382707_7_19_20_26_27::medicine.disease.symptoms::neuroticism/NN ,/, current/JJ depression/NN ,/, and/CC tendencies/NNS toward/IN catastrophic/JJ and/CC anxiety/NN -/: provoking/VBG appraisals/NNS 
95871_3_10_11_1_2::None::We/PRP hypothesize/VBP that/IN adding/VBG CS/NN following/VBG injury/NN or/CC injury/NN and/CC shock/NN in/IN rats/NNS will/MD 
944_944_10_11_4_5::None::dynamics/NNS of/IN Dictyostelium/NNP cofilin/NN suggests/VBZ a/DT role/NN in/IN remodeling/VBG actin/NN latticework/NN into/IN bundles/NNS 
391631_1_8_9_3_4::None::The/DT test/NN is/VBZ based/VBN on/IN a/DT double/JJ -/: antibody/NN sandwich/NN format/NN and/CC 
865_865_7_8_33_35::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
456531_7_17_18_2_3::None::DTR/SYM -/: QOL/NN was/VBD associated/VBN with/IN self/NN -/: reported/VBN levels/NNS of/IN self/NN -/: care/NN activities/NNS in/IN insulin/NN injection/NN ,/, particularly/RB among/IN 
161_161_17_18_11_12::None::COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN binding/VBG to/TO CBP/NN ,/, whereas/IN beta-catenin/NN 
189641_0_17_18_4_5::None::the/DT face/NN of/IN urbanisation/NN ,/, surplus/NN energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD diabetes/NN has/VBZ developed/VBN into/IN 
1546_1546_12_13_8_11::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
445671_0_9_10_19_20::None::,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN 
126724_0_6_7_0_1::None::Back/RB to/TO the/DT Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN Bacteria/NNS 
607_607_21_22_23_24::None::viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
691776_2_9_10_15_16::None::,/, about/IN the/DT evolutionary/JJ history/NN and/CC gene/NN content/NN of/IN primordial/JJ cyanobacteria/NN [/( 7/CD 
101_101_22_23_36_37::POS_ACTION_Physical::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
2222_2222_17_18_39_40::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
342702_0_20_21_29_30::None::have/VBP fuelled/VBN the/DT development/NN of/IN targeted/VBN therapies/NNS that/WDT block/VBP cytokine/NN networks/NNS and/CC pathogenic/JJ immune/JJ cells/NNS ,/, 
1227_1227_22_23_2_3::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, 
1758_1758_4_5_22_23::POS_ACTION_RELATE::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
479047_2_35_36_39_42::medicine.disease.risk_factors::(/( 87/CD %/NN stroke/NN ,/, 42/CD %/NN transient/JJ ischemic/JJ attacks/NNS )/) ./. 
318370_0_17_18_24_25::None::simple/JJ green/JJ method/NN assisted/VBN by/IN water/NN plasma/NN at/IN a/DT low/JJ temperature/NN and/CC atmospheric/JJ pressure/NN 
284647_4_38_39_19_20::None::as/RB well/RB as/IN impact/NN on/IN disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, anticipating/VBG the/DT possibility/NN to/TO at/IN last/JJ control/NN pertussis/NN in/IN this/DT vulnerable/JJ age/NN group/NN ./. 
1757_1757_15_16_8_9::POS_ACTION_INTERACT::subcellular/JJ distribution/NN of/IN cofilin/NN as/RB well/RB as/IN its/PRP$ interaction/NN with/IN actin/NN in/FW vivo/FW is/VBZ 
1074_1074_7_8_5_6::None::proteins/NNS ,/, including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN 
719083_0_10_11_8_9::None::Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: Asghar/NNP Children/NNP 
410591_0_9_11_20_21::medicine.disease.symptoms::leading/VBG causes/NNS of/IN nephrotic/JJ syndrome/NN in/IN adults/NNS ,/, which/WDT is/VBZ characterized/VBN by/IN edema/NN ,/, hypoalbuminemia/NN ,/, hyperlipidemia/NN ,/, 
445433_1_9_10_6_7::None::neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ 
932_932_1_2_3_4::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB 
28475_4_123_124_48_49::None::GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) ,/, an/DT oxadiazole/NN N/NN -/: oxide/NN previously/RB identified/VBN as/IN an/DT inhibitor/NN of/IN fluke/NN and/CC tapeworm/NN TGRs/NNS Finally/RB ,/, we/PRP show/VBP that/IN mice/NNS experimentally/RB infected/VBN with/IN M/NN vogae/FW tetrathyridia/FW and/CC treated/VBN with/IN either/CC praziquantel/NN ,/, the/DT reference/NN drug/NN for/IN flatworm/NN infections/NNS ,/, or/CC VL16E/NN exhibited/VBD a/DT 28/CD %/NN reduction/NN of/IN intraperitoneal/JJ larvae/NNS numbers/NNS compared/VBN to/TO vehicle/NN 
996_996_5_7_31_34::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
287181_0_30_31_11_14::None::heart/NN disease/NN or/CC coronary/JJ artery/NN disease/NN ,/, accounts/NNS for/IN &/CC gt/NN ;/: 50/CD %/NN of/IN cardiovascular/JJ events/NNS and/CC is/VBZ a/DT leading/VBG cause/NN worldwide/RB of/IN morbidity/NN and/CC 
257215_0_45_46_17_18::None::(/( MSN/NNP -/: SS/NN -/: HA/NN )/) based/VBN on/IN mesoporous/JJ silica/NN nanoparticles/NNS (/( MSN/NNP )/) for/IN targeted/VBN drug/NN delivery/NN has/VBZ been/VBN developed/VBN ,/, in/IN which/WDT hyaluronic/JJ acid/NN (/( HA/NN )/) was/VBD conjugated/VBN on/IN the/DT surface/NN 
583_583_14_15_17_18::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
75211_5_27_29_4_5::None::report/VBP on/IN the/DT cases/NNS of/IN five/CD Indian/JJ women/NNS with/IN breast/NN cancer/NN ,/, in/IN the/DT age/NN group/NN of/IN 34/CD to/TO 60/CD years/NNS ,/, who/WP had/VBD poorly/RB differentiated/VBN breast/NN carcinoma/NN and/CC underwent/VBD modified/VBN 
275849_11_14_15_14_16::medicine.drug.active_moieties::was/VBD treated/VBN with/IN acetic/JJ acid/NN and/CC salt/NN in/IN 
865_865_33_35_21_24::None::)/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
988_988_15_16_20_21::POS_ACTION_SIMILAR::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN 
379000_0_5_6_10_12::None::block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD ultrasound/NN for/IN analgesic/JJ applications/NNS 
319920_0_25_27_30_31::None::,/, mania/NN ,/, sleep/NN disturbance/NN ,/, judgment/NN //: impulsivity/NN ,/, and/CC irritability/NN 
402511_2_5_6_21_22::None::study/NN ,/, high/JJ resolution/NN metabolomics/NNS (/( HRM/NN )/) was/VBD employed/VBN to/TO identify/VB malaria/NN parasite/NN -/: specific/JJ metabolites/NNS in/IN Plasmodium/NN falciparum/NN in/FW vitro/FW culture/NN 
36424_0_12_13_31_33::None::of/IN CT/NNP Density/NNP Model/NNP Variations/NNPS and/CC the/DT Impact/NN On/IN the/DT Accuracy/NNP of/IN Monte/NNP Carlo/NNP (/( MC/NNP )/) Dose/NNP Calculation/NN in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN for/IN Lung/NN Cancer/NN 
76705_14_8_9_0_1::None::Patients/NNS with/IN a/DT recent/JJ -/: onset/NN AF/NN and/CC troponin/NN -/: rise/NN showed/VBD 
761186_8_10_11_20_21::medicine.disease.symptoms::presence/NN of/IN any/DT CAD/NN (/( n/NN =/JJ 176/CD )/) ,/, including/VBG MI/NNP ,/, angina/NN ,/, and/CC stroke/NN 
1913_1913_5_6_7_8::POS_ACTION_DISASSEMBLE::the/DT possibility/NN that/IN TD77/NN disrupts/VBZ actin/NN stress/NN fibers/NNS by/IN 
787_787_7_8_13_14::None::cofilin-dependent/JJ regulation/NN of/IN actin/NN assembly/NN in/IN muscle/NN cells/NNS ,/, cofilin/NN tagged/VBD with/IN fluorescence/NN 
363177_0_8_9_3_4::people.cause_of_death.includes_causes_of_death::Multiple/JJ sclerosis/NN (/( MS/NN )/) is/VBZ characterized/VBN by/IN inflammatory/JJ demyelination/NN and/CC deposition/NN 
905933_12_7_8_13_14::None::DIR/NN -/: based/VBN dose/NN accumulation/NN may/MD be/VB acceptable/JJ for/IN assessing/VBG cumulative/JJ dose/NN distributions/NNS 
112017_4_4_5_12_13::medicine.symptom.symptom_of::patients/NNS had/VBD situational/JJ disorders/NNS ,/, with/IN a/DT slight/JJ prevalence/NN of/IN situational/JJ depression/NN ./. 
599869_3_14_15_13_14::medicine.risk_factor.diseases::considered/VBN after/IN whole/JJ breast/NN radiation/NN therapy/NN ,/, TNBC/NN 
119285_0_14_15_17_18::medicine.drug.active_moieties::OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) 
816_816_11_12_2_3::None::Interaction/NN of/IN Munc-18-2/NN with/IN syntaxin/NN 3/CD controls/VBZ the/DT association/NN of/IN apical/JJ SNAREs/NNS in/IN epithelial/JJ cells/NNS 
489_489_15_16_9_10::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN 
76765_3_84_85_10_11::people.cause_of_death.includes_causes_of_death::high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN (/( hsTnT/NN )/) and/CC FPG/NNP categorized/VBD as/IN normal/JJ fasting/NN glucose/NN (/( NFG/NN :/: FPG/NNP &/CC lt/NN ;/: //: =/JJ 6.0/CD mmol/NN //: L/NN )/) ,/, impaired/JJ fasting/NN glucose/NN (/( IFG/NN :/: FPG/NNP 6.1/CD -/: 6.9/CD mmol/NN //: L/NN )/) ,/, and/CC diabetes/NN mellitus/NN (/( DM/NN :/: FPG/NNP &/CC gt/NN ;/: //: =/JJ 7.0/CD mmol/NN //: L/NN )/) ,/, in/IN 535/CD men/NNS and/CC 226/CD women/NNS aged/JJ 56/CD -/: 79/CD years/NNS without/IN overt/JJ cardiovascular/JJ disease/NN who/WP received/VBD 
149493_0_35_36_14_17::None::developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS and/CC nonpregnant/JJ women/NNS aged/VBN 18/CD years/NNS and/CC 
1657_1657_12_13_8_9::None::with/IN respect/NN to/TO cofilin/NN binding/NN to/TO filamentous/JJ actin/NN which/WDT may/MD be/VB 
210955_0_30_31_9_10::None::related/JJ disease/NN (/( IgG4/NN -/: RD/NN )/) is/VBZ characterized/VBN by/IN elevated/JJ serum/NN IgG4/NN and/CC infiltration/NN of/IN IgG4/NN (/( +/CC )/) plasma/NN cells/NNS into/IN multiple/JJ organs/NNS ./. 
179835_3_30_31_14_15::None::imaging/NN techniques/NNS and/CC potential/JJ clinical/JJ applications/NNS and/CC limitations/NNS of/IN those/DT techniques/NNS for/IN the/DT evaluation/NN of/IN major/JJ SLE/NN -/: related/JJ heart/NN disorders/NNS ./. 
1474_1474_9_10_29_31::POS_ACTION_Dynamics::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
1758_1758_17_18_22_23::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
600709_1_23_25_16_17::medicine.disease.risk_factors::alcoholic/JJ steatohepatitis/NN (/( NASH/NN )/) ,/, which/WDT may/MD develop/VB into/IN hepatic/JJ fibrosis/NN ,/, cirrhosis/NN ,/, 
641_641_37_38_37_38::NEG_ACTION_CORELATE::nuclear/JJ transport/NN of/IN cofilin/NN ./. 
850254_13_10_12_0_1::None::HbA1c/NN and/CC fructosamine/NN were/VBD significantly/RB increased/VBN in/IN diabetic/JJ patients/NNS with/IN acute/JJ infection/NN ./. 
1810_1810_2_3_0_1::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR 
411_411_15_16_13_14::None::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, 
489359_3_14_15_10_11::None::OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC daytime/JJ sleepiness/NN 
18_18_18_20_6_7::POS_ACTION_INTERACT::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
865_865_11_14_21_24::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
1834_1834_6_7_15_17::None::three/CD structures/NNS of/IN actin/NN complexed/VBN with/IN different/JJ monomer-binding/JJ proteins/NNS ,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 
292034_0_5_8_2_3::None::[/( Pulmonary/JJ Clear/JJ Cell/NN Type/NN Squamous/JJ Cell/NN Carcinoma/NN that/WDT Required/NNP Differential/JJ 
471565_0_24_25_11_12::medicine.disease.treatments::low/JJ or/CC high/JJ dialysate/NN sodium/NN concentration/NN (/( DNa/NN (/( +/CC )/) )/) should/MD be/VB advocated/VBN in/IN chronic/JJ haemodialysis/NN patients/NNS ./. 
1411_1411_18_19_1_5::None::The/DT cardiac/JJ myosin/NN heavy/JJ chain/NN Arg-403/NN --/: >/JJR Gln/NN mutation/NN that/WDT causes/VBZ hypertrophic/JJ cardiomyopathy/NN does/VBZ not/RB affect/VB the/DT actin/NN -/: or/CC ATP-binding/JJ 
71_71_6_7_0_1::None::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN filaments/NNS ./. 
356086_0_1_3_16_17::None::Cancer/NN stem/NN cells/NNS (/( CSCs/NNS )/) play/VBP an/DT important/JJ role/NN in/IN cancer/NN growth/NN ,/, self/NN -/: renewal/NN ,/, metastasis/NN ,/, 
162483_5_34_35_37_38::None::,/, smoking/NN ,/, obesity/NN ,/, metabolic/JJ syndrome/NN ,/, hyperuricaemia/NN ,/, 
1286_1286_8_9_3_6::None::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, 
1427_1427_3_4_32_33::POS_ACTION_BIND::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1759_1759_40_41_40_41::POS_REG(+)_POLYMERIZE::the/DT nucleation/NN of/IN actin/NN polymerization/NN ./. 
322394_2_23_24_12_13::None::evaluate/VB effects/NNS of/IN ACR/NN on/IN dopamine/NN and/CC its/PRP$ metabolite/NN levels/NNS ,/, dopamine/NN transport/NN and/CC metabolic/JJ gene/NN expression/NN in/IN 
667_667_6_7_14_15::POS_ACTION_BIND::that/IN ,/, like/IN Abp1p/NN ,/, cofilin/NN is/VBZ associated/VBN with/IN the/DT membrane/NN actin/NN cytoskeleton/NN ./. 
799053_0_16_17_8_9::None::malignancies/NNS :/: unique/JJ genetic/JJ events/NNS ,/, frozen/JJ development/NN and/CC enduring/VBG apoptotic/JJ potential/NN ./. 
1075_1075_6_7_20_21::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
1633_1633_25_26_26_27::POS_ACTION_MEMBER::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
98_98_29_30_31_32::POS_ACTION_LOCALIZE::the/DT affinity/NN of/IN profilin/NN for/IN actin/NN may/MD be/VB under/IN 
1507_1507_17_18_6_7::None::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, 
370669_2_8_9_7_8::people.cause_of_death.includes_causes_of_death::are/VBP predictive/JJ of/IN high/JJ cardiovascular/JJ mortality/NN in/IN maintenance/NN 
1094_1094_18_19_22_23::None::,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
1372_1372_18_19_1_2::POS_ACTION_BIND::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB 
779_779_49_52_21_24::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
422_422_21_22_31_33::POS_REG(-)_Assembly::inhibitory/JJ activity/NN of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN of/IN the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
21_21_16_17_21_22::POS_ACTION_DOWNREGULATE::is/VBZ revealed/VBN by/IN RAD51/NN overexpression/NN suppression/NN of/IN C-terminal/JJ rad52/NN truncation/NN alleles/NNS ./. 
72_72_19_20_17_18::None::disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS ./. 
315964_1_6_7_37_38::None::evidence/NN support/VBP the/DT idea/NN that/IN exposure/NN to/TO trace/NN and/CC toxic/JJ metals/NNS ,/, such/JJ as/IN aluminum/NN (/( Al/NNP )/) and/CC manganese/NN (/( Mn/NN )/) ,/, may/MD be/VB factors/NNS or/CC cofactors/NNS in/IN the/DT etiopathogenesis/NN of/IN a/DT variety/NN of/IN psychiatric/JJ disorders/NNS 
337732_11_42_43_36_37::None::times/NNS in/IN specific/JJ runs/NNS of/IN a/DT task/NN designed/VBN to/TO assess/VB phasic/JJ alertness/NN in/IN 
1219_1219_0_1_11_12::POS_REG(+)_Change::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC 
438998_0_5_6_3_4::None::Antagonistic/JJ effects/NNS of/IN chloroquine/NN on/IN autophagy/JJ occurrence/NN potentiate/VB the/DT 
878537_3_18_19_16_17::None::a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT 
1137_1137_15_16_11_12::None::physiological/JJ role/NN of/IN profilin/NN ,/, a/DT 12-15-kD/JJ actin/NN -/: and/CC phosphoinositide-binding/JJ 
242314_4_164_165_29_30::medicine.drug.active_moieties::of/IN HC/NNP IVs/NNP Procaine/NNP benzyl/NN penicillin/NN injection/NN powder/NN for/IN treatment/NN of/IN sepsis/NN was/VBD available/JJ in/IN the/DT majority/NN of/IN all/DT HCs/NNS with/IN :/: 100/CD %/NN of/IN HC/NN of/IN IVs/NNS ,/, 83/CD %/NN of/IN HC/NN IIIs/NNS and/CC 82/CD %/NN of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN only/RB 30/CD %/NN of/IN the/DT HC/NNP IIs/NNPS and/CC 40/CD %/NN of/IN the/DT HC/NN IVs/NNS The/DT most/RBS uncommon/JJ were/VBD child/NN -/: friendly/JJ priority/NN medicines/NNS for/IN malaria/NN with/IN :/: Artesunate/NN injection/NN in/IN only/RB 6/CD %/NN of/IN HC/NNP IIs/NNP ,/, 14/CD %/NN of/IN HC/NN IIIs/NNS and/CC 20/CD %/NN of/IN HC/NN IVs/NNS ;/: Artemether/NNP lumefantrine/NN dispersible/JJ tablets/NNS and/CC rectal/JJ artesunate/NN were/VBD missing/VBG in/IN all/PDT the/DT 32/CD HCs/NNS Less/RBR than/IN a/DT third/JJ of/IN the/DT health/NN workers/NNS reported/VBD prescribing/VBG zinc/NN sulphate/NN and/CC ORS/NN for/IN diarrhea/NN ,/, 86/CD %/NN reported/VBD procaine/NN benzyl/NN penicillin/NN injection/NN 
1768_1768_4_7_10_11::POS_ACTION_INTERACT::sites/NNS on/IN the/DT myosin/NN heavy/JJ chain/NN that/WDT interact/VBP with/IN actin/NN and/CC are/VBP responsible/JJ 
540626_0_10_11_3_4::None::C/NN -/: peptide/NN immunoreactivity/NN index/NN is/VBZ associated/VBN with/IN improvement/NN of/IN HbA1c/NN :/: 2/LS -/: 
202727_3_8_9_15_16::None::mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN or/CC pneumonia/NN ,/, and/CC improves/VBZ 
63_63_44_45_59_60::POS_ACTION_MEMBER::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
225032_8_23_25_1_2::None::In/IN contrast/NN with/IN the/DT conventional/JJ two/CD -/: dimensional/JJ culture/NN ,/, three/CD -/: dimensional/JJ culture/NN system/NN could/MD give/VB rise/VB to/TO an/DT up/RB -/: regulated/VBN insulin/NN gene/NN expression/NN ./. 
924463_2_16_17_8_9::None::a/DT patient/NN with/IN acute/JJ ischemic/JJ stroke/NN who/WP was/VBD deemed/VBN ineligible/JJ for/IN intravenous/JJ recombinant/JJ tissue/NN plasminogen/NN 
1850_1850_2_3_8_9::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
750926_1_55_56_49_50::None::,/, expression/NN of/IN Ki67/NN and/CC Erk1/NN //: 2/CD ,/, antioxidant/JJ capacity/NN ,/, and/CC 
1341_1341_4_5_12_13::None::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
604581_3_13_14_0_1::None::We/PRP further/RB explored/VBD the/DT central/JJ mechanisms/NNS of/IN fatigue/NN at/IN the/DT premovement/NN level/NN in/IN MS/NN patients/NNS during/IN a/DT 
370155_0_32_33_29_30::None::events/NNS and/CC similar/JJ recommendations/NNS for/IN lipid/NN control/NN ./. 
349493_0_3_4_2_3::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN 
926591_11_5_7_26_27::medicine.disease.treatments::rate/NN of/IN deciduous/JJ dental/JJ caries/NNS among/IN public/JJ kindergartens/NNS was/VBD 45.92/CD %/NN (/( 1,064/CD //: 2,317/CD )/) ,/, with/IN a/DT mean/NN dmft/NN of/IN 1.95/CD and/CC filling/VBG rate/NN of/IN 2.14/CD 
238332_6_35_36_20_21::medicine.risk_factor.diseases::pain/NN relief/NN from/IN chronic/JJ pancreatitis/NN is/VBZ the/DT primary/JJ goal/NN of/IN total/JJ pancreatectomy/NN in/IN TPIAT/NNP ,/, whereas/IN treatment/NN of/IN diabetes/NN ,/, and/CC certainly/RB 
956369_1_7_8_13_14::None::known/VBN about/IN its/PRP$ efficacy/NN and/CC safety/NN as/IN a/DT periprocedural/JJ anticoagulant/NN therapy/NN for/IN patients/NNS 
93_93_54_55_50_51::None::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
721_721_9_10_15_16::None::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC PRP21/NN and/CC 
567_567_18_19_20_21::None::TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
2074_2074_16_17_12_13::None::the/DT nucleocapsid/NN (/( N/NN )/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) 
996_996_29_30_12_13::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
449_449_10_11_19_20::NEG_ACTION_Change::cells/NNS indicated/VBD that/IN UL8/NN could/MD interact/VB separately/RB with/IN both/CC the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
2222_2222_19_20_39_40::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
1782_1782_20_22_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
497715_6_0_1_22_23::None::Drawing/VBG from/IN literature/NN on/IN weight/NN bias/NN ,/, critical/JJ weight/NN studies/NNS ,/, and/CC Health/NNP at/IN Every/DT Size/NN (/( HAES/NN )/) ,/, we/PRP highlight/VBP pedagogical/JJ approaches/NNS to/TO address/VB 
255381_4_2_3_0_1::None::The/DT National/NNP Cancer/NNP registry/NN was/VBD searched/VBN 
367_367_28_30_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
411_411_17_18_13_14::None::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
313724_3_11_12_8_9::medicine.risk_factor.diseases::these/DT tumors/NNS presenting/VBG acutely/RB with/IN intracranial/JJ hemorrhage/NN in/IN adult/JJ patients/NNS 
637206_9_10_11_7_8::None::cause/NN of/IN ESRD/NNP The/DT prevalence/NN and/CC incidence/NN of/IN RRT/NNP continues/VBZ 
582775_5_119_120_87_88::medicine.disease.symptoms::402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN ;/: 4/CD //: 402/CD )/) ,/, hypertension/NN (/( 2.2/CD %/NN 
763152_3_19_20_8_9::None::unique/JJ form/NN of/IN nonassociative/JJ behavior/NN in/IN Drosophila/FW where/WRB female/JJ flies/NNS detect/VBP the/DT presence/NN of/IN endoparasitoid/JJ predatory/JJ wasps/NNS and/CC 
1748_1748_27_28_4_5::None::results/NNS suggest/VBP that/IN LIMK2/NN functions/NNS downstream/RB of/IN the/DT Rho-ROCK/JJ signalling/NN pathway/NN and/CC plays/VBZ a/DT role/NN in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN structures/NNS ,/, by/IN phosphorylating/VBG cofilin/ADF/NN proteins/NNS ./. 
63_63_49_50_59_60::None::.2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
404541_2_4_5_8_10::None::,/, the/DT ATG6/NN functions/VBZ in/IN wheat/NN (/( Triticum/FW aestivum/FW L/NN ./. 
93_93_4_5_54_55::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
453075_8_8_9_22_23::None::the/DT micro/JJ -/: dystrophin/NN gene/NN restored/VBD some/DT aspects/NNS of/IN normal/JJ muscle/NN histology/NN and/CC pathology/NN such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO 
448173_0_0_1_1_2::None::The/DT tumorigenic/JJ potential/NN of/IN dulaglutide/NN 
631669_5_10_12_5_6::None::or/CC phlebectomy/NN shows/VBZ good/JJ results/NNS in/IN patients/NNS with/IN varicose/NN veins/NNS of/IN pelvic/JJ origin/NN 
387237_8_28_30_2_3::None::A/DT high/JJ proportion/NN of/IN C/NN canis/NN was/VBD observed/VBN from/IN dogs/NNS and/CC cats/NNS in/IN the/DT current/JJ study/NN and/CC phylogeny/NN revealed/VBD that/IN C/NN canis/JJ forms/NNS a/DT sister/NN clade/NN to/TO the/DT oriental/JJ cat/NN flea/NN Ctenocephalides/NNS orientis/NN 
1061_1061_24_25_36_37::None::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
2089_2089_4_5_8_10::None::have/VBP found/VBN that/IN cofilin/NN ,/, a/DT 21-kDa/JJ actin-binding/JJ protein/NN ,/, is/VBZ a/DT 
1061_1061_25_27_36_37::None::to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
382707_7_2_3_7_8::None::These/DT findings/NNS represent/VBP an/DT early/JJ but/CC important/JJ step/NN towards/IN the/DT clarification/NN 
1957_1957_36_37_38_39::None::by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
2013_2013_9_10_20_21::POS_ACTION_MODULATE::the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
695014_15_5_6_11_12::None::a/DT relationship/NN between/IN psychological/JJ variables/NNS and/CC the/DT presence/NN of/IN depressive/JJ symptoms/NNS 2/CD months/NNS 
1568_1568_4_5_17_18::None::NH2-terminal/JJ 16kD/NN of/IN Abp1p/NN ,/, a/DT 65-kD/JJ yeast/NN protein/NN identified/VBN by/IN its/PRP$ ability/NN to/TO bind/VB to/TO actin/NN filaments/NNS ,/, is/VBZ 
34897_2_36_37_42_43::None::energy/NN estimate/NN (/( EEE/NN )/) and/CC iodine/NN contrast/NN to/TO noise/NN ratio/NN (/( CNR/NN 
423761_7_10_11_18_19::medicine.drug.active_moieties::the/DT synthesis/NN of/IN IgG1/NN ,/, IgG2b/NN ,/, IgG3/NN ,/, and/CC total/JJ IgG/NN in/IN female/JJ mice/NNS 
1008_1008_10_11_8_9::None::,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
591167_7_28_30_18_19::medicine.disease.risk_factors::robust/JJ number/NN of/IN elderly/JJ and/CC very/RB elderly/JJ participants/NNS ,/, although/IN the/DT risk/NN of/IN heart/NN failure/NN hospitalization/NN was/VBD increased/VBN 
520105_8_21_23_11_12::None::a/DT non/JJ -/: age/NN -/: dependent/JJ index/NN with/IN higher/JJR applicability/NN to/TO screen/NN for/IN cardiovascular/JJ risk/NN factors/NNS in/IN adolescents/NNS 
505690_0_21_22_15_16::None::candidiasis/NN patients/NNS :/: Correlation/NN between/IN cell/NN surface/NN hydrophobicity/NN and/CC biofilm/NN forming/VBG activities/NNS ./. 
991_991_15_16_17_18::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN 
16153_0_19_20_3_6::None::Elderly/JJ patients/NNS with/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) are/VBP underrepresented/JJ in/IN trials/NNS evaluating/VBG fludarabine/NN ,/, cyclophosphamide/NN ,/, and/CC rituximab/NN (/( FCR/NN )/) 
315600_15_23_24_8_9::None::well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN 
1593_1593_27_28_22_25::None::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
881131_8_29_30_31_32::None::among/IN smokers/NNS and/CC drinkers/NNS with/IN respect/NN to/TO ESCC/NN prevention/NN 
1850_1850_0_1_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ 
196_196_9_10_2_3::None::A/DT truncated/VBN beta-catenin/NN disrupts/VBZ the/DT interaction/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN :/: a/DT cause/NN 
130_130_15_16_4_5::POS_REG(+)_LOCALIZE::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC enzymic/JJ activities/NNS ,/, and/CC the/DT UL8/NN protein/NN has/VBZ been/VBN 
808734_0_23_24_25_26::None::risk/NN of/IN liver/NN fibrosis/NN and/CC carcinogenesis/NN ./. 
1069_1069_26_27_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
151537_7_15_18_28_29::None::(/( osteosarcoma/NN ,/, soft/JJ tissue/NN sarcoma/NN ,/, histiocytic/JJ sarcoma/NN ,/, hemangiosarcoma/NN )/) ,/, haematological/JJ malignancies/NNS (/( lymphoma/NN ,/, leukaemia/NN )/) 
386745_4_27_28_21_22::None::(/( Reporting/NNP Information/NNP Online/NNP )/) ,/, an/DT Internet/NN -/: based/VBN sports/NNS injury/NN surveillance/NN 
133249_2_10_11_1_3::None::Although/IN cigarette/NN smoke/NN increases/VBZ TLR4/NN expression/NN ,/, TLR4/NN signaling/NN is/VBZ altered/VBN in/IN smokers/NNS and/CC 
1334_1334_17_18_0_1::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN 
264611_0_4_5_19_20::None::of/IN mobility/NN in/IN conjunction/NN with/IN an/DT independent/JJ life/NN style/NN is/VBZ one/CD of/IN the/DT major/JJ goals/NNS of/IN rehabilitation/NN after/IN stroke/NN ./. 
247832_2_37_38_34_35::None::a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ damage/NN risk/NN 
425469_7_28_29_43_44::None::concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN high/JJ baseline/NN purging/VBG had/VBD greater/JJR change/NN when/WRB treated/VBN with/IN FBT/NN relative/JJ to/TO SPT/NNP Age/NNP 
1122_1122_23_24_23_24::POS_REG(0)_Change::the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
828493_2_18_19_19_20::medicine.disease.symptoms::gene/NN methylation/NN in/IN breast/NN tumors/NNS ./. 
1372_1372_18_19_31_32::None::amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
1478_1478_9_10_4_5::None::essential/JJ role/NN of/IN profilin/NN in/IN the/DT assembly/NN of/IN actin/NN for/IN microspike/NN formation/NN 
868_868_4_5_9_11::None::this/DT study/NN ,/, profilin/NN is/VBZ identified/VBN as/IN an/DT actin-binding/JJ protein/NN in/IN higher/JJR plants/NNS 
865_865_7_8_11_14::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC 
93_93_50_51_54_55::None::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
423051_1_4_5_5_6::medicine.symptom.symptom_of::evidence/NN suggests/VBZ that/IN accelerated/VBN atherosclerosis/NN and/CC related/JJ cardiovascular/JJ 
1248_1248_19_20_4_5::None::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1528_1528_4_5_10_11::None::interactions/NNS of/IN the/DT UL52/NN protein/NN with/IN the/DT UL8/NN and/CC UL5/NN proteins/NNS were/VBD analysed/VBN 
20599_4_18_22_27_28::medicine.disease.treatments::with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC 
714308_1_5_6_30_31::medicine.medical_treatment.used_to_treat::last/JJ decade/NN the/DT anticancer/JJ potential/NN of/IN poly/NN ADP/NN -/: ribose/NN polymerase/NN (/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ PARP/NN inhibitors/NNS are/VBP being/VBG developed/VBN to/TO treat/VB various/JJ malignancies/NNS ./. 
402845_14_7_8_2_3::None::The/DT rabbit/NN model/NN of/IN MSU/NNP crystal/NN -/: induced/VBN acute/JJ arthritis/NN efficiently/RB 
1843_1843_12_13_19_20::POS_ACTION_Causal::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT 
930_930_6_7_1_2::None::Like/IN actin/NN ,/, the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC 
422_422_31_33_23_24::POS_REG(0)_POLYMERIZE::of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN of/IN the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
988_988_26_27_20_21::None::homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
2107_2107_7_8_9_10::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
278424_0_4_5_7_8::None::kinase/NN signaling/NN :/: tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD 
1782_1782_11_12_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS 
1426_1426_5_6_14_15::POS_ACTION_BIND::denominator/NN is/VBZ impaired/JJ beta-catenin/NN association/NN with/IN either/CC E-cadherin/NN (/( PaTuII/NN )/) or/CC alpha-catenin/NN (/( BxPc3/NN and/CC 
2052_2052_17_18_6_7::POS_ACTION_BIND::axonal/JJ transport/NN of/IN actin/NN and/CC its/PRP$ monomer/NN binding/NN proteins/NNS ,/, actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
1646_1646_8_9_2_3::None::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ 
313_313_8_9_29_30::POS_ACTION_BIND::75-100/CD microM/NN unpolymerized/JJ actin/NN and/CC at/IN least/JJS four/CD proteins/NNS which/WDT can/MD bind/VB actin/NN monomers/NNS ,/, actin/NN depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, gelsolin/NN ,/, profilin/NN ,/, and/CC thymosin/NN 
213993_5_6_7_11_12::None::and/CC 2.7/CD %/NN reported/VBD a/DT past/JJ history/NN of/IN diabetes/NN and/CC stroke/NN ,/, 
1790_1790_25_26_22_24::None::interferon-induced/JJ ,/, dsRNA-activated/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
1270_1270_37_38_31_32::None::PIP2/NN binding/NN and/CC actin/NN binding/NN may/MD be/VB important/JJ for/IN profilin/NN function/NN ./. 
583_583_4_5_17_18::None::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
489_489_15_16_20_21::None::histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP 
185609_1_39_40_8_9::None::increasing/VBG age/NN of/IN cancer/NN patients/NNS ,/, the/DT number/NN of/IN patients/NNS with/IN various/JJ comorbidities/NNS such/JJ as/IN membranous/JJ nephropathy/NN is/VBZ also/RB rising/VBG ,/, and/CC problems/NNS associated/VBN with/IN the/DT administration/NN of/IN chemotherapy/NN to/TO elderly/JJ patients/NNS with/IN these/DT conditions/NNS are/VBP becoming/VBG more/RBR 
1771_1771_19_20_11_14::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
425469_7_8_9_29_30::medicine.disease.risk_factors::)/) and/CC baseline/NN purging/VBG severity/NN (/( p/NN =/JJ 0.03/CD )/) moderated/VBD the/DT relationship/NN between/IN treatment/NN condition/NN and/CC change/NN in/IN eating/VBG concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN 
288485_0_7_8_47_48::None::study/NN was/VBD to/TO optimize/VB the/DT biological/JJ safety/NN scheme/NN of/IN spinal/JJ image/NN -/: guided/VBN radiotherapy/NN (/( IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP Thirty/CD -/: six/CD adult/JJ male/JJ beagles/NNS were/VBD assigned/VBN according/VBG to/TO a/DT random/JJ number/NN table/NN and/CC subjected/VBN 
865_865_33_35_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
1147_1147_22_23_0_1::None::Profilins/NNP also/RB bind/VBP polyphosphoinositides/NNS ,/, which/WDT can/MD disrupt/VB the/DT profilin-actin/NN complex/NN ,/, and/CC proline-rich/JJ ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG extensive/JJ actin/NN filament/NN accumulation/NN ./. 
1779_1779_29_30_5_7::POS_ACTION_BIND::of/IN pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
1144_1144_0_2_11_13::None::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP 
172875_8_19_20_28_30::None::=/JJ 12779/CD )/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ predictor/NN of/IN 10/CD Years/NNS Risk/NN of/IN coronary/JJ 
781998_2_5_6_35_36::None::the/DT amelioration/NN of/IN reversible/JJ beta/NN -/: cell/NN dysfunction/NN through/IN the/DT early/JJ institution/NN of/IN short/JJ -/: term/NN insulin/NN -/: based/VBN therapy/NN has/VBZ emerged/VBN as/IN a/DT strategy/NN that/WDT can/MD yield/VB temporary/JJ remission/NN of/IN type/NN 2/CD diabetes/NN ./. 
350698_1_16_17_8_11::None::increased/VBN incidence/NN of/IN type/NN 2/CD diabetes/NN ,/, accompanied/VBN by/IN an/DT accelerated/VBN atherosclerosis/NN ./. 
279_279_30_31_12_13::POS_ACTION_BIND::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
367_367_5_7_26_27::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
544721_14_24_26_10_11::None::of/IN palpable/JJ breast/NN masses/NNS had/VBD been/VBN used/VBN ,/, biopsy/NN could/MD have/VB been/VBN reduced/VBN by/IN 89/CD %/NN in/IN group/NN I/CD and/CC deemed/VBD not/RB 
349493_0_5_6_3_4::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN Mismatch/NNP Repair/NNP 
654472_6_26_27_22_23::None::reported/VBN non/JJ -/: ocular/JJ pain/NN measures/NNS (/( numerical/JJ rating/NN scale/NN and/CC 
487559_4_1_2_6_7::None::This/DT case/NN raises/VBZ the/DT possibility/NN that/IN cerebral/JJ vasoconstriction/NN may/MD be/VB 
389319_8_3_4_20_21::None::Liver/NN tissue/NN was/VBD assessed/VBN for/IN inflammatory/JJ cytokine/NN expression/NN and/CC radiation/NN -/: induced/VBN SEC/NNP injury/NN based/VBN on/IN serum/NN hyaluronic/JJ acid/NN (/( HA/NN )/) level/NN ,/, 
233540_0_33_34_10_11::None::with/IN diabetes/NN ,/, measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN the/DT increased/VBN risk/NN of/IN death/NN from/IN cardiovascular/JJ disease/NN ./. 
748_748_20_21_10_11::POS_ACTION_BIND::binding/NN proposed/VBN for/IN fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
1417_1417_9_10_4_5::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS 
1491_1491_6_7_16_17::None::assay/NN using/VBG an/DT actin/NN cross-linking/NN protein/NN and/CC the/DT nucleation/NN assay/NN also/RB suggested/VBD that/IN cofilin/NN shortens/VBZ the/DT actin/NN 
1977_1977_24_25_22_23::None::molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
1782_1782_27_28_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
288_288_10_12_19_20::None::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ substrates/NNS of/IN calpain/NN ./. 
501715_7_24_26_13_14::None::mm/NN Hg/NN is/VBZ recommended/VBN in/IN patients/NNS with/IN chronic/JJ kidney/NN disease/NN and/CC in/IN those/DT with/IN diabetes/NN mellitus/NN ./. 
645520_5_15_17_18_19::medicine.disease.treatments::the/DT radioresistant/JJ laryngeal/NN cancer/NN cells/NNS to/TO irradiation/NN ,/, indicating/VBG that/IN 
1775_1775_21_22_3_4::POS_ACTION_STSIMILAR::The/DT structure/NN of/IN Ykt6pN/NN differed/VBD entirely/RB from/IN that/DT of/IN syntaxin/NN and/CC resembled/VBD the/DT overall/JJ fold/NN of/IN the/DT actin/NN regulatory/JJ protein/NN ,/, profilin/NN ./. 
965433_2_25_26_21_22::biology.organism_classification.lower_classifications::targets/NNS components/NNS from/IN Peucedanum/NN praeruptorum/NN Dunn/NNP (/( Umbelliferae/NNP )/) crude/JJ extracts/NNS 
1341_1341_4_5_1_2::None::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC 
2107_2107_7_8_15_16::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
300324_0_50_51_10_11::None::HA/NN )/) //: poly/NN (/( lactic/NN -/: co/SYM -/: glycolic/JJ acid/NN ,/, PLGA/NN )/) core/NN //: shell/NN fiber/NN meshes/VBZ loaded/VBN with/IN epigallocatechin/NN -/: 3/LS -/: O/SYM -/: gallate/NN (/( EGCG/NN )/) (/( HA/NNP //: PLGA/NNP -/: E/NN )/) for/IN application/NN to/TO tissue/NN engineering/NN scaffolds/NNS for/IN skin/NN regeneration/NN 
116203_2_5_6_36_37::None::study/NN ,/, we/PRP assessed/VBD the/DT efficacy/NN and/CC safety/NN of/IN the/DT retroflexed/JJ view/NN in/IN colorectal/JJ ESD/NN From/IN April/NNP 2009/CD to/TO December/NNP 2013/CD ,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 128/CD patients/NNS treated/VBN with/IN ESD/NN A/NN total/NN of/IN 119/CD patients/NNS 
422_422_31_33_31_33::POS_REG(-)_Assembly::the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
489_489_26_27_9_10::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
28_28_11_13_3_4::POS_ACTION_MEMBER::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
350196_12_5_6_4_5::people.cause_of_death.includes_causes_of_death::,/, uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB 
6359_3_17_18_30_31::None::ulcerative/JJ colitis/NN (/( UC/NN )/) ,/, and/CC 719/CD healthy/JJ controls/NNS ,/, was/VBD genotyped/VBN for/IN the/DT NOD2/NN SNP/NN rs72796353/NN and/CC the/DT 
149877_5_17_18_24_25::None::better/JJR post/NN -/: diagnosis/NN survival/NN than/IN those/DT cases/NNS whose/WP$ tumours/NNS lost/VBD p16/NN expression/NN (/( 
410_410_9_10_11_12::None::of/IN both/DT histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ 
71_71_3_4_0_1::None::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN 
1810_1810_2_3_20_21::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
831385_3_66_67_3_4::None::The/DT PfATP6/NN L263E/NN mutation/NN has/VBZ been/VBN studied/VBN in/IN relation/NN to/TO the/DT artemisinin/NN inhibitory/JJ effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN is/VBZ more/RBR susceptible/JJ to/TO CPA/NNP Here/RB ,/, we/PRP characterized/VBD ,/, for/IN the/DT first/JJ time/NN ,/, the/DT interaction/NN of/IN CPA/NN with/IN PfATP6/NN and/CC its/PRP$ mammalian/JJ counterpart/NN to/TO understand/VB similarities/NNS and/CC differences/NNS in/IN the/DT mode/NN of/IN binding/NN of/IN the/DT inhibitor/NN to/TO the/DT two/CD 
1977_1977_24_25_16_17::None::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
991_991_15_16_20_21::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
429997_1_1_3_26_27::None::Recent/JJ postmarketing/VBG reports/NNS and/CC a/DT US/NNP Food/NNP and/CC Drug/NNP Administration/NNP analysis/NN have/VBP documented/VBN uncommon/JJ persistent/JJ sexual/JJ and/CC nonsexual/JJ side/NN -/: effects/NNS in/IN a/DT subset/NN of/IN younger/JJR men/NNS who/WP have/VBP taken/VBN 
346_346_24_25_24_25::None::of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
865_865_15_16_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) 
1515_1515_26_27_21_22::None::focal/JJ adhesion/NN protein/NN talin/NN and/CC the/DT yeast/NN protein/NN Sla2p/NN ./. 
249535_0_12_14_4_5::None::profile/NN of/IN serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: onset/NN diabetes/NN mellitus/NN ./. 
128605_11_32_33_1_2::None::These/DT data/NNS indicate/VBP that/IN disturbance/NN of/IN the/DT XIAP/NN //: Smac/JJ balance/NN may/MD be/VB a/DT driver/NN of/IN radio/NN chemotherapy/NN resistance/NN ,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN 
1373_1373_11_12_16_17::None::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1440_1440_12_13_4_5::None::C-terminal/JJ region/NN of/IN ORC3/NN was/VBD ,/, however/RB ,/, necessary/JJ to/TO bring/VB ORC4/NN and/CC ORC5/NN into/IN 
1861_1861_12_13_15_16::None::of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
2076_2076_28_29_42_43::None::residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) ;/: its/PRP$ aa/NN sequence/NN is/VBZ 35/CD %/NN identical/JJ to/TO porcine/NN Cof/NN ./. 
235160_8_22_23_39_40::biology.organism_classification.lower_classifications::that/IN the/DT domain/NN Bacteria/NNS was/VBD dominated/VBN by/IN Firmicutes/NNS (/( mainly/RB Clostridia/NNP )/) ,/, Bacteroidetes/NNP ,/, delta/NN -/: and/CC gamma/NN -/: Proteobacteria/NNP ,/, Cloacimonetes/NNP and/CC 
265468_0_11_12_5_7::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS ./. 
1534_1534_32_33_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
467_467_2_3_4_6::None::Expression/NN of/IN c-Myc/NN or/CC cyclin/NN D1/NN was/VBD sufficient/JJ to/TO 
1061_1061_19_20_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
227_227_3_6_7_9::POS_ACTION_BIND::Binding/NN to/TO human/JJ dipeptidyl/NN peptidase/NN IV/CD by/IN adenosine/NN deaminase/NN and/CC antibodies/NNS that/WDT 
798_798_4_5_11_12::POS_ACTION_HUMANMADE::reconstitution/NN experiments/NNS ,/, actin/NN filaments/NNS incubated/VBN in/IN EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP 
240754_0_9_10_19_20::None::+/CC )/) )/) signalling/NN triggered/VBN by/IN insect/NN herbivory/NN is/VBZ an/DT intricate/JJ network/NN with/IN multiple/JJ components/NNS ,/, involving/VBG 
206151_6_7_8_0_1::None::We/PRP accurately/RB linked/VBD the/DT PHIS/NN and/CC NTDB/NN records/NNS for/IN 69/CD %/NN 
567_567_20_21_18_19::None::TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
280_280_13_14_46_47::None::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
1760_1760_1_3_3_4::POS_ACTION_MEMBER::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP 
270415_4_35_36_33_35::None::by/IN boosted/VBN ensemble/NN machine/NN learning/VBG algorithm/NN into/IN a/DT novel/JJ 
395871_8_30_31_40_41::people.cause_of_death.includes_causes_of_death::resection/NN of/IN esophageal/NN malignancies/NNS ,/, especially/RB in/IN patients/NNS with/IN stage/NN III/CD -/: IV/CD tumors/NNS ./. 
1498_1498_8_9_21_22::None::thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
406221_0_3_4_13_17::medicine.medical_treatment.used_to_treat::Antibiotic/JJ and/CC oral/JJ corticosteroid/NN prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ exacerbations/NNS of/IN chronic/JJ obstructive/JJ pulmonary/JJ disease/NN (/( COPD/NN )/) 
359239_0_10_12_25_26::None::tumor/NN -/: suppressing/VBG immune/JJ responses/NNS and/CC the/DT difference/NN between/IN them/PRP ultimately/RB determine/VBP whether/IN a/DT cancer/NN escapes/VBZ immune/JJ recognition/NN mechanisms/NNS ./. 
574337_0_14_15_2_4::None::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN the/DT main/JJ etiologies/NNS of/IN cervical/JJ cancer/NN ./. 
524639_5_30_31_12_13::None::COX/NNP -/: 2/CD inhibitors/NNS ,/, diclofenac/NN and/CC high/JJ -/: dose/NN ibuprofen/NN cause/NN adverse/JJ cardiovascular/JJ effects/NNS to/TO a/DT problematic/JJ extent/NN ,/, whereas/IN naproxen/NN consistently/RB exhibits/VBZ low/JJ 
280859_11_6_7_5_6::None::and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN 
21613_1_3_4_15_16::None::Ninety/CD -/: five/CD patients/NNS with/IN MI/NN treated/VBN with/IN PCI/NN were/VBD divided/VBN into/IN two/CD groups/NNS [/( coronary/JJ (/( n/NN =/JJ 
640_640_29_30_25_26::POS_ACTION_BIND::can/MD not/RB increase/VB profilin/NN 's/POS affinity/NN for/IN actin/NN ./. 
441_441_9_11_2_3::NEG_ACTION_BIND::Even/RB the/DT Munc18-2/NN mutants/NNS that/WDT do/VBP not/RB detectably/RB bind/VBP syntaxin/NN 3/CD were/VBD membrane/NN associated/VBN 
333054_4_25_26_14_15::None::affected/VBN by/IN water/NN stress/NN and/CC ,/, depending/VBG on/IN the/DT genotype/NN ,/, a/DT higher/JJR lignin/NN accumulation/NN may/MD occur/VB in/IN 
467137_1_9_10_23_25::biology.organism_classification.lower_classifications::factor/NN in/IN global/JJ honeybee/NN (/( Apis/NN mellifera/NN )/) declines/VBZ since/IN shifting/VBG hosts/NNS from/IN the/DT Asian/JJ honeybee/NN (/( Apis/NN cerana/NN )/) &/CC gt/NN 
761772_0_1_3_4_6::None::The/DT jungle/NN crow/NN (/( Corvus/NN macrorhynchos/NNS )/) belongs/VBZ to/TO 
1069_1069_46_47_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
185_185_4_5_6_7::None::of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, p53/NN ,/, 
540626_0_19_20_24_27::medicine.medical_treatment.used_to_treat::-/: up/IN of/IN sitagliptin/NN use/NN in/IN patients/NNS with/IN type/NN 2/CD diabetes/NN ./. 
865_865_17_18_7_8::POS_ACTION_SIMILAR::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
178597_0_23_26_30_31::None::cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN 
355_355_16_17_14_15::None::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
405799_1_10_11_32_33::None::development/NN of/IN DR/NN This/DT study/NN aimed/VBN to/TO investigate/VB whether/IN genetic/JJ variants/NNS of/IN CRP/NN are/VBP associated/VBN with/IN DR/NN A/NN total/NN of/IN 1,018/CD patients/NNS with/IN type/NN 2/CD diabetes/NNS were/VBD recruited/VBN in/IN 
103419_1_47_48_35_36::None::and/CC Cu/NN -/: NPs/NNS ;/: AgNO3/NN ,/, Ag/NN NM300K/NN ,/, Ag/NN -/: NPs/NNS Non/SYM -/: coated/JJ and/CC Ag/NN -/: 
1758_1758_17_18_4_5::POS_ACTION_MEDIATE::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, 
476387_6_21_22_0_1::None::The/DT absence/NN of/IN pyruvate/NN groups/NNS renders/VBZ the/DT xanthan/JJ gum/NN less/RBR sensitive/JJ to/TO the/DT influence/NN of/IN salt/NN ,/, and/CC hence/RB decreases/VBZ the/DT ultrasonic/JJ degradation/NN efficiency/NN ./. 
389319_8_20_21_17_19::medicine.drug_ingredient.active_moiety_of_drug::based/VBN on/IN serum/NN hyaluronic/JJ acid/NN (/( HA/NN )/) level/NN ,/, 
70381_3_1_2_32_33::None::Three/CD days/NNS after/IN the/DT second/JJ injection/NN (/( day/NN 10/CD )/) ,/, the/DT rats/NNS were/VBD intraperitoneally/RB given/VBN sTNFRII/NN -/: gAD/NN or/CC sTNFRII/NN -/: Fc/NN ,/, or/CC PBS/NNP Effects/NNS of/IN treatments/NNS were/VBD examined/VBN with/IN respect/NN of/IN CIA/NNP incidence/NN 
597121_2_23_24_27_28::None::lifestyle/NN activities/NNS concurrently/RB impact/VBP the/DT progression/NN of/IN hypertension/NN -/: related/JJ comorbidities/NNS 
540626_0_22_23_19_20::None::-/: up/IN of/IN sitagliptin/NN use/NN in/IN patients/NNS with/IN type/NN 2/CD 
1593_1593_22_25_27_28::POS_ACTION_MEMBER::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
367_367_0_2_5_7::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP 
1344_1344_20_21_22_23::POS_ACTION_BIND::helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
569500_0_24_25_18_19::None::with/IN non/JJ -/: operated/VBN obese/JJ and/CC non/JJ -/: obese/JJ control/NN women/NNS ./. 
336146_1_6_7_4_5::None::study/NN aims/VBZ to/TO determine/VB the/DT prevalence/NN of/IN Chinese/JJ herbal/JJ 
274753_0_21_22_25_26::medicine.drug.active_moieties::alternative/JJ vehicle/NN for/IN nicotine/NN delivery/NN and/CC a/DT smoking/NN -/: cessation/NN tool/NN 
21613_1_15_16_5_6::medicine.medical_treatment.used_to_treat::five/CD patients/NNS with/IN MI/NN treated/VBN with/IN PCI/NN were/VBD divided/VBN into/IN two/CD groups/NNS [/( coronary/JJ (/( n/NN =/JJ 
468819_2_70_71_10_11::None::the/DT safety/NN of/IN intravenous/JJ thrombolysis/NN (/( IVT/NN )/) in/IN specific/JJ conditions/NNS :/: dissection/NN of/IN the/DT aortic/JJ arch/NN of/IN extracranial/JJ and/CC intracranial/JJ arteries/NNS ,/, concomitant/JJ presence/NN of/IN unruptured/JJ intracranial/JJ aneurysms/NNS ,/, arteriovenous/JJ malformations/NNS and/CC dural/JJ fistulas/NNS ,/, co/SYM -/: existing/VBG brain/NN tumors/NNS as/RB well/RB as/IN in/IN conditions/NNS mimicking/VBG AIS/NNP The/DT review/NN systematically/RB evaluates/VBZ the/DT safety/NN of/IN off/JJ -/: label/NN use/NN of/IN IVT/NNP and/CC summarizes/VBZ data/NNS from/IN case/NN reports/NNS 
469705_8_15_16_12_13::None::and/CC evidence/NN -/: based/VBN interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN 
426927_1_18_19_5_6::None::toxicity/NN of/IN a/DT hexane/NN extract/NN of/IN Lithospermum/NN erythrorhizon/NN root/NN (/( LEH/NN )/) was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ 
149493_0_35_36_5_6::medicine.risk_factor.diseases::Kaiser/NNP Permanente/NNP Care/NNP Management/NNP Institute/NNP National/NNP Hypertension/NN Guideline/NN was/VBD developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS and/CC nonpregnant/JJ women/NNS aged/VBN 18/CD years/NNS and/CC 
526387_8_14_15_12_13::biology.organism_classification.lower_classifications::of/IN the/DT genus/NN Enterovirus/NN in/IN Picornaviridae/NNP ./. 
670_670_12_13_14_15::None::post-TGF-beta1/NN showed/VBD that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, 
2030_2030_3_4_22_23::None::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
22_22_36_37_0_1::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT 
471043_1_3_4_20_21::medicine.disease.treatments::Intraperitoneal/JJ lavage/NN with/IN sterile/JJ water/NN is/VBZ sometimes/RB used/VBN during/IN radical/JJ cystectomy/NN to/TO lyse/VB cancer/NN cells/NNS that/WDT might/MD have/VB escaped/VBN the/DT surgical/JJ specimen/NN ./. 
2222_2222_13_14_21_22::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
1843_1843_12_13_31_32::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
322970_7_15_16_10_11::None::characteristics/NNS and/CC testedfor/NN interaction/NN between/IN period/NN and/CC SES/NN In/IN both/DT periods/NNS ,/, 
926591_11_1_2_0_1::None::The/DT prevalence/NN rate/NN of/IN deciduous/JJ 
831553_2_6_7_5_7::None::associated/VBN with/IN morbid/JJ obesity/NN ,/, including/VBG psychological/JJ 
13078_0_4_5_0_1::None::IL/NN -/: 10/CD gene/NN polymorphism/NN and/CC influence/NN of/IN 
116203_2_26_27_25_27::medicine.symptom.symptom_of::,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 
452763_3_6_7_10_11::None::observations/NNS suggest/VBP that/IN Vit/NN D/NN and/CC its/PRP$ analogues/NNS may/MD be/VB effective/JJ 
787_787_13_14_7_8::POS_REG(0)_ASSEMBLE::cofilin-dependent/JJ regulation/NN of/IN actin/NN assembly/NN in/IN muscle/NN cells/NNS ,/, cofilin/NN tagged/VBD with/IN fluorescence/NN 
142623_1_8_9_0_2::None::Eucalyptus/NN camaldulensis/NN were/VBD studied/VBN under/IN stress/NN conditions/NNS in/IN response/NN to/TO aluminum/NN (/( 
1439_1439_26_27_16_17::None::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
618_618_1_2_3_4::POS_REG(+)_ASSEMBLE::How/WRB profilin/NN promotes/VBZ actin/NN filament/NN assembly/NN in/IN 
1760_1760_13_14_3_4::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
1608_1608_7_8_24_25::POS_ACTION_BIND::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
6359_3_4_5_14_16::medicine.risk_factor.diseases::DNA/NN from/IN 2256/CD Caucasians/NNS ,/, including/VBG 1073/CD CD/NN patients/NNS ,/, 464/CD patients/NNS with/IN ulcerative/JJ colitis/NN (/( UC/NN )/) 
1637_1637_27_29_7_8::None::similar/JJ to/TO authentic/JJ profilin/NN from/IN Acanthamoeba-based/JJ on/IN fluorescence/NN monitored/VBD urea/NN denaturation/NN ,/, circular/JJ dichroism/NN ,/, actin-nucleotide/JJ exchange/NN rate/NN and/CC the/DT Kd/NN for/IN rabbit/NN skeletal/JJ actin/NN ./. 
2137_2137_15_18_4_5::None::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
468525_8_8_9_3_4::None::Systolic/JJ prehypertension/NN and/CC overweight/NN are/VBP associated/VBN with/IN incident/NN AF/NN in/IN Japanese/JJ population/NN 
242_242_2_3_17_21::None::Neuropilin-1/NN mediates/VBZ collapsin-1/NN //: semaphorin/NN III/CD inhibition/NN of/IN endothelial/JJ cell/NN motility/NN :/: functional/JJ competition/NN of/IN collapsin-1/NN and/CC vascular/JJ endothelial/JJ growth/NN factor-165/NN ./. 
629883_0_36_37_21_22::None::MSC/NN )/) into/IN rabbit/NN models/NNS of/IN corneal/NN allograft/NN rejection/NN with/IN either/CC normal/JJ -/: risk/NN or/CC high/JJ -/: risk/NN vascularized/VBN corneal/NN beds/NNS was/VBD 
1450_1450_23_24_23_24::POS_REG(+)_Assembly::coordination/NN in/IN the/DT actin/NN central/JJ cleft/NN ./. 
236148_4_11_12_29_30::None::have/VB a/DT higher/JJR prevalence/NN of/IN previously/RB diagnosed/VBN comorbidities/NNS ,/, to/TO have/VB developed/VBN heart/NN failure/NN acutely/RB ,/, and/CC to/TO have/VB a/DT longer/RBR hospital/NN stay/NN compared/VBN with/IN 
834587_19_32_33_0_1::None::VMAT/NN can/MD be/VB a/DT better/JJR option/NN in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ resulted/VBD in/IN equivalent/JJ or/CC superior/JJ dose/NN distribution/NN with/IN a/DT reduction/NN in/IN the/DT dose/NN to/TO lung/NN and/CC heart/NN ./. 
169759_4_5_6_15_16::None::to/TO -/: serine/NN substitutions/NNS at/IN the/DT other/JJ sites/NNS lead/VBP to/TO the/DT loss/NN of/IN expression/NN and/CC //: or/CC 
470116_0_12_13_8_9::medicine.symptom.symptom_of::Wall/NNP Thickening/NNP and/CC Emphysema/NNP Is/VBZ Associated/VBN with/IN Dyspnea/NN and/CC Hospitalization/NN for/IN 
1434_1434_14_15_75_76::None::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
667084_2_7_8_18_20::None::with/IN an/DT increased/VBN prevalence/NN of/IN mental/JJ health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, and/CC suicidal/JJ thoughts/NNS ./. 
747093_0_5_6_4_5::None::surgery/NN in/IN supermorbidly/JJ obese/JJ patients/NNS with/IN endometrial/JJ cancer/NN 
576_576_9_10_13_15::None::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ 
1568_1568_17_18_4_5::POS_ACTION_BIND::NH2-terminal/JJ 16kD/NN of/IN Abp1p/NN ,/, a/DT 65-kD/JJ yeast/NN protein/NN identified/VBN by/IN its/PRP$ ability/NN to/TO bind/VB to/TO actin/NN filaments/NNS ,/, is/VBZ 
769684_3_64_65_55_56::None::Scale/NNP (/( FACES/NNP II/NNP ,/, Chinese/NNP version/NN )/) and/CC the/DT Social/NNP Functioning/NNP Questionnaire/NNP (/( SFQ/NNP )/) 
259511_0_36_37_25_26::None::of/IN decreased/VBN urinary/JJ flow/NN ,/, inability/NN to/TO fully/RB empty/VB his/PRP$ bladder/NN ,/, and/CC gross/JJ hematuria/NN ./. 
1683_1683_10_12_8_9::POS_REG(0)_Assembly::co-operativity/NN between/IN the/DT profilin/NN and/CC DNase/NN I/CD binding/NN sites/NNS on/IN 
106581_3_23_24_4_5::None::there/EX is/VBZ little/JJ doubt/NN regarding/VBG potential/JJ benefit/NN of/IN MD/NN for/IN obesity/NN ,/, diabetes/NN type/NN II/CD ,/, metabolic/JJ syndrome/NN and/CC fatty/NN liver/NN ,/, critical/JJ evaluation/NN has/VBZ to/TO 
403501_2_33_34_10_11::None::and/CC Plasmodium/NN nested/JJ PCR/NN were/VBD compared/VBN in/IN a/DT region/NN of/IN declining/VBG malaria/NN transmission/NN in/IN southern/JJ Zambia/NNP using/VBG samples/NNS from/IN community/NN -/: based/VBN ,/, cross/NN -/: sectional/JJ surveys/NNS from/IN 2008/CD to/TO 
480543_0_15_16_32_33::medicine.drug.active_moieties::irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN by/IN organic/JJ extraction/NN and/CC used/VBN in/IN a/DT medical/JJ isotope/NN generator/NN to/TO produce/VB Gallium/NNP -/: 68/CD PET/NN 
2222_2222_13_14_19_20::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
620872_0_3_4_1_2::None::Dose/NN Levels/NNS in/IN Particulate/NNP -/: Containing/NNP Formulations/NNPS 
454283_3_25_26_18_19::medicine.drug_ingredient.active_moiety_of_drug::the/DT formation/NN of/IN ferric/JJ arsenate/NN with/IN the/DT increasing/VBG As/IN :/: Fe/NNP ratio/NN ./. 
1075_1075_6_7_8_9::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN 
1221_1221_18_19_21_22::None::bind/VBP to/TO the/DT armadillo/NN repeats/NNS of/IN beta-catenin/NN ,/, but/CC not/RB 
872597_0_2_3_0_1::biology.organism_classification.lower_classifications::Coyotes/NNS (/( Canis/NN latrans/NNS )/) are/VBP 
739268_3_30_32_15_16::medicine.symptom.symptom_of::(/( ie/FW ,/, depressive/JJ and/CC bipolar/JJ disorders/NNS ,/, social/JJ phobia/NN ,/, borderline/JJ personality/NN disorder/NN ,/, schizophrenia/NN and/CC other/JJ psychotic/JJ disorders/NNS ,/, certain/JJ drug/NN 
454963_14_2_4_0_3::people.cause_of_death.includes_causes_of_death::Type/NN 2/CD Diabetes/NNP Mellitus/NNP was/VBD the/DT 
350850_8_31_32_32_33::None::0.001/CD )/) ,/, facial/JJ lipodystrophy/NN (/( P/NN =/JJ 
1082_1082_11_12_31_34::None::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
251166_0_6_7_19_20::None::evidence/NN that/IN the/DT predictive/JJ value/NN of/IN HDL/NN cholesterol/NN levels/NNS for/IN cardiovascular/JJ risk/NN stratification/NN is/VBZ limited/VBN in/IN patients/NNS with/IN coronary/JJ artery/NN 
1147_1147_17_18_0_1::None::Profilins/NNP also/RB bind/VBP polyphosphoinositides/NNS ,/, which/WDT can/MD disrupt/VB the/DT profilin-actin/NN complex/NN ,/, and/CC proline-rich/JJ ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG 
350196_12_2_3_5_6::None::Cervical/JJ ,/, uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB 
778878_10_39_40_5_6::medicine.symptom.symptom_of::with/IN non/JJ -/: CF/NN bronchiectasis/NN ,/, long/JJ -/: term/NN inhaled/VBD antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN P/NN A/NN eradication/NN and/CC attenuate/VB the/DT risk/NN of/IN exacerbation/NN ,/, however/RB ,/, accompanied/VBN with/IN higher/JJR risk/NN of/IN wheeze/NN and/CC bronchospasm/NN ./. 
349493_0_5_6_0_1::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN Mismatch/NNP Repair/NNP 
658012_2_18_19_19_20::None::PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB 
243_243_27_28_27_28::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
139515_2_25_26_62_63::None::and/CC later/RB HSP/NN In/IN this/DT patient/NN ,/, the/DT diagnosis/NN of/IN HSP/NN was/VBD demonstrated/VBN clinically/RB by/IN his/PRP$ palpable/JJ purpura/NN ,/, diarrhea/NN ,/, hematuria/NN ,/, and/CC abdominal/JJ pain/NN and/CC confirmed/VBD pathologically/RB by/IN his/PRP$ renal/JJ and/CC skin/NN biopsies/NNS demonstrating/VBG leukocytoclastic/JJ vasculitis/NN and/CC IgA/NN complexes/NNS ./. 
68_68_20_21_14_15::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB beta-catenin/NN ,/, with/IN increased/VBN 
711_711_22_23_14_15::None::,/, stimulation/NN with/IN TNF-alpha/NN led/VBD to/TO a/DT 2.4-fold/JJ increase/NN in/IN net/JJ actin/NN protein/NN synthesis/NN and/CC 
453075_8_15_16_28_29::None::aspects/NNS of/IN normal/JJ muscle/NN histology/NN and/CC pathology/NN such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO contraction/NN -/: induced/VBN injury/NN ./. 
1532_1532_17_18_31_33::POS_ACTION_CORELATE::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD complexes/NNS when/WRB overexpressed/VBN 
927981_0_17_19_8_9::None::for/IN the/DT simultaneous/JJ determination/NN of/IN nine/CD antidepressants/NNS in/IN traditional/JJ Chinese/JJ medicines/NNS and/CC health/NN food/NN by/IN ultra/NN performance/NN 
419773_1_9_10_1_3::None::In/IN developed/JJ countries/NNS ,/, up/RB to/TO 18/CD %/NN of/IN nursing/NN home/NN residents/NNS suffer/VBP 
373723_3_1_2_3_5::None::We/PRP performed/VBD a/DT systematic/JJ review/NN to/TO determine/VB the/DT 
507_507_3_4_28_29::None::For/IN example/NN ,/, profilin/NN with/IN a/DT deletion/NN of/IN the/DT eight/CD C-terminal/JJ residues/NNS has/VBZ many/JJ of/IN the/DT physical/JJ properties/NNS of/IN a/DT molten/JJ globule/NN ,/, yet/RB remarkably/RB still/RB binds/VBZ to/TO actin/NN ./. 
512095_3_2_3_9_10::None::A/DT failed/VBD procedure/NN was/VBD defined/VBN as/IN requiring/VBG a/DT second/JJ surgery/NN for/IN the/DT UPJO/NNP 
849947_0_6_7_7_8::None::hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
163_163_5_6_8_9::None::from/IN Acanthamoeba/NN binds/VBZ profilin/NN and/CC cross-links/NNS actin/NN filaments/NNS ./. 
244414_9_7_8_5_6::None::nasopharynx/NN cancer/NN patients/NNS treated/VBN with/IN IMRT/NN and/CC chemotherapy/NN ,/, 
1546_1546_26_27_8_11::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
1608_1608_26_27_7_8::None::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
235372_5_0_1_20_22::None::Race/NN ,/, family/NN history/NN of/IN osteoporosis/NN ,/, BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN ,/, length/NN of/IN time/NN on/IN oral/JJ contraceptives/NNS ,/, age/NN at/IN 
668570_12_11_13_7_8::medicine.symptom.symptom_of::association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN 
303_303_23_24_23_24::POS_REG(0)_Assembly::are/VBP independent/JJ of/IN beta-catenin/NN binding/NN to/TO alpha-catenin/NN 
776_776_4_6_24_26::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN 
425469_7_45_46_22_23::None::treatment/NN condition/NN and/CC change/NN in/IN eating/VBG concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN high/JJ baseline/NN purging/VBG had/VBD greater/JJR change/NN when/WRB treated/VBN with/IN FBT/NN relative/JJ to/TO SPT/NNP Age/NNP and/CC purging/VBG 
280_280_14_15_46_47::None::observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
822_822_6_7_4_5::POS_ACTION_INTERACT::of/IN the/DT yeast/NN RAD51/NN and/CC RAD52/NN proteins/NNS plays/VBZ a/DT 
749940_1_28_29_15_16::medicine.medical_treatment.used_to_treat::old/JJ )/) with/IN AML/NN (/( n/NN =/JJ 363/CD )/) who/WP received/VBD allogeneic/JJ peripheral/JJ blood/NN stem/NN cell/NN transplantation/NN from/IN HLA/NN -/: 
1075_1075_11_12_20_21::None::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
856_856_24_25_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
1580_1580_18_19_23_24::None::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, 
414579_11_44_45_20_21::None::developed/VBD AKI/NNP These/DT differences/NNS in/IN arterial/JJ pressures/NNS and/CC use/NN of/IN norepinephrine/NN between/IN the/DT groups/NNS were/VBD not/RB found/VBN to/TO be/VB significant/JJ when/WRB entered/VBN in/IN the/DT binary/JJ logistic/JJ regression/NN model/NN ./. 
416067_10_3_4_5_6::people.cause_of_death.includes_causes_of_death::The/DT ratio/NN of/IN malignant/JJ //: tumor/NN in/IN NPC1L1/NN (/( 
432927_5_15_16_26_27::None::denervation/NN in/IN the/DT aetiology/NN of/IN parkinsonian/JJ apathy/NN with/IN a/DT cardinal/JJ role/NN of/IN decreased/VBN tonic/NN D2/NN //: D3/NN receptor/NN 
609976_0_11_12_0_1::None::Hypertension/NN and/CC diabetes/NN as/IN risk/NN factors/NNS for/IN dementia/NN :/: A/DT secondary/JJ post/NN -/: hoc/FW analysis/NN 
710948_4_5_6_23_24::medicine.risk_factor.diseases::course/NN of/IN the/DT disease/NN ,/, the/DT patient/NN developed/VBD immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB 
130735_2_16_17_29_30::None::of/IN the/DT structure/NN transformation/NN during/IN the/DT interaction/NN process/NN ,/, providing/VBG a/DT potential/JJ FL/NN tool/NN for/IN monitoring/VBG dopaminergic/JJ neurotoxicity/NN ./. 
172875_8_32_33_10_11::None::from/IN the/DT Atherosclerosis/NNP Risk/NN in/IN Communities/NNP Study/NNP (/( n/NN =/JJ 12779/CD )/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ predictor/NN of/IN 10/CD Years/NNS Risk/NN of/IN coronary/JJ heart/NN disease/NN ./. 
394705_2_101_102_4_6::None::%/NN switched/VBD from/IN group/NN A/NN to/TO B/NN versus/CC 43/CD %/NN switching/NN from/IN B/NN to/TO A/DT Intent/NN -/: to/TO -/: treat/VB patient/NN survivals/NNS at/IN 5/CD and/CC 8/CD years/NNS were/VBD 88/CD %/NN and/CC 85.5/CD %/NN for/IN group/NN A/NN ,/, and/CC 78/CD %/NN and/CC 73/CD %/NN for/IN group/NN B/NN Death/NN -/: censored/VBN graft/NN survivals/NNS were/VBD 93/CD %/NN for/IN group/NN A/NN and/CC 95/CD %/NN for/IN group/NN B/NN Graft/NN function/NN was/VBD significantly/RB better/JJR at/IN 8/CD years/NNS ,/, with/IN 91/CD %/NN of/IN group/NN A/NN patients/NNS compared/VBN with/IN 50/CD %/NN in/IN group/NN B/NN having/VBG estimated/VBN glomerular/JJ filtration/NN rates/NNS &/CC gt/NN ;/: 45/CD mL/NN //: min/NN //: 1.73/CD m2/NN ,/, and/CC a/DT 
580543_2_13_14_11_12::medicine.risk_factor.diseases::risk/NN of/IN maternal/JJ anemia/NN ,/, infections/NNS ,/, eclampsia/NN and/CC 
1087_1087_23_24_25_26::POS_ACTION_ASSEMBLE::flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
167593_4_2_3_8_11::None::Following/VBG an/DT injection/NN with/IN the/DT HDAC/NN inhibitor/NN ,/, suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) 
856_856_16_18_24_25::POS_ACTION_UPREGULATE::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
112987_0_47_48_44_46::medicine.drug.active_moieties::CH3OH/NN )/) and/CC dimethyl/JJ sulfoxide/NN (/( DMSO/NN )/) for/IN the/DT 
768572_0_28_30_21_22::None::after/IN acute/JJ ischemic/JJ stroke/NN has/VBZ been/VBN well/RB demonstrated/VBN in/IN past/JJ clinical/JJ trials/NNS ./. 
1889_1889_5_6_7_8::None::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
513_513_17_19_9_10::None::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
1334_1334_0_1_17_18::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN 
510001_0_4_5_8_10::None::chromosomes/NNS have/VBP evolved/VBN independently/RB in/IN phylogenetically/RB diverse/JJ flowering/NN plant/NN lineages/NNS ./. 
2165_2165_14_15_20_21::POS_ACTION_MEMBER::presence/NN of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN histone/NN H3/NN ./. 
954_954_9_10_6_7::None::LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
406187_0_27_28_19_20::None::level/NN of/IN light/JJ perception/NN within/IN 24/CD hours/NNS of/IN having/VBG fever/NN and/CC myalgias/NNS heralding/VBG H1N1/NN influenza/NN 
890409_7_12_13_35_37::None::(/( age/NN and/CC sex/NN )/) ,/, clinical/JJ condition/NN (/( diagnosis/NN and/CC the/DT length/NN of/IN hospital/NN stay/NN )/) and/CC possible/JJ risk/NN factors/NNS for/IN infection/NN as/IN smoking/NN ,/, diabetes/NN mellitus/NN ,/, hypertension/NN and/CC 
1164_1164_39_40_33_34::POS_ACTION_ATTACH:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN 
1686_1686_15_18_47_48::None::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
1850_1850_8_9_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
1771_1771_19_20_1_2::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
523643_0_25_27_19_20::medicine.risk_factor.diseases::LAA/NN )/) and/CC stroke/NN risk/NN score/NN in/IN patients/NNS with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) 
792558_0_8_9_1_2::None::Polymorphonuclear/JJ neutrophils/NNS (/( PMNs/NNS )/) ,/, the/DT main/JJ effectors/NNS of/IN the/DT innate/JJ 
557_557_3_4_15_16::None::Green/NNP fluorescent/JJ protein-tagged/JJ ORC1/NN associated/VBN with/IN chromatin/NN throughout/IN mitosis/NN in/IN living/NN cells/NNS and/CC co-localized/VBN with/IN ORC4/NN in/IN metaphase/NN spreads/NNS 
91440_0_2_4_0_1::None::Risk/NN of/IN cardiovascular/JJ events/NNS and/CC mortality/NN among/IN 
6567_1_0_1_12_13::None::Sodium/NN appetite/NN ,/, or/CC the/DT desire/NN of/IN terrestrial/JJ animals/NNS to/TO seek/VB and/CC consume/VB sodium/NN -/: containing/VBG 
1087_1087_10_12_7_9::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT 
1771_1771_11_14_1_2::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, 
237202_1_26_28_0_1::None::Here/RB we/PRP describe/VBP the/DT first/JJ use/NN of/IN daclatasvir/NN ,/, simeprevir/NN ,/, and/CC ribavirin/NNP (/( RBV/NN )/) as/IN an/DT all/DT -/: oral/JJ triple/JJ regimen/NN administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN recurrent/JJ 
226308_2_9_10_12_13::None::CRA/NNP agar/NN and/CC hydrophobicity/NN of/IN 20/CD Salmonella/FW strains/NNS isolated/VBN from/IN 
566167_0_25_26_10_11::None::studies/NNS conducted/VBN in/IN acute/JJ inpatient/JJ stroke/NN rehabilitation/NN ,/, though/IN such/JJ studies/NNS are/VBP greatly/RB needed/VBN in/IN order/NN to/TO shed/VB light/NN on/IN the/DT most/RBS 
1394_1394_8_9_5_6::None::constants/NNS of/IN Acanthamoeba/NN profilin/NN to/TO fluorescein-labeled/JJ actin/NN from/IN Acanthamoeba/NN and/CC 
347064_0_21_22_3_5::None::The/DT transplantation/NN of/IN Schwann/NN cells/NNS (/( SCs/NNS )/) holds/VBZ considerable/JJ promise/NN as/IN a/DT therapy/NN for/IN spinal/JJ cord/NN injury/NN ,/, but/CC the/DT optimal/JJ source/NN of/IN these/DT 
590_590_33_34_35_36::POS_ACTION_ACETYLATE::protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN activity/NN ./. 
1793_1793_14_15_16_17::None::and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
356156_0_32_33_30_31::medicine.symptom.symptom_of::(/( eg/FW ,/, depression/NN and/CC suicidality/NN )/) as/IN a/DT 
783888_0_29_30_13_15::None::IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ ambulatory/JJ surgery/NN patients/NNS to/TO control/VB established/JJ 
266669_0_26_27_8_10::medicine.disease.risk_factors::old/JJ woman/NN with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) treated/VBN with/IN warfarin/NN had/VBD a/DT cortical/JJ left/JJ middle/JJ cerebral/JJ artery/NN (/( MCA/NNP )/) stroke/NN (/( October/NNP 2009/CD 
718366_2_21_22_19_20::None::or/CC persistence/NN into/IN adulthood/NN ,/, epilepsy/NN ,/, severe/JJ learning/NN 
112017_4_9_10_12_13::None::with/IN a/DT slight/JJ prevalence/NN of/IN situational/JJ depression/NN ./. 
1889_1889_0_2_7_8::None::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
337142_1_0_1_47_48::None::We/PRP examined/VBD changes/NNS in/IN the/DT expression/NN of/IN three/CD NRs/NNS (/( NR1/NN ,/, NR2B/NN ,/, and/CC NR2C/NN )/) ,/, olfactory/JJ receptor/NN (/( OR/NN )/) ,/, and/CC adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) in/IN chum/NN salmon/NN Oncorhynchus/NNP keta/NN using/VBG quantitative/JJ polymerase/NN chain/NN reaction/NN (/( QPCR/NN )/) during/IN salinity/NN change/NN (/( seawater/NN -/: gtgt/NN 50/CD 
320906_2_0_1_12_13::None::This/DT study/NN seeks/VBZ to/TO better/RBR understand/VB consumer/NN antimalarial/JJ prices/NNS by/IN documenting/VBG and/CC exploring/VBG the/DT pricing/NN behaviour/NN 
490714_0_7_8_9_10::biology.organism_classification.lower_classifications::content/NN of/IN wawo/NN worms/NNS (/( Polychaeta/NN ,/, Annelida/NN )/) 
1457_1457_34_35_56_57::None::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
1503_1503_13_14_5_7::POS_ACTION_ENCODE::simplex/NN virus/NN type-1/NN DNA/NN helicase-primase/NN is/VBZ a/DT heterotrimer/NN encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, 
87_87_41_45_37_38::None::the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
188913_0_25_26_2_3::None::In/IN the/DT plasma/NN of/IN dairy/NN cows/NNS with/IN 1/LS -/: 5/CD points/NNS of/IN lameness/NN ,/, the/DT mineral/NN elements/NNS [/( calcium/NN (/( Ca/NN )/) ,/, iron/NN (/( Fe/NNP )/) ,/, copper/NN 
149017_0_21_22_23_24::None::cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN the/DT central/JJ 
101_101_24_25_36_37::POS_ACTION_Dynamics::of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
1140_1140_20_21_24_25::None::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
365_365_12_15_15_16::POS_ACTION_MEMBER::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN 
669734_0_10_11_44_45::None::forms/NNS of/IN cognitive/JJ control/NN (/( proactive/JJ and/CC reactive/JJ )/) between/IN early/JJ and/CC midadolescence/NN was/VBD associated/VBN with/IN the/DT onset/NN of/IN major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) during/IN the/DT same/JJ period/NN and/CC if/IN it/PRP prospectively/RB predicted/VBD MDD/NN onset/NN between/IN mid/JJ -/: and/CC late/JJ 
1758_1758_4_5_19_20::None::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
875_875_7_8_19_20::POS_ACTION_AFFECT::we/PRP demonstrate/VBP that/IN profilin/NN isoforms/NNS expressed/VBN in/IN a/DT single/JJ cell/NN can/MD have/VB different/JJ effects/NNS on/IN actin/NN in/IN living/NN cells/NNS 
97537_3_24_25_5_6::None::1/CD is/VBZ also/RB expressed/VBN in/IN a/DT variety/NN of/IN cancers/NNS (/( prostate/NN ,/, lung/NN ,/, pancreatic/JJ ,/, or/CC colon/NN carcinoma/NN ,/, melanoma/NN ,/, astrocytoma/NN ,/, glioblastoma/NN ,/, 
487559_4_34_35_45_46::None::typical/JJ signs/NNS and/CC symptoms/NNS ,/, especially/RB in/IN the/DT setting/NN of/IN pregnancy/NN complications/NNS associated/VBN with/IN liver/NN dysfunction/NN ./. 
252268_2_39_41_34_35::None::central/JJ nervous/JJ system/NN striatal/JJ dopamine/NN (/( DA/NN )/) receptor/NN binding/NN (/( BPND/NN )/) 
1160_1160_2_3_22_23::None::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
168553_2_11_12_13_14::medicine.drug_ingredient.active_moiety_of_drug::pituitary/JJ or/CC ectopic/JJ corticotropin/NN (/( ACTH/NN )/) overproduction/NN ,/, 
723866_2_1_2_8_9::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN from/IN India/NNP ./. 
2131_2131_7_8_9_10::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC 
1434_1434_14_15_7_8::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
373923_0_54_55_109_110::None::-/: stage/NN or/CC refractory/JJ heart/NN failure/NN (/( stage/NN D/NN )/) This/DT review/NN outlines/VBZ the/DT key/JJ role/NN of/IN diabetes/NN mellitus/NN as/IN a/DT stage/NN A/DT risk/NN factor/NN for/IN heart/NN failure/NN with/IN preserved/JJ ejection/NN fraction/NN ,/, and/CC asymptomatic/JJ diabetic/JJ cardiomyopathy/NN ,/, referring/VBG to/TO the/DT presence/NN of/IN left/JJ ventricular/JJ diastolic/JJ dysfunction/NN in/IN diabetic/JJ patients/NNS without/IN coronary/JJ artery/NN disease/NN ,/, hypertension/NN or/CC other/JJ potential/JJ aetiologies/NNS ,/, as/IN 
14211_8_14_15_20_21::None::vitro/FW drug/NN sensitivity/NN test/NN ,/, which/WDT is/VBZ easy/JJ to/TO perform/VB ,/, may/MD predict/VB 
511797_2_23_24_33_34::None::and/CC mean/VB MS/NN duration/NN =/JJ 13.1/CD years/NNS )/) who/WP underwent/VBD measurements/NNS of/IN aerobic/JJ fitness/NN and/CC muscular/JJ strength/NN 
474123_0_1_2_0_2::people.cause_of_death.includes_causes_of_death::Oesophageal/JJ cancer/NN is/VBZ the/DT sixth/JJ 
1486_1486_41_44_60_61::POS_ACTION_STIMULATE::protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
398_398_8_9_10_11::None::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO 
1901_1901_25_28_29_30::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC 
1055_1055_2_3_22_23::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
1308_1308_6_9_9_10::POS_ACTION_MEMBER::transformation/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p57KIP2/NN requires/VBZ binding/VBG to/TO 
118239_0_15_16_13_14::medicine.drug.active_moieties::ceria/NN -/: supported/VBN gold/NN (/( Au/NN //: meso/SYM -/: 
576_576_13_15_9_10::POS_ACTION_MEMBER::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ 
640_640_29_30_29_30::None::'s/POS affinity/NN for/IN actin/NN ./. 
12271_2_60_61_24_25::medicine.drug_ingredient.active_moiety_of_drug::coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
1773_1773_6_7_10_11::None::between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO actin/NN was/VBD confirmed/VBN experimentally/RB 
699_699_22_23_19_22::None::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) 
436129_1_8_9_17_18::None::studies/NNS suggest/VBP that/IN ASA/NN use/NN reduces/VBZ the/DT risk/NN of/IN different/JJ cancers/NNS including/VBG breast/NN cancer/NN (/( BC/NN 
93665_0_2_3_16_18::medicine.disease.symptoms::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN 
311826_8_46_47_8_9::None::induced/VBN Fas/NN -/: mediated/JJ apoptosis/NN following/VBG treatment/NN with/IN anti/JJ -/: Fas/NN activating/VBG mAb/NN or/CC control/NN IgG/NN ,/, were/VBD assessed/VBN by/IN Annexin/NN V/NN staining/NN ,/, FACS/NN analysis/NN ,/, and/CC confocal/JJ microscopy/NN ;/: caspase/NN cleavage/NN by/IN Western/NN blot/NN ;/: FLIP/NN or/CC Fas/NN molecule/NN detection/NN by/IN Western/NN blot/NN 
13078_0_8_9_17_18::medicine.risk_factor.diseases::and/CC influence/NN of/IN chemotherapy/NN on/IN cytokine/NN plasma/NN levels/NNS in/IN childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN patients/NNS :/: IL/NN 
1178_1178_2_3_14_15::NEG_ACTION_BIND::Recombinant/JJ human/JJ beta-catenin/NN can/MD simultaneously/RB bind/VB to/TO the/DT alpha-catenin/actin/NN complex/NN but/CC does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
423051_1_27_28_31_32::None::also/RB by/IN a/DT number/NN of/IN immune/JJ and/CC inflammatory/JJ pathways/NNS ./. 
91811_0_16_17_9_10::None::tumors/NNS that/WDT usually/RB affect/VBP women/NNS in/IN the/DT second/JJ and/CC third/JJ decade/NN of/IN life/NN ./. 
405577_1_5_6_16_17::None::plasma/NN ,/, PCI/NN physiologically/RB inhibits/VBZ an/DT anticoagulant/JJ serine/NN protease/NN ,/, activated/VBN protein/NN C/NN (/( APC/NN )/) ./. 
1843_1843_31_32_31_33::POS_ACTION_MEMBER::the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
739338_5_13_14_4_5::None::were/VBD older/JJR than/IN men/NNS at/IN stroke/NN onset/NN and/CC more/JJR men/NNS had/VBD a/DT history/NN of/IN smoking/NN and/CC 
844136_3_12_13_24_25::None::targets/VBZ cancer/NN -/: specific/JJ expression/NN and/CC limits/NNS toxicity/NN ,/, is/VBZ a/DT new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
242622_9_12_13_17_19::people.cause_of_death.includes_causes_of_death::associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ mortality/NN among/IN prostate/NN cancer/NN patients/NNS taking/VBG beta/NN 
87_87_12_13_41_45::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
2222_2222_23_24_17_18::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1546_1546_8_11_5_6::POS_ACTION_MEMBER::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) 
888419_2_11_12_1_3::medicine.risk_factor.diseases::Noninvasive/JJ hepatic/JJ fibrosis/NN scores/NNS have/VBP been/VBN developed/VBN for/IN adult/JJ patients/NNS with/IN NAFLD/NN ;/: however/RB ,/, 
2131_2131_21_22_13_14::None::UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
1075_1075_22_23_8_9::POS_ACTION_PHOSPHORYLATE::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
322602_4_2_3_3_5::None::The/DT most/RBS common/JJ heart/NN diseases/NNS were/VBD congenital/JJ heart/NN 
2181_2181_17_18_25_26::POS_ACTION_BIND::determine/VB how/WRB much/JJ profilin/NN is/VBZ bound/VBN to/TO its/PRP$ known/JJ ligands/NNS :/: actin/NN ,/, membrane/NN PIP/NN 
513_513_9_10_5_6::None::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
1908_1908_5_6_19_20::None::results/NNS indicate/VBP that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
242622_9_6_7_11_12::None::that/IN beta/NN -/: blocker/NN use/NN was/VBD associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ 
549_549_9_10_11_12::POS_REG(-)_Change::was/VBD due/JJ to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP 
2064_2064_28_29_49_50::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
620873_8_10_11_46_47::None::a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN silicone/NN oil/NN microdroplets/NNS ,/, glass/NN microparticles/NNS ,/, or/CC Alhydrogel/NNP (/( Registered/NNP )/) showed/VBD greater/JJR ADA/NN responses/NNS that/IN those/DT that/WDT received/VBD particle/NN -/: free/JJ mAb1/NN preparations/NNS ,/, and/CC responses/NNS were/VBD greater/JJR for/IN formulations/NNS containing/VBG lower/JJR doses/NNS of/IN antibody/NN ./. 
627_627_19_20_24_25::None::up-regulation/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CKI/NN )/) ,/, and/CC 
311702_2_22_23_28_29::None::significant/JJ risk/NN for/IN development/NN of/IN inflammation/NN -/: mediated/VBN acute/JJ cardiac/JJ events/NNS that/WDT may/MD 
490079_2_8_9_22_23::people.cause_of_death.includes_causes_of_death::statin/NN treatment/NN after/IN cancer/NN diagnosis/NN is/VBZ associated/VBN with/IN longer/JJR survival/NN in/IN those/DT with/IN pancreatic/JJ ductal/JJ adenocarcinoma/NN (/( PDAC/NN )/) ./. 
426927_1_6_7_29_30::None::of/IN a/DT hexane/NN extract/NN of/IN Lithospermum/NN erythrorhizon/NN root/NN (/( LEH/NN )/) was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ escalating/VBG doses/NNS ,/, two/CD -/: week/NN dose/NN range/NN -/: finding/NN ,/, 
1375_1375_7_8_14_15::None::for/IN polymerization/NN of/IN actin/NN is/VBZ increased/VBN by/IN the/DT addition/NN of/IN profilin/NN ./. 
322082_9_15_18_24_25::None::C/NN Patients/NNS with/IN chronic/JJ kidney/NN disease/NN demonstrated/VBD higher/JJR NGAL/NN levels/NNS compared/VBN with/IN subjects/NNS with/IN preserved/JJ renal/JJ 
29775_1_38_39_27_28::None::to/TO hold/VB major/JJ cultural/JJ significance/NN around/IN the/DT world/NN as/IN a/DT perceived/VBN biological/JJ indicator/NN of/IN virginity/NN ./. 
275947_1_7_8_16_18::None::of/IN coxsackie/NN and/CC adenovirus/NN receptor/NN (/( CAR/NN )/) and/CC alphanu/NN integrin/NN in/IN bladder/NN cancer/NN decreases/VBZ the/DT infection/NN 
846534_0_0_3_19_20::None::Deep/JJ Brain/NN Stimulation/NN (/( DBS/NN )/) has/VBZ been/VBN a/DT successful/JJ technique/NN for/IN alleviating/VBG Parkinson/NNP whosewhat/NN disease/NN (/( PD/NN )/) symptoms/NNS especially/RB for/IN whom/WP 
783888_0_22_24_13_14::None::IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ 
609_609_21_22_10_11::POS_ACTION_ENCODE::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN three/CD polypeptides/NNS encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
403501_2_24_25_22_23::None::transmission/NN in/IN southern/JJ Zambia/NNP using/VBG samples/NNS from/IN community/NN -/: 
467137_1_0_1_1_2::None::Varroa/NNP destructor/NN has/VBZ been/VBN a/DT 
1008_1008_4_5_10_11::POS_ACTION_ENCODE::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
199283_3_20_21_29_31::None::improving/VBG children/NNS whosewhat/JJ health/NN -/: related/JJ outcomes/NNS such/JJ as/IN perioperative/JJ anxiety/NN and/CC postoperative/JJ pain/NN ./. 
566758_0_14_17_5_7::medicine.disease.treatments::derived/VBN sedentary/JJ and/CC physical/JJ activity/NN time/NN in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 2/CD diabetes/NN :/: cross/NN -/: 
609813_2_2_3_36_38::None::In/IN this/DT manuscript/NN ,/, we/PRP review/VBP microbial/JJ relationships/NNS with/IN plants/NNS ,/, outline/NN steps/NNS necessary/JJ to/TO develop/VB invasive/JJ species/NNS control/VBP strategies/NNS that/WDT are/VBP based/VBN on/IN those/DT relationships/NNS ,/, and/CC use/VB the/DT invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ reed/NN )/) as/IN an/DT 
856_856_22_23_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN 
1069_1069_26_27_33_35::POS_ACTION_ATTACH::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
124453_5_32_33_28_29::None::antioxidant/JJ and/CC glyoxalase/NN systems/NNS ,/, and/CC thereby/RB demonstrated/VBD the/DT important/JJ role/NN 
243_243_32_35_0_2::POS_ACTION_MEDIATE::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
110315_0_7_8_1_2::None::Chronic/JJ inguinodynia/NN is/VBZ one/CD of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN 
74367_0_5_6_1_2::None::The/DT genus/NN Neisseria/NNP contains/VBZ two/CD pathogenic/JJ species/NNS of/IN prominant/JJ 
1901_1901_33_34_25_28::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
588835_2_7_8_31_32::None::development/NN of/IN this/DT feature/NN in/IN 56/CD fetal/JJ specimens/NNS from/IN 10/CD different/JJ families/NNS of/IN toothed/JJ (/( odontocete/NN )/) and/CC baleen/NN (/( mysticete/NN )/) whales/NNS ,/, using/VBG X/NN -/: ray/NN computed/VBD tomography/NN ./. 
848984_1_5_6_3_4::None::Methods/NNS :/: We/PRP calculated/VBD the/DT polygenic/JJ risk/NN score/NN based/VBN 
173839_13_0_1_7_8::None::Graphical/JJ abstractCompounds/NNS isolated/VBN from/IN Helichrysum/NNP species/NNS (/( Compositae/NNS )/) ./. 
265468_0_8_9_5_7::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS 
1337_1337_4_5_7_8::None::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, 
578166_0_10_11_15_16::None::phenolic/JJ content/NN and/CC antioxidant/JJ capacity/NN of/IN almond/NN (/( Amygdalus/JJ communisL/NN ./. 
172257_0_6_8_19_20::None::the/DT Anaemia/NN in/IN Lung/NN Cancer/NN in/IN Spain/NNP study/NN was/VBD to/TO provide/VB epidemiological/JJ data/NNS and/CC treatment/NN of/IN anemia/NN in/IN 349/CD lung/NN 
248756_2_10_11_50_51::None::that/WDT have/VBP different/JJ numbers/NNS of/IN integuments/NNS :/: bitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP armeniaca/NN (/( apricot/NN )/) and/CC Prunus/NNP persica/NN (/( peach/NN )/) ,/, and/CC unitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP incisa/NNP ,/, analyzing/VBG the/DT expression/NN pattern/NN of/IN genes/NNS that/WDT are/VBP involved/VBN in/IN integument/NN development/NN in/IN Arabidopsis/NNP 
1061_1061_36_37_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
18729_3_15_16_11_12::medicine.medical_treatment.used_to_treat::drug/NN -/: resistant/JJ epilepsy/NN referred/VBN for/IN possible/JJ surgical/JJ intervention/NN ,/, we/PRP 
776_776_26_27_4_6::POS_ACTION_COLOCALIZE::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
372_372_28_29_9_10::None::virus/NN type/NN 1/CD UL8/NN protein/NN :/: effect/NN on/IN DNA/NN synthesis/NN and/CC ability/NN to/TO interact/VB with/IN and/CC influence/VB the/DT intracellular/JJ localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS 
28653_0_23_24_25_26::medicine.drug_ingredient.active_moiety_of_drug::a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN 
1560_1560_39_40_13_14::None::acetylation/NN of/IN histone/NN H4/NN versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN the/DT purified/VBN acetylase/NN ,/, histone/NN H4/NN in/IN nucleosomes/NNS was/VBD acetylated/VBN to/TO a/DT much/RB greater/JJR extent/NN than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
1507_1507_17_18_19_20::POS_ACTION_BIND::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
1760_1760_5_6_1_3::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC 
162721_4_25_26_7_8::None::,/, ovaries/NNS from/IN newborn/JJ mice/NNS were/VBD collected/VBN and/CC cultured/VBN with/IN vehicle/NN (/( dimethyl/JJ sulfoxide/NN ,/, DMSO/NN )/) or/CC different/JJ doses/NNS of/IN BPA/NN (/( 0.1/CD ,/, 
2064_2064_8_9_49_50::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
121583_0_38_39_6_7::None::believed/VBN that/IN the/DT archaeal/JJ ancestor/NN was/VBD hyperthermophilic/JJ ,/, but/CC during/IN archaeal/NN evolution/NN ,/, several/JJ lineages/NNS -/: including/VBG haloarchaea/NN and/CC their/PRP$ sister/NN methanogens/NNS ,/, the/DT Thaumarchaeota/NNP ,/, and/CC the/DT uncultured/JJ Marine/NNP Group/NNP II/NNP and/CC Marine/NNP Group/NNP III/NNP Euryarchaeota/NNP (/( MGII/NNP 
243_243_36_37_30_32::None::VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
1526_1526_10_11_17_18::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN (/( N/NN )/) and/CC large/JJ 
451755_0_3_4_19_20::None::Lesions/NNS in/IN the/DT corpus/NN callosum/NN (/( CC/NN )/) are/VBP important/JJ radiological/JJ clues/NNS to/TO the/DT diagnosis/NN of/IN multiple/JJ sclerosis/NN (/( MS/NN )/) ,/, but/CC 
1850_1850_2_3_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB 
25753_2_9_10_23_24::medicine.disease.treatments::may/MD lead/VB to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) ,/, which/WDT can/MD progress/VB to/TO end/VB -/: stage/NN renal/JJ disease/NN (/( ESRD/NN 
1266_1266_2_3_4_5::None::Since/IN both/DT caldesmon/NN and/CC profilin/NN have/VBP been/VBN found/VBN 
392437_4_32_33_32_34::people.cause_of_death.includes_causes_of_death::the/DT prediction/NN of/IN cardiovascular/JJ events/NNS ./. 
1633_1633_25_26_25_26::None::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: 
324774_0_8_9_4_5::None::of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB smoking/NN behavior/NN ./. 
590_590_29_31_21_22::None::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN 
204981_8_14_15_37_38::None::blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN a/DT central/JJ importance/NN of/IN TLR4/NN Taken/VBN together/RB ,/, multiple/JJ lines/NNS of/IN evidence/NN converge/VBP to/TO raise/VB TLR4/NN as/IN a/DT promising/JJ therapeutic/JJ target/NN for/IN 
263791_3_12_13_38_39::None::of/IN inflammation/NN in/IN RA/NN patients/NNS ,/, particularly/RB those/DT with/IN seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC gt/NN ;/: 10/CD years/NNS )/) ,/, and/CC //: or/CC extra/JJ -/: articular/JJ manifestations/NNS 
178116_0_6_7_14_15::biology.organism_classification.lower_classifications::regulatory/JJ subunits/NNS affecting/VBG plant/NN innate/JJ immunity/NN ,/, energy/NN metabolism/NN ,/, and/CC flowering/NN time/NN -/: -/: 
1726_1726_14_15_16_17::None::increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
435_435_4_5_15_16::POS_ACTION_BIND::domains/NNS of/IN the/DT PRP21/NN splicing/NN factor/NN are/VBP implicated/VBN in/IN the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS and/CC are/VBP 
544721_14_10_11_15_16::None::of/IN palpable/JJ breast/NN masses/NNS had/VBD been/VBN used/VBN ,/, biopsy/NN could/MD have/VB been/VBN 
38537_2_9_10_13_14::medicine.drug.active_moieties::for/IN 153/CD -/: Samarium/NN (/( 153/CD -/: Sm/NN )/) was/VBD done/VBN 
365_365_8_10_12_15::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB 
1248_1248_4_5_19_20::POS_ACTION_BIND::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1889_1889_7_8_0_2::POS_ACTION_BIND::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
142199_1_0_1_19_20::None::As/IN an/DT intra/NN -/: erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN causes/VBZ a/DT spectrum/NN of/IN symptomatology/NN ranging/VBG from/IN asymptomatic/JJ bacteremia/NN to/TO fever/NN ,/, 
29775_1_14_15_12_13::medicine.symptom.symptom_of::no/DT guarantee/NN that/IN rupture/NN or/CC bleeding/NN will/MD occur/VB at/IN 
739268_3_8_9_34_36::None::social/JJ withdrawal/NN or/CC potential/JJ liability/NN to/TO others/NNS (/( ie/FW ,/, depressive/JJ and/CC bipolar/JJ disorders/NNS ,/, social/JJ phobia/NN ,/, borderline/JJ personality/NN disorder/NN ,/, schizophrenia/NN and/CC other/JJ psychotic/JJ disorders/NNS ,/, certain/JJ drug/NN dependence/NN )/) were/VBD uniquely/RB 
91441_7_16_17_9_10::None::risk/NN for/IN cardiovascular/JJ events/NNS and/CC mortality/NN compared/VBN with/IN long/JJ -/: term/NN residents/NNS ,/, an/DT 
2222_2222_11_12_37_38::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
295529_1_9_10_11_12::None::the/DT RAF/NN family/NN activated/VBN by/IN mutation/NN in/IN human/JJ cancers/NNS 
520523_1_14_15_38_40::None::amygdali/NNS on/IN four/CD tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW )/) ,/, apricot/NN (/( Prunus/FW armeniaca/FW )/) ,/, peach/NN (/( Prunus/FW persica/FW )/) ,/, and/CC plum/NN (/( Prunus/NNP domestica/NNP )/) ./. 
259065_5_0_1_19_20::None::Correlations/NNS between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN ,/, depression/NN 
1341_1341_12_13_4_5::POS_ACTION_RELATE::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
1508_1508_16_18_10_11::None::UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
1341_1341_4_5_4_5::None::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC 
108257_1_20_21_3_4::None::Expectations/NNS of/IN high/JJ pain/NN can/MD exacerbate/VB pain/NN while/IN expectations/NNS of/IN low/JJ pain/NN during/IN a/DT consistently/RB noxious/JJ stimulus/NN can/MD produce/VB significant/JJ reductions/NNS in/IN pain/NN ./. 
593_593_19_20_5_6::None::show/VBP that/IN the/DT Arp2/NN subunit/NN of/IN the/DT complex/NN can/MD be/VB chemically/RB cross-linked/VBN to/TO the/DT actin-binding/JJ site/NN of/IN profilin/NN ./. 
323444_1_11_12_15_16::None::ischaemia/NN secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP 
1957_1957_10_11_10_11::POS_ACTION_COOCCUR::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN 
489359_3_12_13_2_5::None::Symptom/NN of/IN obstructive/JJ sleep/NN apnea/NN syndrome/NN (/( OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC 
379000_0_7_8_4_5::medicine.disease.risk_factors::conduction/NN block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD 
252268_2_39_41_3_4::None::We/PRP describe/VBP a/DT cohort/NN of/IN rhesus/NN macaques/NNS displaying/VBG SIB/NNP as/IN adults/NNS ,/, in/IN which/WDT changes/NNS within/IN the/DT central/JJ nervous/JJ system/NN were/VBD associated/VBN with/IN the/DT SIB/NNP In/IN these/DT macaques/NNS ,/, increases/VBZ in/IN central/JJ nervous/JJ system/NN striatal/JJ dopamine/NN (/( DA/NN )/) receptor/NN binding/NN (/( BPND/NN )/) 
162721_4_5_6_12_13::None::our/PRP$ hypothesis/NN ,/, ovaries/NNS from/IN newborn/JJ mice/NNS were/VBD collected/VBN and/CC cultured/VBN with/IN vehicle/NN (/( 
93_93_6_7_28_29::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
988_988_15_16_26_27::POS_ACTION_SIMILAR::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
1061_1061_36_37_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1728_1728_9_11_15_16::None::of/IN cytoskeletal/JJ and/CC sarcomeric/JJ actins/NNS is/VBZ regulated/VBN differently/RB by/IN profilin/NN in/IN the/DT developing/VBG 
106581_3_53_54_14_15::None::obesity/NN ,/, diabetes/NN type/NN II/CD ,/, metabolic/JJ syndrome/NN and/CC fatty/NN liver/NN ,/, critical/JJ evaluation/NN has/VBZ to/TO be/VB aimed/VBN at/IN reported/VBN benefits/NNS of/IN MD/NN in/IN such/JJ widely/RB metabolic/JJ diverse/JJ disorders/NNS as/IN cancer/NN ,/, pulmonary/JJ disease/NN and/CC cognition/NN defects/NNS ,/, including/VBG Alzheimer/NN disease/NN (/( Ref/NN ./. 
2222_2222_17_18_23_24::POS_ACTION_COLOCALIZE::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1652_1652_45_46_31_32::POS_ACTION_RELATE::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
490079_2_22_23_18_21::None::in/IN those/DT with/IN pancreatic/JJ ductal/JJ adenocarcinoma/NN (/( PDAC/NN )/) ./. 
246_246_3_4_11_13::POS_ACTION_ENCODE::A/DT 2.2-kb/JJ truncated/VBN NRP1/NN cDNA/NN was/VBD cloned/VBN that/IN encodes/VBZ a/DT 644-aa/JJ soluble/JJ NRP1/NN (/( sNRP1/NN )/) 
537465_2_25_26_10_11::None::of/IN T/NN cell/NN exhaustion/NN ,/, placing/VBG recent/JJ findings/NNS on/IN PD/NN -/: 1/CD blockade/NN therapies/NNS in/IN cancer/NN in/IN the/DT context/NN of/IN the/DT broader/JJR 
75337_1_10_11_19_21::medicine.medical_treatment.used_to_treat::adjuvant/JJ regimens/NNS with/IN trastuzumab/NN for/IN the/DT treatment/NN of/IN small/JJ HER2/NN -/: positive/JJ breast/NN cancer/NN in/IN routine/JJ clinical/JJ 
324774_0_8_9_2_3::medicine.drug.active_moieties::Components/NNP of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB smoking/NN behavior/NN ./. 
515_515_7_8_10_11::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
984_984_33_34_0_1::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
1486_1486_60_61_41_44::None::protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
71991_0_0_1_5_6::None::To/TO investigate/VB the/DT relationship/NN between/IN musculoskeletal/JJ disorders/NNS and/CC comorbid/NN 
20599_4_44_45_6_7::None::)/) was/VBD a/DT double/JJ -/: blind/JJ ,/, phase/NN 2/CD study/NN in/IN patients/NNS with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC with/IN high/JJ or/CC low/JJ doses/NNS of/IN patritumab/NN ,/, a/DT monoclonal/JJ antibody/NN targeted/VBN against/IN human/JJ epidermal/JJ growth/NN factor/NN 
387871_6_2_3_25_26::None::Straw/NNP significantly/RB promoted/VBD CO2/NN and/CC N2O/NN emissions/NNS but/CC inhibited/VBD CH4/NN emission/NN ,/, while/IN interactions/NNS between/IN nematodes/NNS and/CC nitrogen/NN fertilization/NN on/IN emissions/NNS of/IN greenhouse/NN gases/NNS were/VBD obvious/JJ ./. 
736878_5_8_10_15_17::None::vaginitis/NN were/VBD unspecific/JJ bacterial/JJ infections/NNS (/( 42.4/CD %/NN )/) and/CC vaginal/JJ candidiasis/NN (/( 44.8/CD %/NN 
1843_1843_12_13_31_33::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
722712_7_1_2_19_21::None::Tumor/NN resection/NN after/IN preoperative/JJ drainage/NN was/VBD effective/JJ in/IN the/DT management/NN of/IN a/DT patient/NN with/IN dyspnea/NN induced/VBN by/IN a/DT giant/JJ ovarian/JJ tumor/NN ./. 
2013_2013_20_21_9_10::None::the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
117943_0_12_13_21_22::medicine.medical_treatment.used_to_treat::coronary/JJ intervention/NN (/( PCI/NN )/) was/VBD reported/VBN to/TO promote/VB better/JJR coronary/JJ and/CC myocardial/JJ reperfusion/NN ./. 
196539_13_11_12_6_7::None::cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ 
754436_8_24_25_9_10::None::and/CC anxious/JJ participants/NNS reported/VBD problems/NNS with/IN their/PRP$ memory/NN and/CC concentration/NN compared/VBN with/IN fewer/JJR than/IN 8/CD %/NN of/IN medical/JJ controls/NNS ./. 
567_567_14_15_7_9::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
410019_0_0_1_16_17::None::Neo/SYM -/: adjuvant/JJ breast/NN cancer/NN clinical/JJ trials/NNS of/IN zoledronic/JJ acid/NN (/( ZOL/NN )/) have/VBP shown/VBN that/IN patients/NNS with/IN oestrogen/NN negative/JJ 
240_240_0_1_11_15::None::Neuropilin-1/NN is/VBZ also/RB expressed/VBN in/IN endothelial/JJ cells/NNS and/CC shown/VBN to/TO bind/VB vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 
822180_0_22_23_1_4::None::Autologous/JJ hematopoietic/JJ stem/NN cell/NN (/( HSC/NN )/) gene/NN therapy/NN for/IN sickle/JJ cell/NN disease/NN has/VBZ the/DT potential/JJ to/TO treat/VB this/DT illness/NN without/IN the/DT major/JJ immunological/JJ complications/NNS associated/VBN 
1337_1337_12_13_4_5::POS_ACTION_BIND::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
1534_1534_16_17_32_33::POS_ACTION_Change::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
323444_1_33_34_12_13::None::secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP evaluation/NN showed/VBD increased/VBN fibrinogen/NN and/CC factor/NN VIII/CD Previous/JJ studies/NNS showed/VBD that/IN venous/JJ thromboembolism/NN (/( VTE/NN )/) increases/VBZ in/IN 
284253_6_47_49_19_20::None::or/CC extended/VBN -/: release/NN formulations/NNS )/) ,/, levodopa/NN with/IN added/VBN -/: on/IN catechol/NN -/: O/SYM -/: methyltransferase/NN (/( COMT/NN )/) inhibitors/NNS ,/, levodopa/NN //: carbidopa/NN gel/NN for/IN intestinal/JJ infusion/NN ,/, some/DT dopamine/NN agonists/NNS (/( ropinirole/NN ,/, 
1160_1160_22_23_2_3::POS_ACTION_BIND::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
714308_1_18_19_9_10::None::potential/NN of/IN poly/NN ADP/NN -/: ribose/NN polymerase/NN (/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ 
28653_0_23_24_38_39::None::a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN (/( Mg/NN )/) ion/NN concentrations/NNS (/( 0.002/CD -/: 20/CD mM/NN )/) ./. 
350981_0_25_26_29_30::None::-/: Mood/NN )/) Syndrome/NN :/: A/DT Preliminary/JJ Report/NNP ./. 
179564_0_6_7_11_13::None::nullifies/VBZ feedback/NN -/: mediated/VBN resistance/NN to/TO erlotinib/NN in/IN lung/NN cancer/NN ./. 
1517_1517_4_5_15_16::POS_ACTION_Location::influence/NN of/IN these/DT collagens/NNS on/IN cell/NN morphology/NN and/CC the/DT distribution/NN pattern/NN of/IN actin/NN ,/, vimentin/NN ,/, talin/NN ,/, 
214_214_6_7_22_25::None::exchange/NN rapidly/RB between/IN actin/NN molecules/NNS ,/, low/JJ concentrations/NNS of/IN profilin/NN can/MD overcome/VB the/DT inhibitory/JJ effects/NNS of/IN high/JJ concentrations/NNS of/IN thymosin/NN beta/NN 4/CD on/IN the/DT nucleotide/NN 
1344_1344_17_18_6_7::None::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN 
676724_2_7_11_31_33::None::non/JJ -/: obese/JJ type/NN 2/CD diabetes/NN mellitus/NN (/( D2/NN )/) was/VBD achieved/VBN by/IN a/DT combination/NN of/IN streptozotocin/NN and/CC nicotinamide/NN (/( NA/NN -/: STZ/NN )/) ,/, whereas/IN a/DT type/NN 1/CD -/: like/IN disease/NN 
1321_1321_23_24_26_27::None::potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
93_93_28_29_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1889_1889_7_8_5_6::None::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
99729_5_9_10_6_7::medicine.disease.risk_factors::-/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ 
1082_1082_38_39_35_36::POS_ACTION_BIND::depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
613549_0_6_7_4_5::None::radiotherapy/NN is/VBZ increasingly/RB common/JJ for/IN patients/NNS with/IN advanced/JJ breast/NN 
1386_1386_1_2_18_19::POS_ACTION_Assembly::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS 
1761_1761_15_16_23_25::None::HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
1407_1407_21_22_15_16::None::polymerizability/NN of/IN the/DT actin/NN ,/, abolished/VBD its/PRP$ binding/NN to/TO profilin/NN ,/, and/CC filaments/NNS 
1017_1017_9_10_4_5::POS_ACTION_SIMILAR::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
379222_0_7_8_18_20::None::congenital/JJ heart/NN disease/NN reduces/VBZ risk/NN of/IN death/NN from/IN cardiovascular/JJ compromise/NN prior/RB to/TO planned/VBN neonatal/JJ cardiac/JJ surgery/NN :/: a/DT meta/NN 
116331_2_3_4_7_8::medicine.disease.treatments::Cumulative/JJ incidence/NN of/IN anemia/NN 7/CD years/NNS post/JJ procedure/NN was/VBD 58/CD %/NN 
1061_1061_6_7_24_25::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
605_605_20_21_23_24::None::the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
93_93_57_58_28_29::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1233_1233_30_31_28_29::None:::/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
405531_0_15_16_13_14::None::widely/RB used/VBN antiviral/JJ active/JJ against/IN influenza/NN A/NN virus/NN ./. 
14901_2_8_9_13_14::None::-/: to/TO -/: cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS 
2030_2030_22_23_3_4::None::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
1392_1392_8_9_1_2::None::The/DT cofilin/NN homology/NN sequence/NN is/VBZ critical/JJ for/IN stimulating/VBG actin/NN nucleation/NN with/IN the/DT 
1917_1917_27_28_14_15::None::profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD the/DT consequences/NNS of/IN specific/JJ point/NN mutations/NNS on/IN growth/NN and/CC actin/NN organization/NN ./. 
441567_0_16_17_0_1::None::To/TO describe/VB the/DT use/NN of/IN combined/JJ ursodeoxycholic/JJ acid/NN (/( UDCA/NN )/) and/CC rifampicin/NN treatment/NN in/IN intrahepatic/JJ cholestasis/NN of/IN pregnancy/NN (/( 
489359_3_7_8_14_15::medicine.disease.symptoms::apnea/NN syndrome/NN (/( OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC daytime/JJ sleepiness/NN 
350838_1_2_3_2_4::biology.organism_classification.lower_classifications::The/DT protozoan/NN Entamoeba/FW histolytica/NN ,/, which/WDT is/VBZ 
373109_2_45_46_28_31::None::proteins/NNS such/JJ as/IN human/JJ serum/NN albumin/NN (/( HSA/NN )/) and/CC human/JJ immunoglobulin/NN G/NN (/( hIgG/NN )/) adsorbed/VBN on/IN PS/NNP substrate/JJ surfaces/NNS were/VBD markedly/RB greater/JJR 
627089_4_22_23_6_7::None::diabetic/JJ vasculopathy/NN ,/, nephropathy/NN ,/, chronic/JJ hypertension/NN ,/, preeclampsia/NN ,/, preterm/NN delivery/NN ,/, and/CC fetal/JJ growth/NN restriction/NN are/VBP frequently/RB observed/VBN ./. 
582775_5_3_5_108_110::None::Short/JJ -/: term/NN adverse/JJ events/NNS occurred/VBD in/IN 20.15/CD %/NN (/( 81/CD //: 402/CD )/) ,/, including/VBG rash/NN (/( 3.5/CD %/NN ;/: 14/CD //: 402/CD )/) ,/, pruritus/NN (/( 1.2/CD %/NN ;/: 5/CD //: 402/CD )/) ,/, nausea/NN (/( 2.2/CD %/NN ;/: 9/CD //: 402/CD )/) ,/, headache/NN (/( 0.7/CD %/NN ;/: 3/CD //: 402/CD )/) ,/, skin/NN allergies/NNS (/( 4.0/CD %/NN ;/: 16/CD //: 402/CD )/) ,/, fever/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, palpitations/NNS (/( 3.0/CD %/NN ;/: 12/CD //: 402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN 
1861_1861_10_11_12_13::POS_ACTION_MUTUALCOMPLEX::containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
159_159_31_33_33_34::POS_ACTION_MEMBER::the/DT small/JJ soluble/JJ actin-binding/JJ protein/NN profilin/NN ./. 
445433_1_6_7_30_31::medicine.drug_ingredient.active_moiety_of_drug::neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ and/CC central/JJ nervous/JJ system/NN has/VBZ been/VBN described/VBN in/IN animals/NNS and/CC humans/NNS ,/, and/CC recently/RB several/JJ non/JJ -/: histaminergic/JJ pathways/NNS for/IN itch/NN 
1779_1779_5_7_29_30::None::of/IN pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
28_28_0_2_11_13::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
776_776_26_27_24_26::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
322394_2_27_28_14_15::medicine.drug_ingredient.active_moiety_of_drug::of/IN ACR/NN on/IN dopamine/NN and/CC its/PRP$ metabolite/NN levels/NNS ,/, dopamine/NN transport/NN and/CC metabolic/JJ gene/NN expression/NN in/IN dopaminergic/JJ neurons/NNS ./. 
516597_4_8_9_5_6::people.cause_of_death.includes_causes_of_death::647/CD children/NNS with/IN severe/JJ isolated/VBN head/NN injuries/NNS :/: 337/CD from/IN 
38537_2_18_19_26_27::None::was/VBD done/VBN by/IN SPECT/NNP -/: CT/NN images/NNS coupled/VBN GATE/NNP Monte/NNP Carlo/NNP package/NN for/IN internal/JJ dosimetry/NN 
745266_0_23_24_13_14::None::type/NN -/: 2/CD diabetes/NN ;/: however/RB ,/, the/DT impact/NN of/IN different/JJ treatment/NN escalation/NN strategies/NNS after/IN metformin/JJ failure/NN 
513_513_7_8_9_10::POS_ACTION_INTERACT::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
135795_9_19_20_6_7::None::The/DT IgG2a/NN //: IgG1/NN antibody/NN response/NN in/IN L/NN tropica/NN infection/NN is/VBZ higher/JJR than/IN that/DT in/IN L/NN major/JJ infection/NN ./. 
1534_1534_32_33_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
1024_1024_39_40_39_40::None::for/IN interaction/NN with/IN CUS1/NN ./. 
76365_0_22_23_43_44::None::with/IN ,/, by/IN order/NN of/IN frequency/NN ,/, phobic/JJ disorders/NNS and/CC generalized/VBN anxiety/NN disorder/NN rank/NN ahead/RB of/IN panic/NN disorders/NNS ,/, obsessive/JJ -/: compulsive/JJ disorder/NN or/CC post/NN -/: traumatic/JJ stress/NN 
139515_2_30_31_27_28::None::HSP/NN In/IN this/DT patient/NN ,/, the/DT diagnosis/NN of/IN HSP/NN was/VBD 
90241_0_8_9_14_15::None::,/, afatinib/NN significantly/RB improved/VBD progression/NN -/: free/JJ survival/NN (/( PFS/NN )/) versus/CC cisplatin/NN 
93_93_11_12_28_29::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1069_1069_21_22_46_47::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
1061_1061_25_27_24_25::POS_ACTION_MEMBER::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
214618_2_19_20_15_16::medicine.disease.symptoms::the/DT diagnosis/NN of/IN acute/JJ MI/NNP However/RB ,/, high/JJ sensitivity/NN troponin/NN assays/NNS 
2057_2057_12_13_3_4::None::We/PRP find/VBP that/IN profilin/NN contributes/VBZ in/IN several/JJ ways/NNS to/TO Cdc42-induced/JJ nucleation/NN of/IN actin/NN filaments/NNS in/IN high/JJ 
33757_12_7_8_25_26::None::while/IN user/NN -/: friendly/JJ platform/NN using/VBG multi/NNS -/: parametric/JJ MRI/NNP combined/VBN with/IN supervised/JJ learning/VBG to/TO be/VB able/JJ to/TO accurately/RB detect/VB cancer/NN foci/NNS and/CC its/PRP$ aggressiveness/NN 
406599_4_7_8_13_14::None::human/JJ ovarian/JJ cancer/NN cells/NNS proliferate/VBP better/JJR if/IN exposed/VBN to/TO cell/NN debris/NN harvested/VBN from/IN 
121781_2_0_1_5_7::None::Diabetes/NNP is/VBZ associated/VBN with/IN various/JJ nervous/JJ disorders/NNS ,/, such/JJ as/IN 
9_9_17_18_12_13::POS_ACTION_CROSS-LINK::acid/NN 364/CD of/IN actin/NN and/CC lysine/NN 115/CD of/IN profilin/NN ./. 
1711_1711_7_8_16_19::None::predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN 
93_93_54_55_22_23::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
275933_7_31_33_15_16::None::6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN repair/NN syndromes/NNS ,/, (/( 
1380_1380_43_44_36_37::None::,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
1094_1094_16_17_22_23::None::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
28939_0_19_20_0_1::None::Acute/JJ psychosis/NN developed/VBN in/IN an/DT elderly/JJ patient/NN with/IN Parkinson/NNPS disease/NN and/CC she/PRP was/VBD admitted/VBN and/CC treated/VBN with/IN quetiapine/NN (/( Seroquel/NN )/) ./. 
459829_1_17_18_7_8::None::the/DT surface/NN of/IN mesoporous/JJ TiO/NN (/( 2/CD )/) by/IN the/DT decomposition/NN of/IN magnesium/NN acetate/NN and/CC ,/, therefore/RB 
1638_1638_8_10_17_20::POS_ACTION_BIND::to/TO authentic/JJ human/JJ platelet/NN profilin/NN based/VBN on/IN the/DT measured/VBN Kd/NN for/IN rabbit/NN skeletal/JJ muscle/NN actin/NN ./. 
121781_2_18_19_10_12::None::,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, depression/NN ,/, and/CC Alzheimer/NN whosewhat/NN disease/NN ,/, and/CC that/DT 
776_776_29_30_28_29::None::protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
1289_1289_13_14_7_8::None::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
444311_5_16_17_18_19::medicine.drug.active_moieties::storage/NN of/IN ferric/JJ iron/NN (/( Fe/NNP (/( 3/CD +/CC 
1652_1652_43_44_20_21::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
93_93_11_12_54_55::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
801582_5_13_14_23_24::medicine.disease.treatments::center/NN of/IN the/DT burn/VBP wound/NN ,/, the/DT burn/VBP wound/NN edge/NN ,/, and/CC the/DT graft/NN donor/NN site/NN in/IN 
365_365_12_15_8_10::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB 
2414_0_22_23_15_17::medicine.risk_factor.diseases::for/IN Incident/NNP Atherosclerotic/JJ Cardiovascular/NNP Disease/NNP Beyond/NNP Ambulatory/NNP Blood/NNP Pressure/NN in/IN Elderly/NNP Men/NNP 
2222_2222_37_38_17_18::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
367_367_32_33_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
1667_1667_5_6_3_4::None::The/DT role/NN of/IN profilin/NN in/IN actin/NN polymerization/NN and/CC nucleotide/NN 
686_686_23_24_33_34::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
2146_2146_14_15_9_10::None::LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
439403_7_34_35_18_20::None::life/NN ,/, more/JJR sleep/NN problems/NNS ,/, and/CC greater/JJR functional/JJ disability/NN than/IN nondepressed/JJ patients/NNS ;/: the/DT two/CD groups/NNS did/VBD not/RB differ/VB in/IN pain/NN severity/NN 
250070_2_39_40_44_45::None::)/) ,/, and/CC estimated/VBN glomerular/JJ filtration/NN rate/NN (/( eGFR/NN )/) ,/, using/VBG 
248192_9_37_38_10_14::None:::/: 40/CD %/NN benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) ,/, 23/CD %/NN suspicious/JJ of/IN central/JJ causes/NNS ,/, 18/CD %/NN undiagnosed/JJ ,/, 15/CD %/NN Meniere/NNP disease/NN ,/, and/CC 4/CD %/NN vestibular/JJ neuronitis/NN ./. 
991_991_20_21_15_16::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
1940_1940_11_12_13_14::None::signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
2222_2222_37_38_39_40::None::contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
125255_5_49_50_18_19::None::as/IN hypertension/NN ,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: myocardial/JJ infarction/NN remodeling/NN or/CC heart/NN failure/NN ,/, and/CC post/NN -/: translationally/RB connexins/NNS are/VBP modified/VBN by/IN phosphorylation/NN //: de/FW -/: phosphorylation/NN and/CC nitros/NNS (/( yl/NN )/) 
1711_1711_19_20_5_6::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
957_957_8_11_23_24::POS_REG(0)_Assembly::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
1234_1234_17_18_15_16::None::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, 
1234_1234_17_18_34_35::None::extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
1373_1373_4_5_13_14::None::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
201_201_20_21_4_5::None::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS necessary/JJ for/IN the/DT interaction/NN of/IN actin/NN ,/, cofilin/NN ,/, and/CC Aip1p/NN in/IN an/DT apparent/JJ 
781998_2_17_18_23_24::None::of/IN short/JJ -/: term/NN insulin/NN -/: based/VBN therapy/NN has/VBZ emerged/VBN as/IN a/DT strategy/NN 
196539_13_4_5_11_12::None::association/NN between/IN cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ 
1174_1174_11_14_27_28::POS_ACTION_BIND::N-terminal/JJ fragment/NN of/IN myosin/NN heavy/JJ chain/NN ,/, which/WDT contains/VBZ the/DT `/`` consensus/NN '/'' ATP/NN binding/NN site/NN ,/, binds/VBZ to/TO actin/NN in/IN an/DT ATP-sensitive/JJ 
723866_2_3_4_1_2::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN 
1373_1373_11_12_13_14::None::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
2222_2222_21_22_11_12::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
391631_1_23_24_21_22::medicine.drug.active_moieties::polyclonal/JJ antibodies/NNS (/( IgG3/NN and/CC IgG4/NN )/) ./. 
919_919_12_13_9_10::POS_ACTION_BIND::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, 
367_367_26_27_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
1798_1798_41_42_24_26::None::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ./. 
515_515_5_6_7_8::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN 
1507_1507_19_20_17_18::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
230298_6_0_1_3_6::None::Management/NN strategies/NNS include/VBP cognitive/JJ behavioral/JJ therapy/NN ,/, mindfulness/NN -/: 
284647_4_24_25_35_36::medicine.risk_factor.diseases::disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, anticipating/VBG the/DT possibility/NN to/TO at/IN last/JJ control/NN pertussis/NN in/IN this/DT vulnerable/JJ 
1457_1457_56_57_34_35::POS_REG(-)_ASSEMBLE::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
499291_35_3_4_20_21::None::The/DT phenotypic/JJ and/CC metabolic/JJ presentations/NNS of/IN women/NNS with/IN PCOS/NN appear/VBP to/TO be/VB significantly/RB different/JJ depending/VBG on/IN ethnicity/NN ,/, obesity/NN and/CC age/NN ./. 
99729_5_4_5_15_18::None::with/IN co/NN -/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ attack/NN ,/, peripheral/JJ arterial/JJ disease/NN ,/, myocardial/JJ infarction/NN 
882908_0_10_11_1_3::None::Complete/JJ mitochondrial/JJ genome/NN of/IN the/DT Sharpnose/NN stingray/NN Himantura/NN gerrardi/NNS (/( Myliobatiformes/NNS :/: Dasyatidae/NNP )/) 
393131_1_25_26_24_26::medicine.drug.active_moieties::production/NN of/IN hydrogen/NN peroxide/NN to/TO damage/VB host/NN 
556_556_7_9_24_25::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
22_22_36_37_54_55::None::)/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
1169_1169_10_11_41_42::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
512613_1_22_23_32_34::None::)/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS ;/: more/JJR moderately/RB with/IN symptoms/NNS of/IN social/JJ phobia/NN ,/, affective/JJ lability/NN 
1180_1180_17_18_17_18::POS_ACTION_BIND::polymerization/NN from/IN the/DT actin/NN :/: thymosin/NN beta4/NN 
210955_0_29_30_11_12::None::(/( IgG4/NN -/: RD/NN )/) is/VBZ characterized/VBN by/IN elevated/JJ serum/NN IgG4/NN and/CC infiltration/NN of/IN IgG4/NN (/( +/CC )/) plasma/NN cells/NNS into/IN multiple/JJ organs/NNS ./. 
378211_8_35_36_20_21::None::-/: 6/CD and/CC TNF/NN -/: alpha/NN )/) release/NN from/IN PBMCs/NNS in/IN non/JJ -/: smokers/NNS ,/, smokers/NNS and/CC COPD/NN patients/NNS ./. 
1379_1379_11_12_27_28::POS_ACTION_BIND::of/IN the/DT human/JJ RAD52/NN protein/NN shows/VBZ no/DT homology/NN with/IN the/DT yeast/NN RAD52/NN protein/NN ,/, indicating/VBG that/IN the/DT interaction/NN between/IN RAD51/NN and/CC RAD52/NN is/VBZ 
1793_1793_16_17_4_5::POS_ACTION_CONTROL::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
350850_8_31_32_3_5::None::With/IN respect/NN to/TO categorical/JJ variables/NNS ,/, a/DT significant/JJ association/NN was/VBD found/VBN for/IN the/DT presence/NN of/IN diabetes/NN (/( P/NN =/JJ 0.006/CD )/) ,/, hypertension/NN (/( P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, facial/JJ lipodystrophy/NN (/( P/NN 
161_161_0_1_17_18::POS_ACTION_Assembly::Armadillo/NN (/( Arm/NN )/) repeat/NN 10/CD to/TO the/DT COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN binding/VBG to/TO CBP/NN ,/, whereas/IN beta-catenin/NN 
206273_1_27_28_26_27::medicine.disease.symptoms::patients/NNS with/IN uremic/JJ accelerated/VBN atherosclerosis/NN (/( UAAS/NN )/) 
1372_1372_31_32_1_2::None::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
685_685_6_7_30_31::POS_ACTION_COPRECIPITATE::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
235710_2_1_2_17_18::None::To/TO investigate/VB the/DT adjuvant/JJ cabergoline/NN therapy/NN effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN in/IN PCOS/NN women/NNS with/IN hyperprolactinemia/NN ./. 
1810_1810_20_21_2_3::POS_ACTION_CORELATE::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
1843_1843_19_20_31_33::None::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
596699_0_5_6_12_13::None::hypertension/NN are/VBP chronic/JJ conditions/NNS that/WDT are/VBP growing/VBG in/IN prevalence/NN as/IN major/JJ causal/JJ factors/NNS of/IN 
1686_1686_15_18_25_28::POS_ACTION_INTERACT::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN 
2107_2107_39_40_24_26::None::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
1526_1526_10_11_12_13::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN 
345914_6_24_25_1_3::None::Duodenal/JJ gene/NN expression/NN studies/NNS related/VBN to/TO the/DT absorption/NN of/IN iron/NN from/IN gamma/NN -/: Fe2O3/NN nanoparticles/NNS indicate/VBP the/DT enhancement/NN of/IN a/DT ferric/JJ over/IN ferrous/JJ pathway/NN supporting/VBG the/DT role/NN of/IN 
129749_7_4_5_12_13::None::hypothyroidism/NN risk/NN for/IN DM/NN was/VBD prominent/JJ only/RB upon/IN statin/NN use/NN (/( RR/NN 1.94/CD [/( 1.13/CD 
14901_2_8_9_18_19::medicine.drug_ingredient.active_moiety_of_drug::-/: to/TO -/: cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS -/: Cys/NN Prx/NN A/NN in/IN 
533311_1_6_7_20_22::None::to/TO identify/VB the/DT depression/NN and/CC anxiety/NN state/NN of/IN diabetic/JJ adolescents/NNS and/CC its/PRP$ impact/NN on/IN the/DT management/NN of/IN diabetes/NN mellitus/NN (/( DM/NN )/) 
1395_1395_26_27_12_13::POS_REG(-)_Assembly::plant/NN and/CC animal/NN actins/NNS can/MD be/VB blocked/VBN by/IN profilin-specific/JJ antibodies/NNS that/WDT react/VBP with/IN different/JJ epitopes/NNS of/IN birch/NN profilin/NN ./. 
231380_9_5_6_10_11::None::current/JJ results/NNS on/IN bone/NN properties/NNS of/IN 16/CD -/: week/NN old/JJ female/JJ M3R/NN 
4599_8_9_10_36_37::None::transmitted/VBN to/TO the/DT future/JJ male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ offspring/NN born/VBN after/IN assisted/JJ reproduction/NN and/CC the/DT 
1486_1486_24_25_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN 
149017_0_18_20_26_29::None::characterized/VBN by/IN progressive/JJ cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN the/DT central/JJ nervous/JJ system/NN ./. 
326118_0_39_40_51_52::medicine.medical_treatment.used_to_treat::22/CD mg/NN )/) sumatriptan/NN powder/NN ,/, vs/CC 100/CD mg/NN oral/JJ sumatriptan/NN for/IN acute/JJ treatment/NN of/IN migraine/NN in/IN a/DT double/JJ 
343970_4_37_38_7_9::None::the/DT growth/NN of/IN planktonic/JJ algae/NN in/IN different/JJ sections/NNS :/: From/IN the/DT point/NN of/IN the/DT whole/JJ lake/NN ,/, CHL/NN was/VBD significantly/RB correlated/VBN with/IN TP/NN ,/, TN/NN ,/, total/JJ dissolved/VBN nitrogen/NN (/( TDN/NN )/) and/CC nitrate/JJ nitrogen/NN (/( NO3/NN 
758270_7_2_3_24_25::None::In/IN chronic/JJ cigarette/NN smoke/NN related/JJ lung/NN disease/NN ,/, the/DT PGP/NN pathway/NN can/MD become/VB a/DT self/NN -/: propagating/VBG cycle/NN of/IN inflammation/NN through/IN cigarette/NN -/: smoke/NN mediated/VBD inhibition/NN of/IN leukotriene/NN 
93_93_4_5_50_51::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
204981_8_20_21_11_12::None::of/IN pharmacological/JJ TLR4/NN blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN a/DT central/JJ importance/NN of/IN TLR4/NN 
154535_13_10_11_1_2::None::Our/PRP$ data/NNS suggest/VBP a/DT complex/JJ interplay/NN among/IN insulin/NN resistance/NN ,/, obesity/NN ,/, and/CC depression/NN 
429131_8_32_33_24_27::None::R/NN -/: induced/VBN apoptotic/JJ cell/NN death/NN ,/, the/DT PI3K/NN //: Akt/NN pathway/NN of/IN EGCG/NN may/MD 
243_243_27_28_32_35::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
1344_1344_22_23_17_18::None::members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
2107_2107_9_10_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
1052_1052_37_38_34_35::None::to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
4599_8_5_6_28_30::None::deletions/NNS can/MD be/VB vertically/RB transmitted/VBN to/TO the/DT future/JJ male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ 
1234_1234_34_35_15_16::None::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
93665_0_19_21_1_3::None::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN features/NNS ./. 
339123_0_10_11_13_14::None::with/IN a/DT ''/'' Naked/JJ ''/'' Triphenylsilyl/NN Anion/NN by/IN Hydrogenolysis/NN of/IN 
687548_0_0_1_10_11::None::Diabetic/NNP polyneuropathy/NN (/( DPN/NN )/) is/VBZ a/DT devastating/JJ complication/NN of/IN diabetes/NN ./. 
142199_1_4_5_7_8::None::an/DT intra/NN -/: erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN 
1758_1758_22_23_17_18::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
566931_0_4_5_30_31::medicine.disease.treatments::the/DT treatment/NN of/IN polymyositis/NN (/( PM/NN )/) and/CC dermatomyositis/NN (/( DM/NN )/) ,/, muscle/NN inflammation/NN and/CC underlying/VBG autoimmunity/NN need/NN to/TO be/VB suppressed/VBN promptly/RB ;/: however/RB ,/, catabolic/JJ effects/NNS of/IN corticosteroids/NNS such/JJ as/IN myopathy/NN 
1248_1248_4_5_12_13::POS_ACTION_MEMBER::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB 
1098_1098_11_12_16_17::POS_ACTION_STIMULATE::binding/NN domain/NN of/IN CBP/NN stimulates/VBZ transcription/NN from/IN the/DT PEPCK/NN gene/NN promoter/NN ./. 
1164_1164_5_6_33_34::None::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ 
776_776_29_30_4_6::POS_ACTION_COLOCALIZE::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
741231_0_3_5_18_19::None::Relationship/NN between/IN low/JJ blood/NN pressure/NN and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN disease/NN under/IN nephrologist/NN care/NN :/: the/DT 
686_686_31_32_29_30::POS_ACTION_BIND::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1782_1782_23_24_27_28::POS_ACTION_INTERACT::RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
473269_0_8_10_29_30::None::)/) is/VBZ a/DT neurodegenerative/JJ disorder/NN characterized/VBN by/IN loss/NN of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ dopamine/NN (/( DA/NN )/) deficiency/NN and/CC 
616400_0_2_3_0_1::None::Housing/NN and/CC maintenance/NN of/IN Ambystoma/NN mexicanum/NN 
14_14_5_6_1_2::None::Acanthamoeba/NN profilin/NN was/VBD cross-linked/VBN to/TO actin/NN via/IN a/DT zero-length/JJ 
98_98_29_30_29_30::None::the/DT affinity/NN of/IN profilin/NN for/IN actin/NN may/MD 
381796_0_5_6_18_22::None::Bilevel/NNP -/: auto/NN Treatment/NN in/IN Patients/NNS with/IN Obstructive/JJ Sleep/NNP Apnea/NNP Not/RB Responsive/JJ to/TO or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
1803_1803_27_28_32_34::POS_ACTION_RELATE::is/VBZ distinct/JJ from/IN FADD/NNP 's/POS functions/NNS at/IN activated/VBN death/NN receptors/NNS ./. 
878537_3_18_19_15_16::medicine.disease.treatments::underwent/VBD a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT 
619459_0_1_2_54_57::medicine.risk_factor.diseases::The/DT antitumor/JJ enzyme/NN asparaginase/NN ,/, which/WDT targets/VBZ essential/JJ amino/NN acid/NN L/NN -/: asparagine/NN and/CC catalyzes/VBZ it/PRP to/TO L/NN -/: aspartic/JJ acid/NN and/CC ammonia/NN ,/, has/VBZ been/VBN used/VBN for/IN years/NNS in/IN the/DT treatment/NN of/IN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) ,/, subtypes/NNS of/IN myeloid/JJ leukemia/NN and/CC T/NN -/: cell/NN lymphomas/NNS ,/, whereas/IN the/DT anti/JJ -/: chronic/JJ myeloid/JJ leukemia/NN (/( CML/NN )/) 
1660_1660_27_28_25_26::None::of/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
534_534_24_25_28_29::POS_ACTION_Change::a/DT role/NN for/IN synaptojanin/NN family/NN members/NNS in/IN actin/NN function/NN ./. 
72969_0_3_4_19_21::None::Close/JJ relatives/NNS (/( CR/NN )/) of/IN patients/NNS with/IN severe/JJ traumatic/JJ brain/NN injury/NN (/( TBI/NN )/) and/CC high/JJ -/: grade/NN subarachnoid/JJ hemorrhage/NN (/( SAH/NN )/) 
2131_2131_7_8_13_14::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
1071_1071_32_33_21_22::None::each/DT other/JJ :/: profilin/NN has/VBZ different/JJ effects/NNS on/IN elongation/NN at/IN the/DT two/CD ends/NNS of/IN actin/NN filaments/NNS ;/: profilin/NN 
142623_1_12_13_8_9::None::stress/NN conditions/NNS in/IN response/NN to/TO aluminum/NN (/( Al/NNP )/) ,/, a/DT 
431_431_15_16_0_1::None::END5/NN encodes/VBZ a/DT proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
523643_0_16_17_0_1::None::Our/PRP$ objective/NN is/VBZ to/TO explore/VB the/DT correlation/NN between/IN the/DT mouth/NN diameter/NN of/IN left/JJ atrial/JJ appendage/NN (/( LAA/NN )/) and/CC stroke/NN 
1866_1866_9_10_12_13::None::use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
151063_0_19_23_21_23::None::of/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) 
1169_1169_17_18_13_16::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
193027_2_0_1_22_23::None::Here/RB ,/, we/PRP provide/VBP data/NNS toward/IN the/DT clinical/JJ translation/NN of/IN an/DT affinity/NN -/: enhanced/VBN version/NN of/IN JO/NNP -/: 1/CD ,/, which/WDT we/PRP call/VBP JO/SYM -/: 4/CD 
2107_2107_24_26_7_8::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
2107_2107_5_7_9_10::POS_ACTION_MEMBER::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
93_93_4_5_57_58::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1737_1737_52_54_58_59::POS_ACTION_MEMBER::the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
431_431_15_16_6_7::None::proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
228362_4_28_29_14_15::None::vitro/FW ribosylation/NN and/CC trypsin/NN digestion/NN for/IN 24/CD or/CC 72h/CD on/IN the/DT viscoelastic/JJ behavior/NN of/IN the/DT whole/JJ murine/JJ IVD/NN Trypsin/NN treatment/NN resulted/VBD 
726738_8_9_10_12_13::medicine.medical_treatment.used_to_treat::lower/JJR for/IN doctors/NNS treating/VBG lung/NN ,/, breast/NN and/CC colorectal/JJ cancers/NNS 
590053_1_7_8_12_13::medicine.symptom.symptom_of::after/IN administration/NN include/VBP headache/NN ,/, nausea/NN ,/, and/CC influenza/NN -/: like/IN symptoms/NNS 
140351_4_6_7_7_8::medicine.risk_factor.diseases::studies/NNS exist/VBP in/IN elderly/JJ IBD/NN as/IN most/JJS authors/NNS 
1169_1169_41_42_17_18::None::Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
1341_1341_1_2_6_7::POS_ACTION_Causal::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS 
430599_3_14_15_18_19::None::than/IN normotensive/JJ group/NN WKY/NN and/CC hypertensive/JJ group/NN SC/NN without/IN mesangial/JJ cell/NN 
434205_2_11_12_9_10::medicine.drug.active_moieties::DA/NN )/) and/CC norepinephrine/NN (/( NE/NN )/) are/VBP influenced/VBN 
2165_2165_20_21_14_15::None::presence/NN of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN histone/NN H3/NN ./. 
1128_1128_4_5_11_14::None::talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
174565_5_51_52_49_50::medicine.drug.active_moieties::different/JJ doses/NNS of/IN dopaminergic/JJ (/( DA/NN )/) neuron/NN toxin/NN 
231123_0_2_3_21_22::None::Nilotinib/NNP in/IN patients/NNS with/IN systemic/JJ mastocytosis/NN :/: analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN ./. 
652_652_13_14_11_12::None::alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
1337_1337_12_13_7_8::None::talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
240510_12_9_10_16_17::biology.organism_classification.lower_classifications::more/RBR recently/RB named/VBN gastropod/NN clades/NNS (/( Vetigastropoda/NNP ,/, Neritimorpha/NNP ,/, Caenogastropoda/NNP ,/, and/CC Heterobranchia/NNP 
397033_2_22_23_5_6::None::birds/NNS (/( carrion/NN crows/NNS ,/, Corvus/NN corone/NN ,/, common/JJ ravens/NNS ,/, Corvus/NNP corax/NN ,/, Goffin/NNP cockatoos/NNS ,/, Cacatua/NN goffiniana/NN )/) performed/VBD comparably/RB to/TO primates/NNS 
1089_1089_20_21_9_10::NEG_ACTION_BIND::studies/NNS demonstrated/VBD that/IN Stat1/NN could/MD directly/RB interact/VB with/IN TNFR1/NN and/CC TRADD/NN but/CC not/RB with/IN FADD/NN ./. 
417653_2_26_27_30_31::None::and/CC long/JJ -/: term/NN feeding/NN of/IN a/DT high/JJ -/: fat/JJ diet/NN 
118239_0_42_43_45_46::None::nitroaromatics/NNS ,/, using/VBG CO/NNP as/IN the/DT sole/JJ deoxygenative/JJ reagent/NN ,/, 
1074_1074_7_8_10_11::None::including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN ,/, are/VBP not/RB 
386606_0_5_6_9_10::None::in/IN oral/JJ cancer/NN surgery/NN :/: Room/NN for/IN improvement/NN ./. 
780438_1_18_19_28_29::medicine.disease.risk_factors::visited/VBD among/IN persons/NNS infected/VBN with/IN HAV/NN and/CC assess/VB reasons/NNS why/WRB travelers/NNS had/VBD not/RB received/VBN hepatitis/NN A/NN vaccine/NN 
829573_1_1_2_14_15::None::Proposed/VBN etiologies/NNS of/IN this/DT rare/JJ condition/NN include/VBP dysregulation/NN of/IN sympathetic/JJ outflow/NN ,/, upper/JJ cervical/JJ pathology/NN ,/, glossopharyngeal/NN and/CC 
1233_1233_26_27_28_29::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
721_721_9_10_13_14::None::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC 
